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ABSTRACT
Equine herpesvirus 4 (EHV-1) is an alphaherpesvirus primarily
associated with respiratory disease. The genome of this virus has been 
characterised (strain 1942) and a BamHI library prepared (Cullinane et 
al., 1988).
This dissertation reports the localisation of five intact EHV-4 
genes within the Uj_ component of the genome . Homologues of HSV-1 genes 
UL22 (gH), UL23 (thymidine kinase), UL24, and UL44 (gC) were 
identified. An additional EHV-4 mapped to the left of the gC gene 
homologue has no apparent HSV-1 homologue. Partial nucleotide sequences 
were determined for EHV-4 homologues of HSV-1 genes UL21, and UL43. The 
map positions, nucleotide sequence, and predicited amino acid sequence 
of the products of these genes are detailed. The EHV-4 polypeptides are 
compared to their counterparts in other herpesviruses. Sequence 
analysis revealed a region of direct repeats and a putative origin of 
DNA replication proximal to the 3' end of the gH gene.
Five peptides derived from the predicted amino acid sequences of the 
EHV-4 gpl3 (gC) and gH polypeptides were tested for their 
immunogenicity in a hamster model.
The implications of these data are discussed in reference to the 
relatedness of EHV-4 to other herpesviruses in terms of sequence 
conservation (at the amino acid level) and in genome organisation. 
Finally, possible applications of the data to the development of novel 
EHV vaccines and diagnostic tests are outlined.
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CHAPTER 1 
GENERAL INTRODUCTION
HERPESVIRUSES
1. The Family Herpesviridae 
The family herpesviridae comprises approximately 90 viruses of 
similar biochemical and morphological characteristics isolated from 
members of all five animal families (Roizman, 1982; Wildy, 1985 ).
Herpesviruses are characterised by a linear double-stranded DNA 
genome of molecular weight 80-150 x 10® which is encapsidated within an 
icosahedral capsid 100-200nm in diameter (Wildy et al.. 1960).
Electron micrography of a herpesvirus particle distinguishes four 
distinct morphological elements - an outer envelope, an electron-dense 
tegument, the capsid, and a core structure comprising an electron-dense 
outer area and an electron-translucent centre (Fig. 1). The capsid, an 
icosahedral structure composed of 162 capsomers, encapsidates the core 
which is composed of the DNA genome of the virus complexed with 
proteins. The tegument , an amorphous proteinaceous layer, separates 
the capsid from the virion envelope which is derived from modified 
regions of host cell internal membranes (Roizman and Furlong, 1974).
The most fully characterised herpesviruses are seven human 
herpesviruses - herpes simplex virus types 1 and 2 ( HSV-1 and HSV-2), 
varicella-zoster virus (VZV), human cytomegalovirus (HCMV) , Epstein- 
Barr virus (EBV), and human herpesviruses type 6 and type 7 (HHV-6 and 
HHV-7) - and viruses such as pseudorabies virus (PRV), bovine 
herpesvirus (BHV-1), and equine herpesviruses 1 and 4 (EHV-1 and 
EHV-4) which cause economically important disease in animals within the 
agricultural or leisure industries.
2. Classification of Herpesviruses 
Herpesviruses can be differentiated by several criteria including 
antigenic structure, genome structure and biological properties. At
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Figure 1.1
Herpesvirus Virion Structure
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Figure 1.1 a) Electron micrograph of EHV-infected cells. 
Magnification X60000. b) Schematic diagram of a herpesvirus 
virion.
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present only the latter is of use with regard to the subclassification 
of herpesviruses into defined groups since only a few herpesvirus 
genome structures have been well characterised and serological data 
gives rise to rather arbitrary groups.
1) Classification on the basis of biological criteria
Approximately two thirds of herpesviruses reported to date have been 
assigned to three subfamilies - alpha-, beta-, and gammaherpesviruses - 
on the basis of biological characteristics such as in vivo properties, 
in vitro host cell range, rate of propagation and features of latent 
infection and cytopathology (Roizman, 1982).
The alphaherpesvirus subfamily comprises herpesviruses of variable 
host range specificity in vivo and in vitro, a short reproductive 
cycle, and a rapid lytic infection in vitro. Further classification 
into alpha 1 and alpha 2 divisions separates viruses such as HSV-1, 
HSV-2, EHV-1, EHV-4 and PRV ( which have a wide in vitro host 
range, a cytolytic capacity and which tend to establish latent 
infection within ganglionic tissue from viruses such as VZV ( c< 2) 
which has a narrow in vitro host range, a slower multiplication rate, a 
greater cell-associated character and an association with neurotropic 
as well as ganglionic latency.
The betaherpesvirus subfamily comprises the cytomegaloviruses, 
characterised by a restricted in vivo and in vitro host range, a slow 
replicative cycle,, a cell-associated character and often a lymphotropic 
latent phase.
Gammaherpesviruses specifically infect B or T lymphocytes in vivo 
and establish latency within lymphoid and epithelial tissue. The length 
of the replicative cycle is variable. EBV and some other 
gammaherpesviruses are capable of immortalising lymphocytes in vitro 
and may initiate lymphoproliterative disease in susceptible hosts.
2
Classification of a gammaherpesvirus as ^  or 2 reflects the 
preference of the virus for B ( j) or T ( 2) lymphocytes. Thus EBV
( 2T j) is typically associated with B lymphocytes whereas herpesvirus 
saimiri (HVS) 2) tends to infect and immortalise T-lymphocytes .
2) Classification by genome biochemistry and size
Differences in genome base composition, size and repeat element 
size and organisation also serve to distinguish herpesviruses. 
Classification according to genome size or base composition (which 
range from 80-150 x 10® and 32-75% G+C moles% respectively) does not 
distribute viruses in a manner consistent with classification by 
biological criteria although there is a degree of correlation between 
%GC composition and biological sub-family in as much as the higher %GC 
(>60%) genomes tend to associated with alphaherpesviruses, the midrange 
(50-60%) with betaherpesviruses and the lower (34-50%) with
gammaherpesviruses (Honess, 1984). The wide range of %GC compositions 
is regarded to be a consequence of the differential fixing of biased 
mutations presumably influenced by the host cell type and replicative 
characteristics of different herpesviruses. It was thought previously 
to be the result of different selective pressures on the protein coding 
regions of the genome but , as mentioned above, correlation between %GC 
and biological properties is limited. The dinucleotide rather than
trinucleotide composition is now the more useful criteria for analysing 
herpesvirus genomes given that the CpG dinucleotide frequency is 
apparently reflective of the latent characteristics of a virus (Honess 
et al.. 1989b).
3) Classification by genome structure
Five viral sub-groups - groups A to E - have been proposed on the
basis of genome structure. Herpesviruses are classified according to
the number, size and organisation of reiterated sequences exceeding 100
3
base pairs (Roizman, 1982) (Fig. 2). It has been hypothesised that the 
different arrangements of repeat regions within genomes may be a 
consequence of rearrangement events. Alternatively they may have arisen 
due to less selective pressure on different parts of the genome of the 
various herpesviruses.
Group A and B genomes possess direct repeat elements at their 
termini. Whereas in A genomes one copy of each element is present at 
the termini, in B genomes multiple reiterations of the element exist. 
These genome structures are exemplified by channel catfish herpesvirus 
(Chousterman et al.. 1979) and by herpesvirus saimiri (Bornkamm et al., 
1976).
Group C genomes such as EBV (Baer et al.. 1984; Raab-Traub et al., 
1980) possess internal tandem reiterations of sequences in addition to 
multiple direct repeats of distinct elements at the genome termini.
Group D genomes possess an internal inverted repeat of a terminal 
sequence element. Part of the repeat element is also reiterated, in the 
same orientation, at the other terminus. Group D genomes may exist in 
two isomeric forms due to the potential for intramolecular 
recombination events between the inverted repeat elements (Ecker and 
Hyman, 1982; Whalley et al., 1981). The two major genome components , 
the long unique component and the shorter component flanked by inverted 
repeats, are designated L and S respectively with the designations U|_ 
and U$ serving to identify the unique portions of those components 
(i.e. the entire L component and the S component minus the repeat 
elements ). Genomes classified as group D include those of EHV-1, EHV- 
4, and PRV (Ben-Porat et al.. 1979; O'Callaghan et al. 1983 ).
Group E genomes are characterised by two sets of inverted repeats, 
one at either terminus with its invert positioned internally. As in 
group D genomes, part of the sequence element is reiterated at each
4
Figure 1.2
Herpesvirus Genome Structures
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Figure 1.2 Schematic representation of the five types of 
herpesvirus genome structure as defined in Roizman, 1982.
termini to give rise to small direct repeat elements. Since two 
inverted repeats are present within E genomes, four isomers may exist
differing only in the relative orientations of the unique sequences 
flanked by the repeats. The prototypic alphaherpesvirus HSV-1 possesses 
a type E genome (Sheldrick and Berthelot, 1975). The designations Uj_ 
and U$ are used as for D genomes while the repeat elements are denoted 
by their position at the termini or internally and the component in 
which they are positioned such that the major repeats are designated 
TR|_, IRl , IR$ and TR$ from left to right.
4) Classification by nucleotide sequence data
The most sensitive determinant of herpesvirus classification is 
likely to be nucleotide sequence data which should allow the fine
analysis of the evolutionary relatedness of different herpesviruses. As
for genome structure though the usefulness of such a system is limited 
in taxonomic terms since such data is available for a minority of 
reported herpesviruses.
Nucleotide sequence data has revealed discrepancies in the current 
biological grouping of several herpesviruses including MDV, HVT, and 
HHV-6 . Molecular analysis of MDV and HVT genes and genomes has
indicated that although these viruses are classified as
gammaherpesviruses on the basis of their lymphotropic nature (Roizman, 
1982) they are more closely associated with alphaherpesviruses in 
molecular and genomic terms with gene sequence and CpG ratio more
closely related to genes in other alphaherpesviruses than to those of 
gammaherpesviruses (Buckmaster et al., 1988; Cebrian et al., 1982;
Honess et al.. 1989b). Likewise, HHV-6 , classified as a 
gammaherpesvirus on account of its lymphotropic nature, is more closely 
related to cytomegalovirus in molecular terms and is now generally 
regarded as a \ z herpesvirus (Lawrence et al.. 1990). In these
instances the biological property of lymphotropism does not correlate 
with genome characteristics at the structural or molecular level and it 
seems likely that this tropism may be associated with different gene 
products in MDV, HVT, and HHV-6 as compared to those in 
gammaherpesvi ruses.
3, Herpesvirus Nucleotide Sequence Data and its 
Implications for Herpesvirus Evolution 
The nucleotide sequence of the entire genome of four herpesviruses 
has been reported and their coding capacity analysed - HSV-1 ( McGeoch 
et al., 1985; McGeoch et al., 1986; McGeoch et al., 1988a; Perry and 
McGeoch, 1988), VZV (Davison and Scott, 1986), HCMV (Chee et al., 
1990), and EBV (Baer et al., 1984). Comparative analyses of these 
genomes and of limited regions of other herpesvirus genomes have 
revealed the molecular relatedness of six biological subgroups of the 
herpesvirus family - alpha 1 and 2, beta 1 and 2, and gamma 1 and 2. On 
the basis of these comparisons albeit limited by the restricted 
sequence data available for certain herpesviruses, and of cross- 
hybridisation data ( Baumann et al.. 1986; Cull inane et al., 1988;
Davison and McGeoch, 1986; Davison and Taylor, 1987; Davison and 
Wilkie, 1983; Gompels et al., 1988a; Kouzarides et al., 1987; Lawrence 
et al.. 1990 ) several conclusions can be drawn. The most diverse
region of herpesvirus genomes is the short component such that viruses 
within the same biological subgroup possess significantly different 
coding arrangements in this region. For example, the short component of 
HSV-1 encodes 13 genes , 6 of which are unique to HSV-1, while that 
of VZV encodes 7 genes all of which have HSV-1 U$ homologues. Neither 
genome possesses homologues of genes within the corresponding region 
of the HCMV and EBV genomes (Davison and McGeoch, 1986). There are also
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significant differences in the arrangement of conserved S component 
genes in different alphaherpesviruses (Cullinane et al♦, 1988; Davison 
and McGeoch, 1986; Petrovskis and Post, 1987). Within the long 
component of the genome many genes are conserved throughout all 
herpesviruses sequenced to date with some arranged in conserved gene 
blocks . These include genes encoding DNA polymerase, the major DNA 
binding protein and two structural glycoproteins gB and gH. The number 
of genes which have homologues in other herpesviruses is obviously 
greater within a specific group such as the alphaherpesviruses than 
between groups and employing this criteria the beta- and 
gammaherpesviruses seem more closely related to each other than to the 
alphaherpesviruses.
Given the extent of gene conservation throughout the herpesvirus 
family it is evident that all herpesviruses are descended from a common 
progenitor. Analysis of the position of these counterparts in the 
respective genomes indicates that in the course of evolution large 
scale rearrangements have occurred since blocks of conserved genes 
arbitrarily designated order ABC in VZV (and HSV-1) are positioned as 
CA'B (where A' represents inversion) in EBV and HVS (Gompels et al.. 
1988a). Whether either of these gene orders corresponds to that of the 
progenitor is unknown. Small scale rearrangements have occurred at 
later stages in evolution as evidenced by the the 0.1-0.4 map unit 
inversion in PRV relative to that in other alphaherpesviruses (Davison 
and Wilkie, 1987).
As increasing sequence data becomes available it is becoming more 
feasible to consider the fine evolutionary relationships within the 
herpesvirus family and herpesvirus evolutionary trees have been 
constructed on the basis of the nucleotide sequence of single genes 
such as thymidine kinase and gB genes (Gentry et al.. 1988; Honess
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Figure 1.3
Derivation of Herpesvirus Evolutionary Trees from
Nucleotide Sequence Data
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Figure 1.3 Herpesvirus evolutionary schemes derived from the
analysis of the nucleotide sequence of genes encoding
thymidine kinase, a) Gentry et al.. 1988, b) Honess et al.. 
1989a, and glycoprotein gB, c) Whallev et al., 1989.
et al., 1989a; Whallev et al.. 1989) (Fig. 3).
4. Herpesvirus Life Cycle 
Herpesvirus lytic infection involves a series of events mediated by 
virus-specified and cell-specified factors which ultimately results in 
the release of infectious progeny from the infected cell (Fig. 4).
1) Virus entry
Two mechanisms have been proposed for the entry of herpesviruses 
into cells on the basis of electron micrography : i) entry within
phagocytic vesicles (viropexis) (Dales and Silverberg, 1969) , and ii)
fusion of virion envelope with cell plasma membrane releasing the
nucleocapsid . into the cytoplasm (Morgan et al.. 1968). The generally 
regarded view is that the latter mechanism is the major mechanism. 
Constituents of the virion envelope are important in facilitating viral 
entry into permissive cells since naked nucleocapsids and DNA have a 
significantly lower specific infectivity than intact virions (Stein et 
al.. 1970). In alphaherpesviruses initial adsorption seems to occur
through the interaction of virion constituents , identified as
glycoprotein g111 in BHV-1 and PRV (Mettenleiter et al.. 1990 ; Okazaki 
et al.. 1987), with heparan sulphate moieties on the cell surface
(Wu.Dunn and Spear, 1989). Although an HSV-1 glycoprotein with a direct 
role in this initial interaction has not been identified, 
glycoproteins have , however, been implicated in the stabilisation of 
adsorption through interaction with cellular receptors (Fuller and
Spear, 1985; Kuhn et al.. 1990).
The penetration process involves fusion of the envelope of an 
adsorbed virion with the plasma membrane of the host cell ( Morgan et 
al., 1968) and is mediated by viral glycoproteins such as gB, gD, and 
gH in HSV-1 (Spear, 1984) . Entry of intact herpesvirions .into cells
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Figure 1.4 Schematic representation of the herpesvirus lytic 
cycle (Ginsberg, 1980).
thus apparently involves interaction between several virion envelope 
glycoproteins and cell surface components.
2) Transcription
HSV-1 mRNA, like cellular RNA, is transcribed by host cell RNA 
polymerase II and is capped, polyadenylated, and internally methylated 
(Wagner, 1982). Transcription is temporally regulated through 
mechanisms mediated by virus-specified proteins. mRNAs are classified 
into three major groups - alpha (immediate early), beta (early), or
gamma (late) - according to their time of synthesis (Honess and
Roizman, 1974, 1975) : alpha mRNAs are synthesised prior to virus-
specified protein synthesis, beta mRNAs are synthesised in response to 
transactivation by products of the alpha mRNAs and prior to viral DNA 
replication, and gamma mRNAs are synthesised maximally ( ^ j  mRNAs)
or exclusively (  ^mRNAs) once viral DNA replication is underway
(Wagner, 1982).
3) Translation
HSV-l-specified proteins are synthesised in a temporally regulated 
manner in a cascade system subject to controls on abundance. As for 
mRNA classification, three general groups of proteins are distinguished 
- alpha, beta , and gamma. Alpha, or immediate early (IE), proteins 
are expressed abundantly without de novo protein synthesis from lhr
postinfection to around 6hr postinfection with a peak at 3-4hr
(Everett, 1987). Genes encoding these proteins map at or near the long
and short major repeats and encode 5 mRNA species which are translated 
into proteins involved in the regulation of expression of later
proteins. Beta, or early (E), proteins are expressed after alpha
proteins and prior to viral DNA replication at 3-6hr postinfection. 
They are encoded by genes which map throughout the genome in 
noncontiguous regions and include proteins such as DNA polymerase which
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are required for DNA synthesis. Gamma proteins are divided into two 
subsets , betagamma and true gamma, the latter expressed prior to DNA 
synthesis and the latter depending stringently on DNA synthesis prior 
to their expression. Genes encoding these proteins map throughout the 
genome and include structural virion protein genes (Wagner, 1982). 
Virus-specified proteins are subjected to co- and post-translational 
modification. Phosphorylation of several immediate early proteins and 
proteolytic cleavage and glycosylation of structural glycoproteins 
occur.
Functions have been assigned to approximately half of the proteins 
encoded by the 70 or so distinct genes of HSV-1 (McGeoch et al.. 1988a; 
Roizman, 1978). Enzymes include DNA polymerase, thymidine kinase, 
ribonucleotide reductase, protein kinases, and DNAses, required 
directly, or indirectly , for viral DNA replication, host shut-off, and 
virion assembly. Regulatory proteins include immediate early proteins 
such as ICPO and ICP4 which regulate transcription of later HSV genes 
and presumably proteins which might contribute to establishment or 
maintenance of a latent state. Structural proteins include constituents 
of the capsid, tegument and virion envelope including the 
glycoproteins.
4) Viral DNA replication
Replication of herpesviral DNA occurs in a semi-conservative manner 
and utilises both host-cell and virus-specified gene products 
(Challberg and Kelly, 1989). Replication of viral genomes is believed 
to occur by the rolling circle model since this would account for the 
presence of extensive head-to-tail concatamers of HSV-1 DNA in infected 
cells late in infection (Jacob et al.. 1979; Jongeneel and
Bachenheimer, 1981; Rabkin and Hanlon, 1990). The site of DNA 
replication initiation is dependent on the position of cis-acting
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origin sequences of which there may be up to three depending on the 
type of herpesvirus (see chapter 5). HSV-1 encodes 7 functions
essential for viral DNA replication^ McGeoch, et al., 1988b)
including a major DNA binding protein (ICP8), DNA polymerase , an 
accessory DNA binding protein (65K DBP), an origin-binding protein 
(OBP), and a putative helicase/primase . There is evidence to suggest 
that some of these proteins are associated in a functional multi enzyme 
complex (Vaughan et al., 1984). DNA isolated from virions is
susceptible to fragmentation on denaturation with alkali indicating 
that gaps exist within the double stranded genome. It is still not 
clear whether these occur at unique or random sites and it is thought
that at least some of these gaps may be a consequence of incorporation
of ribonucleotides into the replicating DNA polymer possibly as 
constituents of the RNA primers of synthesis.
5) Virion assembly
The core and capsid are assembled within the nucleus. Envelopment 
of the capsid by a budding process through several internal membranes, 
most notably the inner nuclear membrane, has been observed by electron 
microscopy (Roizman and Furlong, 1974).
6) Virus egress
Several theories exist as to how the enveloped virion is 
transported to the extracellular space : the continuous theory proposes 
that the virion travels through the ER and is released at a point of 
connection between the ER and the plasma membrane; discontinuous 
theories propose i) that capsids bud into and out of any cellular
membrane and that the envelope is derived from the last membrane 
encountered , or ii) that virions are transported in vacuoles and
secreted from the cell (Roizman, 1978).
The effect of productive herpesvirus infection is cellular death
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due to inhibition of cellular processes such as DNA, RNA, and protein 
synthesis, so-called host shut-off, alteration in organelle structure 
and alteration of the immunological characteristics of the plasma 
membrane.
5. Latency
Latency , the ability to remain within the host for a long period of 
time following primary infection with the potential to reinitiate 
productive infection, is a characteristic of herpesviruses (Hill, 1982; 
Roizman, 1982). In the course of primary lytic infection a proportion 
of the progeny virus enter specific target cells, primarily neurones in 
the case of HSV-1, lymphocytes in the case of EBV, in which a non­
productive latent infection is maintained. On entry into these cells 
the virus is no longer directly accessible to host immune defence 
mechanisms. The host and/or viral factors which favour establishment 
and maintenance of latency as opposed to lytic infection have yet to be 
formally identified although lymphokines have been implicated in the 
maintenance of MDV latency (Buscaglia and Calneck, 1988). Virus- 
specified gene products involved in establishment and maintenance of 
latency would be expected to be immediate early or early functions 
since expression of beta or gamma genes would presumably lead to lytic 
cycle events.
In the latent state the viral genome seems to be maintained in 
various forms - HSV-1 as circular or concatameric molecules 
(Mellerick and Fraser, 1987), PRV as circular, concatameric or linear 
molecules (Rziha, 1986), and EBV as a super-coiled plasmid or 
integrated genome (Lindahl et al., 1976; Matsuo et al., 1984) - and is 
subject to limited expression. Transcripts expressed during HSV, PRV, 
and BHV-1 latent infection (latency-associated transcripts or LATs) 
have been characterised (Cheung, 1989; Rock et al., 1987; Wagner et
12
al.. 1988 ) - these are partially complementary to immediate early (IE) 
gene products, ICPO in the case of HSV-1 or the sole IE gene in PRV , 
and have thus been implicated in a role in the establishment and 
maintenance of latency by repressing expression of IE genes (Stevens et 
al.. 1987). However, recently LAT" HSV-1 mutants which can establish
latency have been isolated but which are defective in reactivation 
suggesting that LAT transcripts may be important in reactivation from 
latency rather than in establishment of latency (Javier et al.. 1988;
Steiner et al.. 1989). Other gene products implicated in latency are 
thymidine kinase (TK) and ribonucleotide reductase (RR). The isolation 
of TK- and RR-deficient mutants capable of latent infection but
impaired in reactivation has , as with LAT transcripts, implied that
these functions are important for reactivation rather than for
establishment or maintenance (Jacobson et al.. 1989a; Tenser et al.,
1989).
Reactivation of latent HSV results in productive infection with
resultant death of the host cells and infection of peripheral tissues 
via axonal transport of infectious virus. This may or may not result in 
clinical disease. Mechanisms by which reactivation is triggered are 
unknown although they are known to be initiated by external or internal 
stimuli such as physical trauma or stress (Hill, 1982).
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HERPESVIRUS GLYCOPROTEINS
Herpesvirus glycoproteins are important in virus attachment and 
penetration into host cells and in the envelopment of progeny virions, 
membrane fusion events and egress. They thus play a role in the 
determination of host range, tissue tropism, and in the mediation of 
cell-virion interaction and cell-cell interaction. Furthermore, they 
are important targets of host humoral and cellular immune responses
given their localisation on the surface of virions and of infected
cells and their consequent exposure to the immune system (Norrild, 
1985; Spear, 1984 ). Several herpesvirus glycoproteins form
morphologically identifiable entities , so-called 'spikes,7 which 
protrude from the surface of the envelope. Analysis of HSV-1 virions
has revealed that gB and gD form distinct spikes (Stannard et al..
1987).
Herpesvirus glycoprotein complements have been determined by the 
radioactive labelling of virion surface components and their resolution 
by electrophoresis or isoelectric focussing. Such techniques are 
limited in that i) low abundance glycoproteins might not be detected, 
ii) co-migrating glycoproteins might not be distinguished, iii) 
different virus growth conditions and electrophoretic conditions result 
in different mobilities for proteins, making the comparison of 
glycoprotein profiles presented by different laboratories difficult, 
and iv) without further investigation the relationship between 
different proteins in terms of co- and post-translational processing is 
unknown. Perhaps the most straightforward analysis of herpesvirus 
glycoprotein complements is performed at the genome level through the 
determination of the number, map position, and coding characteristics 
of glycoprotein genes by nucleotide sequence analysis. Putative 
glycoprotein-encoding genes are identified by the potential of the
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predicted polypeptide product to possess one or more of the following 
features - i) an N-terminal hydrophobic 'signal sequence' which is 
required for insertion of the primary translation product during 
synthesis into the endoplasmic reticulum , ii) a further hydrophobic 
sequence - the transmembrane domain (TMD) - towards the C-terminal end 
which is required for passage through the bilayer of cellular membranes 
or virion envelope, iii) a charged region of amino acids downstream of 
the predicted TMD, and iv) N-X-S/T amino acid sequences in the region 
of the polypeptide N-terminal to the TMD which might serve as targets 
for N-linked glycosylation. Such analysis is currently limited by the 
amount of complete genome sequence data available since this has been 
reported for only HSV-1, VZV, HCMV, and EBV. Antigenic, functional, and 
biochemical investigation of glycoprotein species will ultimately 
lead to the identification of the product(s) of each glycoprotein 
gene, their relatedness to each other in terms of post-translational 
processing, their similarity to glycoproteins specified by other 
herpesvirus, and their function(s). Identified homologues of HSV-1 
glycoproteins in other herpesviruses are presented in Table 1.
HSV-1 specifies at least eight envelope glycoproteins - gB, gC, gH, 
gD, gE, gG, gl, and gJ - which are located on the virion envelope and 
on the surface of infected cells (Gao and Spear, 1990; McGeoch et al.. 
1988a; Spear, 1984). Five HSV-1 glycoproteins , gD, gE, gG, gl, and 
gJ, are encoded within the U$ component of the genome. The full 
complement of functions of these glycoproteins has yet to be 
determined. However, functional and mutational studies have revealed 
several roles for glycoproteins in the virus life cycle. gB, gD, and 
gH are essential for viral replication in vitro (Cai et al.. 1988;
Desai et al., 1988; Little et al.. 1981 ) and are involved in
virus penetration (Fuller and Spear, 1987; Fuller et al.. 1989;
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Highlander et al., 1988). gH is involved in viral egress and cell- 
cell spread of virus (Buckmaster et al.. 1984). gB and gC may be 
important in natural killer cell recognition (Bishop et al.. 1986) and 
in cell-mediated immunity (Rosenthal et al.. 1987). Glycoproteins gC, 
gE, gG, and gl are nonessential for viral replication in vitro ( 
Holland et al.. 1984a; Longnecker and Roizman, 1987; Weber et al., 
1987).
Three HSV-1 glycoproteins elicit the production of antibody which 
will neutralise viral infectivity in the presence or absence of 
complement , gB* gD, and gH , the major target being gD (Para et al.. 
1985; Spear, 1984 ). Other glycoproteins , including gC, specify 
complement-dependent neutralising epitopes. Three glycoproteins of 
HSV-1 have been implicated in the modulation of the host immune
reponse: gE and gl in complexed form bind the Fc portion of IgG (
Johnson et al., 1988; Para et al.. 1982) and gC binds complement
component C3b fragment (Friedman et al.. 1984; McNearney et al.. 1987).
VZV specifies six to eight major glycoproteins which associate in 
three complexes - gpl, gpII, and gpIII - on the basis of reactivity of 
the glycoproteins with monoclonal and polyclonal antibody preparations 
(Davison et al.. 1986). These glycoproteins elicit virus-neutralising 
antibody and apparently possess all the virus-neutralising epitopes of 
the VZV virion reported to date with gpl the most immunoreactive and 
abundant followed by gpll and gplII (Keller et al., 1984, 1986). The
nucleotide sequences of genes encoding gpl, gpII, and gplII and two 
minor glycoproteins , gpIV and gpV have been determined (Davison,
1983; Davison and Scott, 1986; Davison et al., 1985; Keller et al..
1987 ). All five VZV glycoprotein genes have counterparts in HSV-1
(Table 1).
PRV specifies at least 7 glycoprotein species , the genes for 6 of
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Table 1.1
Analogues of HSV-1 glycoproteins identified 
within specific herpesviruses
HSV-1 VZV PRV BHV-1 EHV-1 EHV-4 HCMV EBV
gB gpll gll gi gpi4 gp58 gpllO
gC gpV gill gill gpl3 - -
gD - gp50 grv gD - -
gE gpl gi gll gE gE - -
gG - gX - -
gH gpin gn gn gp86 gp85
gi gpIV gp63 gi - -
gJ — - -
Table 1.1 Analogues of HSV-1 glycoproteins as identified by 
analyses of viral proteins or nucleotide sequence data. Dashes 
indicate no analogue exists; blanks indicate published data is 
insufficient to determine whether an analogue is or is not 
encoded.
which have been mapped and sequenced - gl, gll, gill, gp50, gp63, and 
gX (Hampl et al., 1984; Mettenleiter et al., 1986; Petrovskis et al., 
1986a,b; Rea et al., 1985; Robbins et al., 1984, 1986a, 1987; Wathen
and Wathen, 1984, 1986). Two further glycoproteins, gIV and gV, have 
been identified in cell extracts. The relationship of these gene 
products to the mapped glycoprotein genes is unknown although it has 
been speculated that the gp50 gene may encode either gIV or gV. A gH- 
type glycoprotein has yet to be identified in infected cell extracts 
but a homologue of the HSV-1 gH gene has been mapped to the central 
region of (Petrovskis et al.. 1988). Four glycoproteins are
nonessential for viral replication in vitro - gl, g111, gp63, and gX. 
gX, the homologue of HSV-1 gG is secreted into the medium and is not a 
virion component (Rea et al.. 1985). One of the essential
glycoproteins, gp50, is unusual in that it has no sites for potential 
N-linked glycosylation (Petrovskis et al., 1986a). Glycoproteins gl and 
gp63 are functional as a complex and , with gIII, affect virus 
virulence (Zuckermann et al.. 1988). gIII is also important for the 
adsorption of virions to cells (Schreurs et al.. 1988).
The glycoprotein complement of beta and gamma herpesviruses is 
significantly different from that of the alphaherpesviruses and is 
likely to be a major factor contributing towards the difference in 
biological properties manifested by herpesviruses of the three 
subgroups. Only two virion glycoprotein species are conserved 
throughout members of all three subgroups of the herpesvirus family - 
glycoproteins gB and gH (Baer et al.. 1984; Cranage et al.. 1986, 1988; 
Davison and Scott, 1986; Gompels and Minson, 1986; McGeoch and Davison, 
1986; McGeoch et al.. 1988a; Mettenleiter et al., 1986; Petrovskis et
i
al., 1988) (Table 1) . This implies these glycoproteins have an
essential role in the herpesvirus life cycle.
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EHV-1 AND EHV-4 
1. Eauine Herpesviruses
The equine herpesviruses comprise a group of serologically distinct 
herpesviruses of related biological and biochemical features 
(Plummer et al.. 1973; O'Callaghan et al♦, 1983). Four types of equine 
herpesviruses are officially recognised by the International Committee 
on nomenclature of viruses - EHV-1, or equine abortion (Randall et 
al., 1953), EHV-2, or equine cytomegalovirus (Plummer and Waterson,
1963), EHV-3, or equine coital exanthema virus (Ludwig et al.. 1971),
and EHV-4, or rhinopneumonitis virus (Studdert et al., 1981). One
further candidate EHV type has been proposed, EHV-5, a novel equine 
betaherpesvirus (Browning and Studdert, 1987a).
The equine betaherpesviruses are ubiquitous viral agents present in 
approximately 90% of the equine population (Kemeny and Pearson, 1970). 
These viruses are associated with upper respiratory tract disease 
(Blakeslee et al.. 1975) and immunosuppression in foals ( Browning and 
Studdert, 1987b; Sugiura et al.. 1983) although they have yet to be 
identified as a causative agent of these disorders. Viral isolates 
differ in their growth rate with a cytopathic effect being manifested 
from 24 hours to one month post infection although the majority of 
isolates tend to exhibit the characteristically slow growth of 
cytomegaloviruses in general and their cell-associated nature 
(O'Callaghan et al., 1983). They also exhibit a narrow host cell range 
(Wharton et al.. 1981) and have the capacity to establish persistent 
infection (O'Callaghan et al.. 1983). Two serologically distinct 
types of cytomegalovirus have been identified - EHV-2, and EHV-5 - 
which differ in their genome size, EHV-2 being 192 kbp and EHV-5 ,148 
kbp, and which have limited sequence homology (Browning and Studdert, 
1987a). The genome of EHV-2 is unusual in structure in that it
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comprises a unique region (m.u. 0.09-0.83) flanked by repeat elements 
(m.u. 0.00-0.90 and 0.83-1.00). The 0.00-0.09 repeat consists of two 
2.4kbp repeats flanking a 6kbp unique sequence. Apparently only one 
genomic isomer exists (Browning and Studdert, 1989; Colacino et al♦,
1989). Such a genome structure does not strictly fit into any of the 
five genome classes specified by Roizman (1982). The EHV-2 genome 
shares less than 3% homology with EHV-3 and EHV-1 genomes (Staczek et 
al., 1983; Wharton et al.. 1981 ).
Three equine alphaherpesviruses have been identified - EHV-1, EHV-3, 
and EHV-4. EHV-3, or equine coital exanthema virus, induces lesions on 
the external genitalia and, less commonly, on facial features 
(O'Callaghan et al.. 1983). Mild systemic disease may occur. EHV-3 does 
not seem to induce abortion in nature or in experimental situations . 
The 96MDa EHV-3 genome possesses a group D type structure akin to that 
of EHV-1 and EHV-4 and exists in two isomeric forms as a consequence of 
recombination at the inverted repeats (Sullivan et al.. 1984). Cross
neutralisation does not occur between EHV-3 and EHV-1 implying the 
viruses are antigenically distinct. Sequence homology does , however, 
exist between the EHV-1, EHV-4, and EHV-3 genomes at limited regions
throughout the genome in a col inear manner ( Baumann et al.. 1986 ).
No homology was detected between the unique short components of the 
EHV-1 and EHV-3 genomes suggesting that the diverse gene products in U$ 
of the two viruses may be responsible in part for the different 
biological characteristics of these viruses.
EHV-1 and EHV-4 are the most important of the equine herpesviruses
in economic terms. Considerable financial losses are incurred by the
horse racing and stud industries as a consequence of the illness and 
death of racing and stud animals and their offspring through the 
respiratory, abortigenic , or paralytic sequelae of infection by these
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viruses. Virus-induced abortion in mares was initially reported in
1933 (Dimmock and Edwards, 1933). By 1954 it became apparent that the 
viral agent involved, named equine abortion virus (EAV), was also 
associated with respiratory disease in young horses (Doll and Wallace, 
1954). Two viral subtypes were subsequently distinguished on the basis 
of serological characteristics and pathological characteristics, one , 
subtype 1, being frequently isolated from aborted foetal tissue and the
other, subtype 2, from respiratory tract tissue (Burrows and
Goodridge, 1973; Shimizu et al.. 1959 ). It became clear that the two 
subtypes differed not only in their antigenic and pathogenic 
characteristics but also in their in vitro host range and in the
electrophoretic mobility of their structural proteins ( Allen and
Bryans , 1986; Studdert and Blackney, 1979; Turtinen et al., 1981).
Analysis of the genomes by restriction endonuclease analysis and by 
liquid hybridisation indicated that the viruses are genetically 
distinct (Allen and Turtinen, 1982; Allen et al.. 1983b; Sabine et 
al.. 1981; Studdert, 1983; Studdert et al.. 1981) bringing about the
proposal that the two subtypes be redesignated as separate viral
types, EHV-1 subtype 1 becoming EHV-1, and EHV-1 subtype 2, or equine 
rhinopneumonitis virus, becoming EHV-4. This revised nomenclature was 
ratified by the International Committeeon Virus Taxonomy in 1987.
All equine herpesviruses studied to date are capable of inducing 
oncogenic transformation in primary hamster embryo cells and of 
establishing persistent infection (O'Callaghan et al.. 1983). However, 
there is no evidence that equine herpesviruses are associated with 
cancer in the horse.
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2. EHV-1 and EHV-4 Pathogenesis
EHV-1 and EHV-4 are a major cause of acute viral respiratory 
disease in horses. Although primarily respiratory pathogens the
viruses can also induce abortion in susceptible hosts , neurological
disease and, in rare cases, mild coital exanthema (Bryans and Allen, 
1973; O'Callaghan et al♦, 1983) (Fig. 5). The viruses are endemic in 
horse populations worldwide and may also infect and cause disease in 
ruminants (Chowdhury et al., 1988; Crandell et al.. 1988). In Great 
Britain horses are exposed to EHV-1 or EHV-4 for the first time at a 
young age, usually within their first year of life. . Sources of
infectious virus include virus shed from infected cohorts, aborted 
foetal tissue and infected bedding or food (O'Callaghan et al., 1983).
Following primary infection the animal is immune to reinfection for 
only 3-6 months (Bryans, 1969). Horses can thus be infected 
periodically throughout their life.
The frequency with which EHV-1 and EHV-4 are identified as the 
causative agents of respiratory disease and abortion varies from 
country to country . A study of 246 American and Canadian isolates 
between 1960 and 1984 revealed that 99% of abortions were caused by 
EHV-1 and 86% of respiratory disease incidences by EHV-4 ( Allen and
Bryans, 1986; Allen et al., 1983b). Similar analysis of 43 EHV-l/EHV-4 
isolates from Australian horses revealed EHV-1 as the cause of 86% of 
abortions and EHV-4 as the cause of all cases of respiratory disease 
(Studdert, 1983). In Australia EHV-1, apparently introduced into the 
continent in 1977, is primarily associated with abortigenic sequelae 
with only one published incidence of EHV-1 induced paresis and none of 
EHV-1 induced respiratory disease (Sabine and Whalley, 1989) . There is 
evidence that the dominance of the two types of virus, and even of 
specific virus strains (Allen and Bryans, 1986) with respect to
21
Figure 1.5
Clinical Manifestations of EHV-1 and EHV-4 Infections
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Figure 1^5 Pathogenesis of EHV-1 and EHV-4. Adapted from Allen
and Bryans, 1986.
Ta
rg
et
 
ce
ll
 
ty
pe
 
- 
ep
it
he
li
al
 
ce
ll
s 
of
 
Ta
rg
et
 
ce
ll
 
ty
pe
 
- 
le
uk
oc
yt
es
 
Ta
rg
et
 
ce
ll
 
ty
pe
 
- 
en
do
th
el
ia
l 
ce
ll
s 
of
 
bl
oo
d 
ve
ss
el
s 
re
sp
ir
at
or
y 
tr
ac
t,
 
en
do
th
el
ia
l 
ce
ll
s 
of 
wi
th
in
 
br
ai
n 
an
d 
sp
in
al
 
co
rd
 
lo
ca
l 
bl
oo
d 
ve
ss
el
s
severity and nature of disease (i.e. whether respiratory or 
abortigenic) may vary temporally. For example, prior to 1979 in the 
U.K. EHV-4 was the major cause of respiratory disease. However, in 
recent years EHV-1 has been isolated from a significant number of 
'respiratory isolates' and has been the major respiratory pathogen in 
certain years (Anon, 1989).
1) EHV-1- and EHV-4-induced respiratory disease
The usual entry route of EHV-1 and EHV-4 into the host is via the 
upper respiratory tract and as a consequence of this, and of the tissue 
tropism of the viruses, initial viral replication occurs in the 
respiratory epithelium. First exposure to EHV-1 or EHV-4 in foals 
often results in an acute febrile respiratory infection which may last 
up to one week (O'Callaghan, et al.. 1983). EHV-1 induced respiratory 
disease tends to be more severe than EHV-4 induced disease since more 
virus tends to be produced in an EHV-1 infection. However, fatalities 
from EHV-induced respiratory disease are rare and often result from 
secondary bacterial infection rather than from respiratory sequelae . 
Virus is disseminated from the respiratory tract to draining lymph 
nodes by macrophages. EHV-1 can also infect endothelial cells of blood 
vessels lining the respiratory tract and of the brain ( Patel and 
Edington, 1983; Patel et al., 1982). An important difference between 
the two viruses is that although both viruses can be recovered from the 
respiratory tract up to 12 days post infection, only EHV-1 is routinely 
recovered, from 2-12 days post-infection, from the white cell 
population due to leukocyte-associated viraemia (Bryans, 1969). 
However, transient EHV-4 viraemias do seem to occur (A.A. Cullinane, 
personal communication). With increased exposures to virus, resistance 
develops against clinical respiratory disease such that an infected 
horse may suffer only mild respiratory symptoms or incur loss of form
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or fitness with no definitive clinical symptoms. In such cases it may 
not be readily apparent that the causative agent is EHV-1 or EHV-4 and 
diagnosis may require identification of the pathogen by virus isolation 
or serological analyses .
Resistance to reinfection is limited to a 3-6 month period following 
infection. Subsequent infections result in productive infection of the 
upper respiratory tract ( with shedding of virus into the environment), 
a cell-associated viraemia , a secondary immune response and in some 
animals abortion or neurological disease (Bryans, 1969). It is the 
latter sequelae of abortion and neurological disease , rather than 
respiratory sequelae, which pose a serious potential threat to the life 
or well-being of the infected animal or its unborn young.
2) EHV-1 and EHV-4-induced abortion
As stated above both EHV-1 and EHV-4 induce abortion in 
susceptible mares. Infection by EHV-1 may lead to sporadic abortion 
from a single mare or may result in a multiple-abortion storm. In 
contrast, EHV-4 is associated with sporadic abortions and reports of 
EHV-4 -induced multiple abortion storms are exceedingly rare. 
Herpesvirus induced abortions tend to occur from months 8 to 12 (Doll, 
1952; Doll and Bryans, 1963). The cause of foetal death is hypoxia due 
to separation of the placenta from the endometrium (Bryans and 
Prickett, 1972). Foals infected with EHV-1 or EHV-4 in utero and 
born alive tend to die soon after birth as a consequence of EHV-induced 
tissue damage and their increased susceptibility to secondary bacterial 
infection ( Hartley and Dixon , 1979). It is thought that EHV-1 reaches 
the foetus by transplacental transport of EHV-1 infected leukocytes. 
Since EHV-4 viraemia is occasionally detected it seems possible that 
EHV-4 might reach unborn animals by a similar route. Mares infected 
with EHV-1 may show no outward manifestation of disease due to a
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resistance to respiratory symptoms and thus multiple abortions may 
occur within a cohort without prior indication of EHV-1 infection.
3) EHV-l-induced neurological disease
EHV-4-induced neurological disease is extremely rare with few 
instances reported (Meyer et al.. 1987). Thus, it is not generally 
regarded as a neurological pathogen. EHV-1, however, causes 
neurological damage with greater frequency and paralytic outbreaks 
result in serious economic losses in stud and racing stables. EHV-l- 
induced neurological disease is a consequence of the infection of 
endothelial cells of central nervous system blood vessels by virus 
transported in the blood in association with leukocytes (Allen and 
Bryans, 1986). Nervous tissue damage is incurred due to hypoxia and 
inflammatory responses which result from endothelial infection (Patel 
et al.. 1982). Clinical symptoms in affected horses range from mild
lack of co-ordination and weakness to paresis, ataxia, and paralysis, 
usually of the hindlimbs. Horses suffering mild disease may recover 
fully or may be left with mild neurological disabilities. Horses with 
more severe symptoms have a poorer prognosis and may die as a 
consequence of secondary bacterial infection, pulmonary congestion or 
paralytic sequelae. As yet no marker has been discovered which 
distinguishes neurological strains of EHV-1 from abortigenic strains. 
The general view is that a combination of host suceptibility and virus 
neurotropicity lead to the development of neurological sequelae (Allen 
and Bryans, 1986).
3. EHV-1 and EHV-4 Genome Structure
1) Standard genomes
The EHV-1 and EHV-4 genomes are type D genomes in that they are 
composed of a long component ( L or Ul ) of 111kbp and 109kbp and a
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short component ( S) of 39kbp and 35kbp respectively, the latter of 
which comprises a short unique sequence (U$) bounded by identical 
inverted repeat elements (IR$ and TR$) (Baumann et al., 1986 ;
Cull inane et al., 1988; Henry et al., 1981; Ruyechan et al., 1982;
Whalley et al.. 1981 ). The %GC content of the EHV-1 genome is 57%
(Soehner et al., 1965) while that of the EHV-4 genome has not been 
determined. Isomerisation of the EHV-1 genome is known to occur such 
that two isomers exist differing with respect to the orientation of the 
S component relative to the ! component . This was deduced by analysis 
of the molarity of terminal restriction fragments relative to that of 
restriction fragments mapping internally ( Henry et al.. 1981; Whalley 
et al., 1981). Predicted BamHI and EcoRI terminal restriction fragments 
of the two hypothetical isomers of EHV-4 are of similar size thus 
isomerisation of the EHV-4 genome has not yet been experimentally 
proved (Cullinane et al.. 1988 ). However, it seems likely that as for
EHV-1 , the EHV-4 genome exists as two isomers. Restriction maps of
EHV-1 strain HVS-25 and of EHV-4 strain 1942 have been reported and
are detailed in Figure 6 (Cullinane et al., 1988; Robertson and
Whalley, 1988; Whalley et al.. 1981).
Comparison of the EHV-1 and EHV-4 genomes to those of other 
alphaherpesviruses by Southern hybridisation indicates that the U|_ 
components of EHV-1 and EHV-4 are apparently col inear with each other 
(Cullinane et al., 1988) and with the corresponding regions of EHV-3 
(Baumann et al.. 1986), HSV-1 (II isomer), HSV-2, and VZV ( Davison 
and Wilkie, 1983) . The Ul component of PRV is colinear apart from 
map units 0.1-0.4 which are inverted relative to this region in 
the other genomes mentioned (Ben-Porat et al.. 1983; Davison and 
Wilkie, 1983).
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Figure 1.6 
EHV-1 and EHV-4 Genome Restriction Maps
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Figure 1.6 BamHI and EcoRI restriction maps of EHV-1 (strain 
HVS25, Whalley et al., 1981; Robertson and Whalley, 1988) and 
EHV-4 (strain 1942, Cullinane et al., 1988).
2) Defective genomes
Passage of EHV-1 and EHV-4 at high multiplicity results in the 
generation of defective interfering particles (DIP) (O'Callaghan et 
al., 1983) which inhibit the replication of standard virus. EHV-1
defective interfering particle genomes are composed of DNA derived from 
map units 0-0.4 (left end of Uj_), 0.78-0.79 and 0.83-0.87 (IRg), and
0.91-0.95 and 0.99-1.00 (TR$) of the standard EHV-1 genome (Baumann et 
al., 1987). Studies of herpesvirus DI particle replication have
indicated that DI DNA specifies cis-acting sequences such as cleavage- 
encapsidation signals and origins of replication (Frenkel et al., 1980) 
but that replication is dependent on functions supplied in trans by 
standard viral DNA sequences. Analysis of DI genomes has led to the 
mapping of an origin of replication within the central region of the 
inverted repeats of EHV-1 (Baumann et al, 1989).
3) Genetic diversity of EHV-1 and EHV-4 genomes
An indication of the genetic diversity of EHV-1 and EHV-4 can be 
obtained through the analysis of the banding pattern of viral DNA 
fragments produced by digestion of genomic DNA with restriction 
enzymes. Viral isolates with different arrangements of restriction 
endonuclease cleavage sites throughout the genome possess distinct 
electropherotypes. As mentioned above, this technique distinguishes 
between EHV-1 and EHV-4 field isolates since the viruses have no 
common restriction sites (Allen et al., 1983b). Extension of such 
analyses to isolates of a given virus type enables the determination of 
the variabilty in number and position of restriction enzyme sites and 
thus of the genetic diversity of the viruses. Comparison of the 
electropherotypes of individual U.S.A. field isolates of both viruses 
by Allen and Bryans (1986) indicated that EHV-1 is less diverse than 
EHV-4 . Of 235 USA field isolates of EHV-1, 90% possessed one of two
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dominant electropherotypes out of a total of 16 identified 
electropherotypes. In contrast, 13 electropherotypes were identified 
within 21 EHV-4 isolates and of these, 50% had unique 
electropherotypes. Similar studies have yet to be performed on British 
EHV-1 and EHV-4 isolates.
Liquid hybridisation of EHV-1 and EHV-4 by Allen and Turtinen (1982) 
suggested the genomes share only 17% homology at the nucleotide level. 
A more accurate analysis of the homology of the two genomes would be 
achieved by comparison of their nucleotide sequences and on the basis 
of sequence data available for restricted regions of the U[_ component 
of EHV-1 and EHV-4, 17% would appear to be an underestimate (see 
Chapter 8).
4. Virus Propagation
1) Transcription
Investigation of the transcription of EHV has been restricted mainly 
to EHV-1. In EHV-1 transcription is coordinately regulated such that 
immediate early, early and late phases can be distinguished as in HSV 
transcription (Gray et al.. 1987a). EHV-1 apparently specifies only one 
immediate early (IE) transcript of 6kb derived from part of the 
inverted repeats (m.u. 0.79-0.83 and 0.96-1.00) . At least four
antigenically related IE proteins are derived from the transcript by 
differential 5' splicing events . A similar IE transcriptional and 
translational arrangement is found in PRV (Fenwick and McMenamin, 
1984). It has been suggested that different splicing patterns of the IE 
transcript may exist within persistently infected and oncogenically 
transformed cells. A gene homologue of HSV-1 US1 which encodes 
immediate early protein Vmw68 has been identified in EHV-4 U$. However, 
immediate early transcripts have yet to be associated with this region
27
of the EHV-4 or EHV-1 genome (Cull inane et al., 1988). Around 45 early 
and 20 late transcripts have been identified (Gray et al., 1987b).
2) Translation
EHV-1 protein synthesis is coordinately regulated in a manner 
similar to that in HSV with immediate early, early, and late phases 
(Caughman et al., 1985, 1988). Four antigenically related immediate- 
early proteins are synthesised, IEl, IE2, IE3, and IE4, which are 
presumably important trans-acting regulatory proteins serving to 
activate early gene expression (Caughman et al.. 1985). 18 early
(beta) and 12 late proteins (beta/gamma rather than true late proteins) 
have been identified. Around thirty virion polypeptides have been 
identified which are distributed between the core of the virion, the 
nucleocapsid, the tegument , and the envelope. Although most of the 
proteins isolated from EHV-1 virions have electrophoretic counterparts 
in EHV-4, at least 8 have distinct electrophoretic mobilities in EHV-1 
and EHV-4 (Allen and Bryans, 1986). Studies have indicated that the 
nucleocapsid contains six polypeptide species (Q'Callaghan et al., 
1983 ) including VP9 (148 kDa), VP22 (46kDa), and VP24. Scanning
electron microscopy studies have indicated that the 150 hexavalent
capsomers of the lOOnm capsid comprise hexamers of p9 (Baker et al.. 
1990; Newcomb et al.. 1989) which accounts for 55-75% of nucleocapsid 
protein (O'Callaghan and Randall, 1976). The constituents of the 
pentameric capsomers have yet to be determined. Eight putative tegument 
proteins have been identified and twelve envelope glycoproteins 
(Allen and Bryans, 1986; Turtinen and Allen, 1982).
3) Virus DNA replication
Replication of EHV DNA is believed to occur, as for other
herpesvirus genomes, by a rolling-circle mechanism. Consistent with 
this is the finding that the genomic termini of EHV-1 seem to comprise
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complementary 3' single-base extensions which could presumably base 
pair within the infected cell to circularise the genome. Sequence 
analysis of the terminal region of EHV-1 has also revealed potential 
signals for cleavage of concatameric replicated DNA (Chowdhury et al.,
1990).
5. EHV-1 and EHV-4 Glycoproteins 
EHV-1 and -4 specify at least twelve glycoproteins, eight of which 
are highly abundant within the virion envelope as identified by 
electrophoretic analysis of virion proteins (Allen and Bryans, 1986; 
Turtinen and Allen, 1982). These have been designated gp 2, 10, 13,
14, 17, 18, 21, 22a and assigned molecular masses of 200, 125, 95, 90,
68, 63, 45, and 41 kd respectively by Turtinen and Allen (1982) and
by Allen and Bryans (1986) . Ten glycosylated proteins of EHV-1 and 
nine of EHV-1 have been identified by similar techniques by Meredith 
and coworkers (Meredith et al.. 1989) and seven by Bridges et al ♦, 
1988 (Table 2). The relatedness of glycoproteins separated by different 
groups cannot be conclusively deduced from comparisons of mobilities 
since the mobility of the proteins depends not only on the 
electrophoretic system and running conditions but on the virus strain 
and cells in which the virus is propagated. Identification of 
glycoproteins will also depend on the labelling system used and the 
limits of sensitivity of the system. Glycoprotein homologues of HSV-1- 
specified glycoproteins have been identified by antigenic cross­
reactivity and, more recently, by sequence analysis (Table 1). Thus gC 
and gB-type EHV-1 glycoproteins and their genes have been identified by 
antigenic analyses, gene expression studies, and sequence data ( Allen 
and Coogle, 1988; Allen and Yeargan, 1987; Bell et al.. 1990; Guo et 
jLL, 1989; Whalley et al.. 1989). Currently two nomenclature systems
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Table 1.2 
Glycoproteins of EHV-1 and EHV-4
a)
EHV-1
b) c) a)
EHV-
b)
4
c)
250 (1) >250 (1 /2 ) 300 250 (1) >250 (1 /2 ) 300
190 -240 (2) - - 190 -240 (2) - 260
- - - -■ - 220
140 (9a) 143 (9 /9a) - - 147 (9 /9a) -
128 (10a) - - - - -
124 (10) 134 (10) 118 124 (10) 134 (10) 138
- - 108 - - 112
96 (13) 99 (13) 88 110 (13) 113 (13) 92
90 (14) 87 (14) 76 87 (14b) 94 (14a) 74
74 (16) - 66 74 (16) - -
68 (17) - 60 68 (17) - 61
63 (18) 64 (18) 58 61 (18) 62 (18) 59
45 (21) 46 (21) 45 45 (21) 46 (21) 45
41 (22a) - - 41 (22a) - -
- - - 33 (23a) - -
24 (25) - - 25 (25) - -
Table 1.2 Molecular weights of the envelope glycoproteins of 
EHV-1 and EHV-4 identified by three research groups, a) Turtinen 
and Allen (1982) and Allen and Bryans (1986), b) Bridges et al. 
(1988) , and c) Meredith et al. (1989) are presented. Authors' 
proposed designations of glycoproteins of specific molecular 
weights under the alternative nomenclature system, gpl3, gpl4 
etc. are indicated in brackets ( a) and b) only).
are in use - glycoproteins are identified either by their mobility 
relative to that of all proteins, as in gpl3 or gpl4 (Allen and 
Bryans, 1986), or by their molecular weight, as in gp88 or gp76 
(Meredith et al., 1989). As increasing data has become available it has 
become clear that although up to 12 glycoprotein species may be 
specified by EHV-1 and EHV-4 some of these glycoproteins are 
specified by the same gene and differ only in the extent of their post- 
translational processing. For example, three species have been
identified which react with gB polyclonal antisera. One of these, 
gpl08/gpl12, (EHV-l/EHV-4) is a precursor and the others , gp76/gp74
and gp58/59, mature glycoprotein subunits which are disulphide linked 
in active dimeric 'gB' but separated by electrophoresis under reducing 
conditions (Meredith et al.. 1989; Sullivan et al.. 1989) .
Little is known of the precise functions of equine herpesvirus 
glycoproteins although more is becoming known of the immunogenicity of 
individual glycoproteins.
6 . Sequence Data and Mapping Studies
Sequencing and mapping of EHV genes has been restricted to
glycoprotein genes and the immediate early gene to date although 
several other genes have been sequenced as a consequence of their 
proximity to the primary genes of interest. Allen and Yeargan (1987) 
were the first to report genomic positions of EHV-1 glycoprotein 
genes. They constructed a lambda gtll library of EHV-1 and identified 
recombinant bacteriophage expressing epitopes of six major
glycoproteins using anti-glycoprotein monoclonal antibodies. The
reported map positions of EHV-1 gpl3, gpl4, gplO, gp21/22a, gp2, and 
gpl7/18 are detailed in Figure 7. Genes gpl3 and gpl4 map at positions 
colinear with HSV-1 genes encoding gC and gB and sequence data has
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confirmed that gpl3 and gpl4 encode gC and gB homologues (Allen and 
Coogle, 1988; Hudson et al.. 1988; Whallev et al.. 1989). That only 
one gene was mapped to the U$ component which is usually the major site 
of glycoprotein genes in alphaherpesviruses and that no gH gene was 
mapped to the component suggests the technique used is limited to 
detection of highly abundant and/or immunogenic glycoproteins and that 
further glycoprotein genes will be mapped as increasing sequence data 
becomes available. To that end, the map positions of EHV-1 gH, gD, gl, 
and gE gene homologues have recently been elucidated on the basis of 
sequence analysis (Audonnet et al., 1990; Robertson and Whalley, 1988; 
Robertson et al., 1991). Several late proteins have been mapped to the 
U$ component of EHV-1 (Robertson et al., 1988). These might include 
products of gD, gl, gE, and as yet unreported U$ glycoprotein genes. To 
date no glycoprotein genes have been mapped in other herpesvirus 
genomes at positions col inear with those reported for gplO , gp2, or 
gp21/22a. Other genes sequenced in part or in entirety include the 
thymidine kinase gene (UL23), the major capsid protein gene (UL19) and 
gene homologues of HSV-1 genes UL15, UL18, UL24, UL25 , and UL28 
(Robertson and Whalley, 1988; Sabine and Whalley, 1989; Whalley et al., 
1989). In U$, an IE175 immediate early gene homologue and US9 gene 
homologue have been characterised (Audonnet et al., 1990; Grundy et 
al.. 1989).
Published EHV-4 sequence data is limited to gB (UL27) and UL28 gene 
homologues mapped to U|_ (Riggio et al.. 1989) and to gE (US8), US9,
US10, and IE68 (US1) gene homologues mapped to U$ (Cullinane et al,
1988).
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7. EHV-1 and EHV-4 Latency 
EHV-1 and EHV-4 are capable of persisting in the host in a latent 
state until reactivation is triggered and productive infection , with 
its potential for inducing pathological sequelae and virus spread, is 
reinitiated. Strategies for demonstration of latent infection are 
based on detection or experimental reactivation of latent genomes in 
an animal which has recovered from productive infection and include 
i) attempted isolation of virus from tissue explants, ii) demonstration 
of corticosteroid-induced reinitiated lytic infection in animals , iii) 
detection of viral genomes in situ or in whole tissue extract by DNA 
hybridisation, and , more recently, iv) detection of latent viral DNA 
using the polymerase chain reaction technique. The major evidence for 
EHV-1 and -4 latency until recently was circumstantial in nature and 
comprised a report by Burrows and Goodridge (1984) that EHV-1/4 
(untyped) had been isolated from ponies in a herd isolated from other 
horses for ten years. More recently the induction of reactivation of 
EHV-1 and EHV-4 by corticosteriod administration has been reported 
(Browning et al.. 1988; Edington et al.. 1985). The site of latency 
of EHV-1 and EHV-4 has not been firmly established. A common site of 
herpesvirus latency is ganglionic tissue yet attempts to consistently 
re-isolate EHV-1 or -4 from explanted ganglia of latently infected 
horses have been unsuccessful with one exception - the isolation of 
EHV-4 from a trigeminal ganglion (Allen and Bryans, 1986). Another 
common target tissue for herpesvirus latency is leukocytes (Roizman, 
1982) . On current evidence this seems the most probable site of EHV-1 
and -4 latency since EHV-1 is known to induce a cell associated 
viraemia infecting T and B lymphocytes and monocytes (Gleeson and 
Coggins, 1980; Scott et al., 1983) and although EHV-4 viraemia is 
comparatively rare, cases have been reported. Due to the differences
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in pathology of the two viruses it cannot be assumed, however, that the 
viruses have identical sites of latency (Mumford, 1985).
8 . The Equine Immune Response to EHV-1 and EHV-4 Infection
The importance of EHV-1 envelope and nucleocapsid antigens in 
inducing a virus-neutralising response in the host was established by 
Papp-Vid and Derbyshire (1978, 1979). Specific key antigens,
glycoproteins 2, 10, 13, 14, and , to a lesser extent, 22a and the
major capsid protein, VP9, were later identified by testing the 
reactivity of equine serum with whole viral proteins by an immunoblot 
procedure (Allen and Bryans, 1986). Glycoproteins 2, 10, 13, and 14 
were identified as type-common in that sera from convalescent horses 
infected with one viral type was reactive with these glycoproteins in 
immunoblots of both EHV-1 and EHV-4 protein preparations (Allen and 
Bryans, 1986). Glycoproteins 18, and 22a are thus apparently type- 
specific. Bridges and Edington (1987a) reported reactivity of equine 
sera with additional non-glycoprotein polypeptides, VP11, 15, 16, 20,
21, and 23a.
Monoclonal antibody studies have indicated that four types of EHV-1 
and EHV-4 epitopes exist - those which are present throughout all 
EHV-1 and EHV-4 isolates (type-common, conserved), those present in 
all isolates of one or other type (type-specific, conserved), those 
present in some isolates of both types (type common, variable), and 
those present only in some isolates of one type (type-specific, 
variable) (Allen and Bryans, 1986).
Cellular immune mechanisms may make a greater contribution to the 
protective immune response in horses than humoral immune mechanisms 
since virus neutralising antibody responses do not seem to correlate 
with resistance to infection ( Bryans, 1969; Mumford and Bates, 1984).
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Information on the key EHV-1 and -4 antigens stimulating a cellular 
immune response in equines is less extensive than the equivalent 
knowledge on humoral immune system targets. Bridges and coworkers 
(1988) found that fractions of EHV-1 proteins which contained 
glycoprotein were capable of inducing lymphocyte transformation. 
Responses were directed against fractions containing glycoproteins of 
molecular mass 140k (gp9a), 128k (gplOa), 124k(gpl0), 96k (gpl3), 90k
(gpl4),and 45k (gp21) of EHV-1 and 134k (gplO), 113k (gpl3), 94k
(gpl4), 62 (gpl8), and 46k (gp21) of EHV-4.
In general, the gross virus-neutralising and complement-fixing (CF) 
antibody response and T-cell mediated cytotoxic immune response are 
type-specific after primary infection but increase in their 
crossreactivity (to heterologous virus targets) following subsequent 
exposures to EHV (Allen and Bryans, 1986; Bridges and Edington, 1987b; 
Fitzpatrick and Studdert, 1984).
Antibody-dependent cellular cytotoxicity (ADCC) and complement- 
dependent lysis (CDL) mediation by sera of EHV-infected horses has been 
demonstrated . These activities , which do not appear to be involved 
in protection against reinfection, are crossreactive with targets 
infected with the heterologous virus (Bridges and Edington, 1987a; 
Stokes and Wardley, 1988).
Experimental primary infection of horses with EHV-1 or EHV-4 induces 
short-lived immunity to challenge by the homologous virus type but not 
to the heterologous virus type. However, following multiple 
administration of one viral type at suitable intervals, the horse is 
protected against challenge by both the administered virus type and the 
heterologous type (Allen and Bryans, 1986; Burrows et al., 1984;
Edington and Bridges, 1990; Fitzpatrick and Studdert, 1984; Mumford and 
Bates, 1984). Conflicting viewpoints exist on which virus type would be
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the more effective in a single virus vaccine preparation administered 
to protect against both EHV-1 and EHV-4-induced disease (Edington and 
Bridges, 1990; Fitzpatrick and Studdert, 1984). It has been suggested 
that a bivalent EHV-1/4 vaccine might be the most effective protective 
agent.
9. Immunoprophvlaxis and Chemotherapy
Two vaccines are at present marketed in the U.K. for protection
against EHV-1 and EHV-4 induced disease : Pneumabort-K , marketed
by ScanVet, a formaldehyde-inactivated oil adjuvant vaccine 
administered to prevent abortion and Rhinomune, marketed by Smith 
Kline, a live attenuated virus administered to protect against 
respiratory disease (Anon, 1987). Multiple, appropriately spaced 
administrations of both viruses are recommended by the manufacturers. 
These vaccines are of limited efficacy and , due to the financial
losses incurred as a result of EHV-1 and EHV-4 infections, development
of a more effective vaccine would be of some benefit to the equine 
industry.
The ultimate aim of a novel EHV vaccine would be to induce an immune 
response in the horse superior to that induced by current vaccines or 
indeed wild type EHV in terms of longevity and quality particularly 
with respect to protection against reinfection. Obviously a considered 
approach to the development of such a vaccine requires i) more 
information on the pathogenicity and latency of the viruses, ii) 
identification of the proteins, and ultimately epitopes, which are 
important in eliciting a protective immune response, iii) 
identification of virus-specified immunosuppressive functions or 
epitopes, and iv) further characterisation of the mechanisms of the 
equine immune response involved in protection against reinfection.
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A novel vaccine should possess the immunodominant epitopes with 
respect to a protective immune response. Since some of these may be 
type-specific or even strain-specific, identification of these epitopes 
would be beneficial to the selection of an optimal vaccine strain. 
However, such dissection of the antigenicity of the key glycoproteins 
is time-consuming and more empirical vaccine selection strategies have 
greater feasibility in the short term.
Approaches to the development of novel EHV vaccines are outlined in 
Figure 7. Four types of live vaccine could be developed - i) a
monovalent attenuated EHV-1 or EHV-4, ii) a bivalent EHV-1/4
recombinant comprising immunodominant glycoprotein genes of one virus 
inserted into the attenuated genome of the heterologous virus , iii) a 
recombinant in which genes of non-EHV origin are inserted into an
attenuated EHV-1 or EHV-4 genome, or iv) a recombinant comprising 
genes of EHV-1 or -4 inserted into a live vector other than EHV which 
can be safely administered to horses. The basis for three of these 
vaccines is an EHV-1 or EHV-4 vector from which virulence functions 
have been deleted. Functions linked to virulence in other herpesviruses 
include thymidine kinase, ribonucleotide reductase, gC, and in U$ 
several glycoproteins and a protein kinase (Cameron et al.. 1988; Kit 
et al.. 1987c;. Mettenleiter et al., 1988). Cornick and coworkers
(1990) produced an attenuated TK- EHV-1 virus by nucleoside analogue- 
induced mutagenesis. The contribution of TK deletion to overall 
attenuation was not, however, evaluated.
A major consideration in the development of live vaccines is their 
safety : the vaccine strain must be incapable of inducing severe
disease within the horse. It must also be borne in mind that vaccine 
virus could potentially recombine with wild type virus, either at the 
time of inoculation or at a later date, on reactivation, to produce a
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Figure 1.7
Potential vaccine design strategies for the
control of EHV-1 and EHV-4
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Figure 1.7 Schematic diagram outlining several approaches to 
the development of a novel vaccine against EHV-1 and/or EHV-4.
recombinant of unknown pathogenicity (Henderson et al., 1990).
Subunit vaccines could be developed comprising mixtures of several 
immunodominant EHV-1 or -4 proteins or of peptides derived from these 
proteins . Candidates for inclusion in subunit vaccines are obviously 
envelope glycoproteins since these have been associated with the 
humoral and cellular immune response in horses (Allen and Bryans, 1986; 
Bridges et al.. 1988) . However, it must be borne in mind that other 
virion components such as the major capsid protein and nonstructural 
polypeptides may be important particularly in eliciting cellular 
immunity (Martin et al.. 1988). The combination of gpl3 and gpl4 
expressed in vaccinia virus recombinants elicited a protective immune 
response in hamsters (Guo et al.. 1989, 1990) suggesting these might 
be potential subunit vaccine candidates. gH, gD, gpl7/18, and indeed as 
yet uncharacterised EHV glycoproteins , may specify epitopes which 
might be important constituents of an EHV vaccine of any type i.e. 
peptide, subunit, or live virus (Stokes et al.. 1989) . An ISCOM
vaccine containing the major glycoproteins of EHV-1 protects hamsters 
against lethal challenge with EHV-1 (Cook et al., 1990).
An alternative approach to the control of EHV-1 and EHV-4 is to 
develop antiviral therapies. Targets for antiviral drugs include 
ribonucleotide reductase and thymidine kinase enzymes (Field and Awan, 
1990; Telford et al.. 1990). The development and characterisation of 
hamster and mouse models of EHV infection should provide an opportunity 
to evaluate potential chemotherapeutic and immunoprophylactic 
strategies in the laboratory prior to expensive clinical trials in 
horses (Awan et al.. 1990; Stokes et al.. 1989).
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OBJECTIVE OF THE PROJECT
The objective of this project was to determine the localisation of 
specific EHV-4 genes with the aim of using this information in the
future development of recombinant EHV-1 or EHV-4 based vaccines. From 
the point of view of live EHV vaccine development three types of gene 
are of particular interest : genes specifying proteins which elicit a 
protective immune response; genes specifying functions involved in 
pathogenicity; genes encoding functions which are involved in
immunosuppression and/or mis-direction of the host protective immune 
response. On the basis of the background of information available on 
other herpesviruses, HSV-1 in particular, we selected three genes for 
investigation. The thymidine kinase (TK) gene was selected due to the 
apparent role of TK in herpesvirus virulence. Its localisation would 
ultimately enable construction of TK- EHV-4 recombinants which could be 
tested for reduced pathogenicity. The other genes selected were those 
encoding homologues of HSV-1 genes encoding gH and gC . Herpesvirus 
gC-type glycoproteins tend to be a major glycoprotein component of the 
virion envelope, specify neutralising antibodies , may stimulate 
cellular immunity, and, in the case of HSV-1 and HSV-2 gC at least, may 
interact with the host complement system. Herpesvirus gH-type
glycoproteins tend to be minor components of the envelope but 
nevertheless may be essential for viral replication and specify one or 
more epitopes which elicit a complement-independent neutralising
antibody response.
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CHAPTER 2 
MATERIALS AND METHODS
MATERIALS
1. Bacteria and DNAs 
E. coli strains JM101 and JM109 were obtained from Northumbria 
Biotechnology Limited (NBL).
pUC8 and lambda Hindi11 and HindlII/EcoRI DNAs were obtained from 
Bethesda Research Laboratories. ^X174 , pBR322 Haelll and Hpall size 
marker DNAs and salmon sperm DNA were obtained from Boehringer- 
Mannheim. Bluescript M13+ , manufactured by Stratagene, was obtained 
from NBL.
BamHI libraries of EHV-1 strain HVS25 in pBR322 and of EHV-4 strain 
1942 in pUC9 were kindly provided by J.M. Whalley (Macquarie 
University, Australia) and A.A. Cull inane (Irish Equine Centre, Eire) 
respectively.
2. Chemicals
Unless stated to the contrary all chemicals were obtained from 
B.D.H. Chemicals Ltd., Poole, Dorset.
Agarose (type II), low melting point agarose, ethidium bromide, 
lysozyme, triton X100, dextran sulphate, ampicillin, spermidine - 
Sigma.
Caesium chloride, IPTG, X-Gal - Boehringer-Mannheim, UK.
TEMED , APS , Sephadex G50, Bind-Silane , Repel cote and nucleotides -
Pharmacia/LKB
Formamide - Fluka
Bacterial agar and tryptone - Oxoid
Yeast extract and bactopeptone - Difco
Tris-equilibrated phenol - Rathburn Chemicals Ltd.
Radiochemicals, o<-?^S-ATP and ^P-dCTP - Amersham Radiochemicals Ltd. 
Gamma ^P-ATP - ICN.
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3. Enzymes
Restriction enzymes and DNA ligase and buffers were obtained from 
BRL or NBL.
T4 polymerase, Exo III - BRL.
Klenow enzyme (sequencing grade), SI nuclease, alkaline phosphatase - 
Boehringer-Mannheim, UK.
T7 DNA polymerase was supplied as part of a sequencing kit by 
Pharmacia/LKB.
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METHODS
Methods used throughout the thesis are described in this chapter 
while methods specific to one section of the work are described in 
later chapters.
1. Recombinant DNA Techniques
1) Storage and growth of bacterial strains
All plasmids were maintained in E. coli strains DH1, JM101, or 
JM109. To facilitate long term storage of these bacterial stocks and of 
transformants obtained in the course of the project, glycerol stocks 
were prepared. A small aliquot of a given bacterial culture was
streaked out on a 1.5% agar plate (1.5% bacterial agar in L-broth 
(Table 1)) supplemented with lOOug/ml ampicillin since all the vector 
plasmids used confer ampicillin resistance to their host bacterium. The 
plate was incubated overnight at 37°C and single colonies picked into 
10ml L-broth /100ug/ml ampicillin the next day. The culture was
incubated for 24 hours in an orbital incubator at 37°C. Confirmation
that the overnight culture was derived from a bacterium containing the 
desired recombinant plasmid was achieved by DNA extraction and 
restriction digestion (see below). 5ml of the culture was then 
centrifuged at 2K for 10 minutes and the bacterial pellet resuspended 
in 1ml 80% glycerol, 2% bactopeptone in L-broth. Glycerol stocks were 
stored at -20°C.
Bacteria were routinely cultured in 2 litre sterile flasks to which 
0.5ml of an overnight culture of the desired bacterial clone and 500 
ml L-Broth/lOOug/ml ampicillin had been added. Cultures were incubated 
for 16-24 hours at 37°C in an orbital incubator.
2) Extraction of plasmid DNA
Bacterial pellets were obtained from 500ml cultures by
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centrifugation of the culture at 7K for 15 minutes and plasmid DNA 
isolated by a modification of the technique of Birnboim and Doly, 
1979). Pellets were resuspended in 50ml solution 1 (25mM Tris, 50mM 
glucose, lOmM EDTA) and 200mg of lysozyme on ice for 30 minutes. 80ml 
solution 2 ( 1% SDS, 200mM NaOH) was added and the lysate left on ice 
for a further 5 minutes. 40ml 3M KOAc was added and , following a 
further 15 minutes on ice , the preparation was spun at 7K for 15 
minutes. The supernatant was filtered through sterile gauze, 100ml 
isopropanol added and DNA precipitated at -20°C for 5-30 minutes. DNA 
was pelleted by centrifugation at 7K for 30 minutes at 0°C and was then 
resuspended in 17ml lxTE (Table 1). To facilitate formation of a 
density gradient during centrifugation and to induce differential 
density of plasmid and chromosomal DNAs 18g CsCl and 1.8 ml ethidium 
bromide were added to the DNA preparation. The optical density (0D) of 
the solution was adjusted to 1.388-1.390 by adding more lxTE or CsCl 
and determining the OD of the solution in a refractometer. The 
preparation was transferred to quick seal tubes which were heat sealed. 
Preparations were spun in a Beckman ultracentrifuge for 36-48 hours at 
45K in a Ti50 rotor or alternatively overnight at 55k in a VTi65 
rotor . The plasmid DNA band was removed from the gradient using a 
sterile needle and syringe and ethidium bromide extracted using three 
to four equal volume extractions with isopropanol. The aqueous phase 
was then transferred to a pre-washed collodian tube and dialysed for a 
minimum of 2 hours against 0.5xTE. DNA was precipitated from the 
dialysed preparation by the addition of 2 volumes of ethanol and l/10th 
volume of 5M NaCl at -20°C. DNA pellets recovered by centrifugation at 
18K for 30 minutes were washed with 70% ethanol, dried and resuspended 
in 2ml dh^O. DNA was reprecipitated, washed, dried and resuspended in 
water or lxTE at a concentration of 0.5 ug/ul.
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3) Determination of nucleic acid concentration
The concentration of DNA within a given preparation was determined 
by the analysis of the optical density of the sample at 260 nm. 5 ul of 
the DNA preparation was diluted 200-fold with water and its OD260 
determined with reference to a water standard. An OD250 of 1-00 
represents a dsDNA concentration of approximately 50 ug/ml or an RNA 
or oligonucleotide concentration of approximately 20ug/ml .
4) Restriction endonuclease digestion and electrophoresis of 
plasmid DNA
Restriction digests of plasmids were carried out in the appropriate 
buffer supplemented with spermidine to a concentration of ImM. 
Routinely, 0.5-1.0 ug DNA were digested for a minimum of 1 hour at 37°C 
in an excess of enzyme. For isolation of specific restriction fragments 
larger quantities of plasmid DNA , 10-20 ug, were digested.
Fractionation of fragments generated by restriction endonuclease 
digestion was achieved by electrophoresis of digests through agarose or 
polyacrylamide gels. 0.7% -1.0% agarose gels were prepared by adding 
the appropriate amount of agarose to lxTBE buffer and heating to 
melting point in a microwave oven. Gel mixes were cooled to 
approximately 50°C before pouring into the gel former, with 
appropriate well comb, of a horizontal gel apparatus. The set gel was 
placed in the electophoretic cell and submersed in lxTBE. The comb was 
removed under buffer.
Analysis of restriction fragments of under 500 bp in size was 
facilitated by electrophoresis of restriction digest products through 
vertical polyacrylamide gels. 5%-8% gels were used according to the 
size of fragments to be distinguished. 5% acrylamide gels were prepared 
by adding 10ml of a 20% acrylamide/1% bisacrylamide solution to 4ml 
lOxTBE and 25.3 ml dH20. 480 ul 10% APS and 240 ul 10% TEMED were
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added, the solution mixed and poured between two glass plates separated 
by 0 .8mm spacers and clamped firmly with metal clips to prevent leakage 
of gel. A gel comb was placed in position and the gel allowed to set. 
On setting the gel was placed in a vertical electrophoresis kit,
clamped in position and lxTBE buffer added to the upper and lower
chambers. The comb was removed and the wells were flushed out with 
lxTBE to remove any unpolymerised acrylamide. Any air bubbles at the 
gel/buffer interface were removed.
An appropriate amount of 5 x bromophenol blue loading buffer (Table
1) was added to the restriction digests prior to electrophoresis. Size 
markers used were lambda Hindi11 or HindlII/EcoRI digests for agarose 
gels or pUC8 Haelll or Hpall digests for polyacrylamide gels. Samples 
were then loaded into the gel wells and the gel run for an appropriate 
time - 2-3 hours at 70V/cm for 0.8% agarose gels, 2-3 hours at 35 mA 
for 5% polyacrylamide gels. Gels were stained with ethidium bromide for 
30 minutes, destained for 30 minutes and viewed and photographed under
UV illumination using instant black and white film.
5) Isolation of purified restriction fragments
Purified restriction fragments required for utilisation as 
hybridisation probes or for recombinant plasmid construction were 
isolated from low melting point agarose. DNA was electrophoresed in 
0.75% low melting point agarose, the gel stained and the desired 
fragment excised from the gel under UV illumination using a sterile 
scalpel blade. Two volumes of TE were added to the gel slices and the 
agarose melted by heating to 65° C for 10 minutes. The preparation was 
phenol extracted and the aqueous phase transferred to a fresh tube. The 
phenol phase was back-extracted with 1 volume of TE and the aqueous 
phase pooled with the previously collected aqueous extract. A further 
two phenol extractions were performed followed by two chloroform
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extractions. DNA released from the gel slices was precipitated at - 
20° C by the addition of l/10th volume of 5M NaCl and 2.5 volumes of 
ethanol. The DNA pellet obtained by centrifugation of the preparation 
at 13K for 20 minutes was washed with 70% ethanol, dried and 
resuspended in lxTE.
An alternative method of restriction fragment purification utilised 
involved spinning gel slices through a 0.2 urn filter according to the 
protocol of Vogel stein (1987). The restriction fragment of interest
was excised from a 0.75% normal melting point agarose gel and the
slices suspended on the 0.2 urn filter of a Costar Spin-X tube. Gel 
slices were subjected to freeze-thawing at -20°C and 37°C and the tubes 
then spun for 40 minutes at 13K. Fluid which had passed through the 
filter was phenol extracted twice and chloroform extracted. DNA was 
precipitated and treated as above.
6) Phosphatase treatment of vector DNA
Subcloning of fragments terminating in blunt ends or in common 
restriction endonuclease sites required plasmid vector DNA digested 
with a single restriction enzyme : an enzyme identical to that used to
generate the target fragment to be cloned or Smal in the case of
cloning blunt-ended fragments into Bluescript M13+ (BS). Digested
vectors were phosphatase-treated to prevent ligation of vector-self or 
vector-vector at the cleavage site. Since dephosphorylated termini can 
only ligate to compatible phosphorylated termini ligation events were 
restricted to those of a vector-fragment or fragment-fragment nature. 
Dephosphorylation of vector termini was achieved by the addition of 1 
unit of alkaline phosphatase to the restriction enzyme digest in the 
final 30 minutes of the incubation period.
7) Ligation of vector and target DNA
Vector and target DNAs were mixed at a concentration of 1:3 in the
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presence of ligase buffer and 2 units T4 DNA ligase. Blunt-ended 
ligations were performed overnight at room temperature. Standard 
ligations were carried out at 15°C overnight.
8) Transformation of competent bacteria
Bacterial cultures were prepared for transformation with recombinant 
plasmids by innoculating 100ml L-broth with 1ml of an overnight culture 
of JM101 or JM109 E. Coli and shaking the culture in an orbital 
incubator for 2 - 2V 2 hours at 37°C. Cells were pelleted by spinning 
the culture at lk for 10 minutes. The pellet was resuspended in 40ml 
lOOmM MgSO^ on ice for 10 minutes. Cells were spun down at IK for 10 
minutes and resuspended in 25ml 50mM CaCl2 on ice for 15 minutes. Cells 
were pelleted once more and resuspended in 2.5ml 50mM CaCl2 . 
Transformed cells were kept for up to 48 hours at 4°C. For longer term 
storage 1/2 volume of 50% glycerol was added and aliquots stored in the 
vapour phase of a liquid nitrogen tank or alternatively at -80°C.
The products of a ligation reaction mix were added to 200 ul 
competant bacteria and placed on ice for a minimum of 15 minutes. The 
bacteria were then heat shocked by transferring the tube to 37°C for 5 
minutes and then returning it to ice for 30 minutes. 1ml of L-broth was 
added to each tube and the contents incubated for 90 minutes at 37°C to 
permit expression of the plasmid ampicillin-resistance function.
Bacteria were then pelleted by centrifugation at 13K for approximately 
20 seconds and resuspended in 100 ul L-broth. 75ul of the suspension
were spread on to ampicillin-supplemented agar plates which were 
subsequently incubated overnight at 37°C.
Cloning of inserts into the multicloning site (MCS) of Bluescript
M13+ disrupts beta-galactosidase expression thus when using BS, 
transformed bacteria were spread on plates supplemented with X-gal 
(40ug/ml) and IPTG (25ug/ml) in addition to ampicillin to assist in
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selection procedures : a blue colony phenotype is associated with
transformants containing a religated vector expressing beta- 
galactosidase; a white colony phenotype is associated with 
transformants containing vectors with a disrupted lac gene due to 
insertion of DNA.
9) Screening of transformants for desired recombinant plasmids
Several colonies were picked from each overnight plate of 
transformed bacteria. Only white colonies were picked on occasions 
when colour selection was utilised. Minipreps were performed to 
establish whether the selected colonies contained plasmid DNA and, if 
so, whether the plasmid constituted a desired recombinant. A 1ml
aliquot of each single colony-derived overnight was spun at 12K for 3 
minutes and the cell pellet resuspended in 70ul lxSTET (Table 1).
Following addition of 25ul of a lOmg/ml lysozyme solution, each 
preparation was placed in a boiling water bath for 45 seconds. 
Supernatant obtained by spinning at 13K for 5 minutes was phenol 
extracted and chloroform extracted . Plasmid DNA was recovered by 
precipitation in two volumes of ethanol and l/10th volume 5M NaCl at
-70°C. DNA was pelleted by spinning at 13K for 10 minutes and was
resuspended in 30 ul lxTE. Restriction digests were then performed in 
order to establish the nature of the plasmid construct within selected 
colonies. Cultures derived from colonies with the desired recombinants 
were then used to prepare glycerol stocks and large scale plasmid 
preparations.
2. Southern Hybridisation
1) Preparation of radiolabelled probe
Radioactive labelling of a purified restriction fragment was 
achieved by introducing nicks into the DNA at which a fill-in reaction
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could be initiated, in the presence of a radioactively labelled 
deoxynucleotide. An Amersham nick translation kit was used. To 1 ug DNA 
on ice the following was added in sequence - 10 ul of nucleotide/buffer 
solution ( 100 uM dATP, dGTP and dTTP in Tris-HCl pH7.8, MgCl2 and 2- 
mercaptoethanol ), 10 ul of <K - ^ P-dCTP (lOmCi/ml), dH20 to bring the
final volume to 50 ul and 5 ul of enzyme solution (2.5U DNA polymerase
1, 50pg DNase 1 in tris-HCl, pH 7.5, MgCl2 , glycerol and bovine serum 
albumin ). The reaction mix was incubated at 15°C for 2 hours and the 
labelled DNA separated from unincorporated radionucleotides by column 
chromatography.
2) Preparation of radiolabelled lambda DNA
Hindlll-digested lambda DNA was radioactively labelled for use as 
size markers, lug lambda HindiII DNA was incubated with lOul ^P-dCTP 
(lOmCi/ml), 5ul Amersham nick translation buffer, and lul T4 polymerase 
in a reaction mix of total volume 50ul for 5 minutes at 37°C . A
further 25 minute incubation at 37°C was performed on addition of lul
lOOmM dCTP. The reaction mix was phenol extracted, dialysed and
radioactivity of the markers determined. An aliquot of radiolabelled 
lamda DNA corresponding to an activity of 5x10^ cpm was added to the 
marker lane of a gel intended for Southern blotting.
3) Gel filtration of radiolabelled DNA or oligonucleotides
Nick-translated restriction fragments or if -^P-ATP labelled
oligonucleotides were purified by passage through a Sephadex G50 column 
or a commercially available nick-column. Restriction fragments and 
oligonucleotides of a length greater than 20 bases were purified using 
pre-packed Pharmacia 'nick columns'. The buffer supplied with the 
column was discarded and three 1ml aliquots of lxTE applied. The radio- 
labelled sample was added once the 3ml of buffer had completely 
entered the gel bed and 400 ul of lxTE added. The leading peak was
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eluted by adding a further 400 ul of lxTE to the column and collecting 
the elutant. Alternatively, a polypropylene column packed with pre­
equilibrated Sephadex G50 was equilibrated with STE buffer (Table 1) .
Immediately prior to loading the labelling reaction product mix, buffer 
was allowed to completely enter the gel phase. The reaction products 
mixed with l/20th volume of 1% Orange G were layered on to the top of 
the column. Once the sample solution had entered the gel bed continous 
addition of STE buffer to the column was resumed. As transport of 
products down the column occurred two peaks of radioactivity could 
generally be distinguished. The leading peak corresponded to 
radionucleotide incorporated into either DNA or oligonucleotide while 
the lagging, Orange G tagged, peak corresponded to unincorporated 
radionucleotides. Purified labelled product was collected as the 
leading peak was eluted from the column. Care was taken to avoid 
collecting eluant at the trailing end of the leading peak since it was 
likely to overlap with the elution profile of the unincorporated 
radionucleotides.
4) Transfer of DNA to membrane 
Transfer of DNA from an agarose gel to a nitrocellulose membrane was 
performed according to the technique of Southern (1975). Restriction 
digests of recombinant constructs containing EHV-4 DNA of interest 
were electrophoresed through 0.7-1.0% agarose gels . Radiolabelled 
lambda HindiII DNA was added to a lane as size markers. 
Electrophoresis was carried out until the bromophenol blue dye had run 
75% of the length of the gel. The gel was then stained with ethidium 
bromide, destained, and photographed. The gel was trimmed to remove 
agarose at the top, bottom, and edges of the gel outwith the region of 
DNA separation. The gel was then prepared for DNA transfer by soaking 
in denaturation buffer (Table 1) for two 15 minute periods, in
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neutralisation buffer (Table 1) for two 15 minute periods, and in 
lxGeneScreen buffer (GS) (Table 1) for three 20 minute periods. 
Meanwhile, GeneScreen membranes were prepared by cutting a piece of 
membrane to the same size as the gel and by soaking this for 10 minutes 
in lxGS. Transfer of DNA to GeneScreen was achieved by placing the gel 
on top of wet 3MM paper suspended in lxGS, arranging the GeneScreen 
membrane on top of the gel and positioning successive layers of dry 
3MM paper and tissue above the membrane. This created a capillary 
effect drawing lxGS from the buffer reservoir through the layers of 
tissues, transferring gel DNA to the membrane in the process. On 
completion of transfer (8-12 hours) the membrane was rinsed in lxGS and 
baked at 80°C for 2 hours.
5) Prehybridisation
Prior to prehybridisation the baked membrane was soaked in 1% triton 
to ensure even distribution of the prehybridisation mix. The membrane 
was placed in a polythene bag sealed on three sides and 
prehybridisation mix added. The constitution of this mix was dependent 
on the stringency of hybridisation required, a parameter affected by 
formamide concentration. Most commonly a 45% prehybridisation mix was 
utilised composed of 45% formamide, 4.2xSSC, 4.2xDenhardts solution , 
8% dextran sulphate, 0.04M NaPPi, 80ug/ml salmon sperm DNA, and 0.08% 
SDS (Table 1). The bag was sealed and placed in a shaking water bath at 
42°C overnight.
6) Hybridisation
Hybridisation was initiated by the addition of 2xl07 cpm of 
radiolabelled probe to the prehybridisation mix. The bag was resealed 
and returned to the shaking water bath for a further overnight 
incubation at 42°C.
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7) Washing of blots
On completion of the hybridisation procedure the membrane was 
rinsed, at room temperature (RT), in 2xSSC (Table 1) and washed for 
three 30 minute periods at 65°C in either lxSSC;0.1% SDS or 2xSSC;0.1% 
SDS depending on the level of stringency required. The membrane was 
rinsed in O.lxSSC at room temperature, dried, sealed in a polythene 
bag, and exposed to autoradiograph film overnight at -70°C in the 
presence of an intensifying screen.
8) Autoradiography
Membranes were autoradiographed at -70°C with Amersham MP hyperfilm 
in the presence of a Dupont lightning fast intensifying screen. Films 
were developed in an automatic processor.
3. DNA Sequence Analysis
1) Preparation of oligonucleotide sequencing primers
17 base oligonucleotides for use as sequencing primers were 
manufactured in an Applied Biosystems oligonucleotide synthesiser on a 
0.2 urn column with trityl off. Oligonucleotides were detached from the 
column by flushing the column with 2ml NH4OH over a 1-2 hour period. 
The NH4OH and the eluted oligonucleotide were then heated at 55° C for 
a minimum of 5 hours to deprotect the oligo. The oligo was then 
precipitated by the addition of 2 volumes of ethanol and l/10th volume 
5M NaCl at -70°C for 30 minutes. The pellet obtained after 
centrifugation at 13K for ten minutes was dried and the oligonucleotide 
resuspended at a concentration of lOng/ul.
2) Sequencing reactions
Sequencing reactions were carried out by the Sanger dideoxy 
technique (Sanger et al.. 1977) using Klenow fragment in the earlier 
part of the project and later with a modified T7 polymerase which was
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found to give superior results in terms of quality of reaction and 
number of base pairs elucidated per reaction. Template DNA in both 
instances was denatured plasmid DNA. Denaturation of plasmid DNA was 
achieved by the addition of 4ul 1M NaOH to DNA resuspended in 16ul 
d^O. In the case of a 6kbp plasmid, 3ug DNA were denatured; the DNA 
amount was adjusted for larger and smaller constructs. After 5 minutes 
at RT the mix was neutralised by the addition of 2ul 2MNH^0Ac (pH5.3) 
and DNA precipitated at -70°C on addition of 55ul ethanol. DNA was 
pelleted by spinning at 13K for 10 minutes, dried, and resuspended in 
6.5ul for Sequenase-catalysed reactions or in 9.5ul for Klenow- 
catalysed reactions.
K1enow-catalysed sequencing was performed as follows. Annealing of 
primer to denatured template was achieved by incubating resuspended DNA 
with 2ul primer (lOng/ul), 1.5ul annealing buffer (lOOmM Tris;50mM 
MgCl2), and 2ul o< -^S-dATP for 15 minutes at 37°C. 3.5ul aliquots of 
the annealing mix were transferred to eppendorfs containing 2ul of A, 
C, G, or T nucleotide mix (Table 2) and incubated as before. A final 
incubation , again at 37°C for 15 minutes, was performed following the 
addition of lul chase solution (Table 2) to each reaction mix. Enzyme 
activity was terminated by the addition of 5ul stop mix to each tube . 
Reactions were stored at -20°C prior to electrophoresis.
T7 polymerase catalysed sequencing was performed using solutions 
supplied by Pharmacia. 1.5ul of an appropriate sequencing primer 
(lOng/ul) and 2ul of kit buffer (final concentration :40mM Tris-HCl 
pH7.5; 20mM MgCl2 ; 50mM NaCl ) were added to the resuspended template 
and the mix incubated for 15 minutes at 37°C to permit annealing of 
primer to template DNA. The extension and labelling reactions were 
carried out for 5 minutes at RT on addition of lul 0.1M DTT, 2ul dGTP 
mix (l,5uM dGTP,dCTP,dTTP), 0.5ul ^SdATP, and 2ul of T7 polymerase
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diluted 1:8 to lOul of the annealed primer/template mix . The reaction 
was terminated by the addition of 3.5ul of labelling reaction mix to 
each of four termination mixes (80uM dGTP, dATP, dCTP, dTTP plus 8uM 
ddATP,50mM NaCl (mix A only), 8uM ddCTP, 50mM NaCl (mix C only), 8uM 
ddGTP, 50mM NaCl (mix G only), or 8uM ddTTP, 50mM NaCl (mix T only)) 
prewarmed for 5 minutes at 37°C. Reaction mixes were incubated at 37°C 
for 5 minutes. 4ul of stop solution was added to terminate all enzyme 
activity and mixes stored at -20°C until required.
3) Electrophoresis
Sequencing reaction products were electophoresed through a 6% 
acrylamide wedge gel prepared and run on an LKB-Macrophor apparatus. To 
ensure that the gel bound only to the glass plate and not to the 
thermostatic back plate plates were treated with binding or repelling 
agents as described in LKB literature.
The acrylamide gel solution was prepared by the addition of 0.4ml 
APS and 40ul TEMED to a 6% acrylamide gel preparation. The gel was 
poured according to LKB literature and left for one hour to set. The 
prepared gel was positioned in the electrophoretic chamber with the 
thermostatic plate connected to a pump circulating water at a 
temperature of 62°C, and the buffer compartments filled with lxTBE. The 
gel comb was removed under buffer and the wells immediately flushed out 
to remove any unpolymerised acrylamide solution. The gel was 
electrophoresed for 30-60 minutes at 2000V prior to addition of 
samples.
Sequencing reaction products were placed in a boiling water bath for 
3 minutes. The gel wells were flushed out again and the samples loaded 
using capillary tubes. Electrophoresis was performed at 2000V for 
approximately 2 hours for a short run or 5 hours for an extended run. 
On completion of electrophoresis the plate assembly was removed from
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the electrophoretic chamber and the notched plate prised apart from the 
thermostatic plate. The notched plate plus gel were then transferred to 
a 10% acetic acid/10% methanol solution and soaked for 30 minutes . The 
gel was dried and exposed to Amersham MP film overnight in a light 
tight box.
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Table 2.1
General Stock Solutions
L-Broth 
20g Tryptone 
20g NaCl
lOg Yeast extract 
to 21 with dH20
Adjusted to approx. pH 7.0 with NaOH. Autoclaved.
lOOxTE
121g Tris
37g EDTA
to 11 with dH20
lOxTBE 
216g Tris 
llOg Boric acid 
200ml 0.25M EDTA 
to 21 with dH20
STE
5ml 1M Tris 
10ml 5M NaCl 
2.5ml 0.2M EDTA 
to 500ml with dH20
lxSTET
5ml Triton X100 
25ml 0.25M EDTA pH8 
5ml 1M Tris pH8 
8g Sucrose 
to 100ml with dH20
5x bromophenol blue loading buffer 
0.125g Bromophenol blue 
12.5g Ficol 1 400 
to 100ml with dH20
IPTG
50mg/ml in dH20 
stored at -20°C
X-Gal
80mg/ml in dimethylformamide 
stored at -20°C
Denaturation buffer 
60g NaOH 
263g NaCl 
to 31 with dH20
Neutralisation buffer 
500ml 1M Tris pH8 
175g NaCl 
to 11 with dH20
40xGS
356g Na2HP04 
312g NaH2P04
20xSSC 
438g NaCl
220g Tri-sodium citrate 
to 2.51 with dH20
45% Prehybridisation mix
13.5ml Formamide
6.25ml 20xSSC
2.5ml 50xDenhardts
5.0ml 50% Dextran sulphate
1.25ml 40xGS
1.2ml dH20
0.25ml Salmon sperm DNA (lOmg/ml), 
0.125ml SDS
Denhardts Solution
5g Fi col 1
5g Polyvinylpyrrolidone 
5g BSA (fraction V) 
to 500ml with dH20 
stored at -20°C
Table 2.1 Stock solutions used in molecular biological
techniques applied throughout the project.
Table 2.2
DNA Sequencing Stock Solutions
Klenow Sequencing Mixes
A mix - 20ul 0.5mM dCTP, dGTP, dTTP; 20ul lxTE; 80ul O.lmM ddATP
C mix - 20ul 0.5mM dGTP, dTTP; lul 0.5mM dCTP; 20ul lxTE; 61ul
0.2mM ddCTP
G mix - 20ul 0.5mM dCTP, dTTP; lul 0.5mM dGTP; 20ul lxTE; 61ul
O.lmM ddGTP
T mix - 20ul 0.5mM dCTP, dGTP; lul 0.5mM dTTP; 20ul lxTE; 61ul
0.5mM ddTTP
Chase Solution
0.5mM dATP, dCTP, dGTP, dTTP
Stop Solution 
95% Formamide 
20mM EDTA
0.05% Bromopenol blue
0.05% Xylene cyanol FF
6% Acrvlamide Gel Mix 
25,2g Urea
8 .8ml 38% Acrylamide:2% Bisacrylamide 
6ml lOxTBE 
24.4 ml dH20
Table 2.2 Stock solutions used in DNA sequencing procedures
CHAPTER 3
LOCALISATION AND SEQUENCING OF THE EHV-4 
THYMIDINE KINASE GENE AND UL24 GENE 
HOMOLOGUE
INTRODUCTION
The cellular enzyme thymidine kinase (ATP:thymidine 5'- 
phosphotransferase; EC 2.7.1.21; TK) operates within the salvage 
pathway of pyrimidine biosynthesis catalysing the conversion of 
thymidine to thymidylate (dTMP) using ATP as phosphate donor (Kit, 
1985a) (Fig. 1). During lytic infection many herpesviruses induce a 
virus-specific thymidine , or more accurately deoxypyrimidine, kinase 
which acts in conjunction with the cellular TK to increase the 
efficiency of deoxythymidine salvage thereby increasing the dTTP pool 
available for viral DNA synthesis. Herpesviruses with TK-coding 
capacity have been identified in all three subgroups, alpha, beta, and 
gamma, through the detection and characterisation of i) virus-specified 
TK activity in infected cells and/or ii) potential TK-coding genes in 
the viral genome (reviewed in Kit, 1985a)(Table 1). The betaherpesvirus 
HCMV is the only herpesvirus sequenced in entirety which does not seem 
to encode a TK function although it does stimulate the host cell TK 
during productive infection (Estes and Huang, 1977). Until recently the 
only evidence that TK was specified in other betaherpesviruses was 
provided by the existence of a bovine cytomegalovirus (BHV-4)- specific 
TK (Kit , 1985a ) . The current view is that this herpesvirus should be 
reclassified as a gammaherpesvirus on the basis of genome structure and 
composition and its gammaherpesvirus-type TK activity (Bublot et al., 
1990; Kit et al.. 1986). However, the betaherpesvirus EHV-2 does seem 
to encode a TK function so presumably TK-coding capacity was deleted 
from the HCMV genome relatively late in the cytomegalovirus 
evolutionary scheme (Colacino et al.. 1988; Staschke et al., 1990).
Herpesvirus TKs differ from cellular TKs and from each other in 
their substrate and phosphate donor specificities. Whereas cellular 
TKs use only ATP and dATP as phosphate donor, some herpesvirus TKs can
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utilise CTP and GTP in addition. Similarly, while cellular TKs 
efficiently utilise only thymidine as a substrate herpesvirus TKs are 
less fastidious and can use deoxycytidine (Kit, 1985a). Herpesvirus TKs 
can be divided into three groups on the basis of their substrate 
specificity - a broad specificity group including HSV-1, HSV-2, MarHV, 
EHV-1, and VZV, an intermediate group including PRV, BHV-1, and EHV-3, 
and a narrow specificity group including BHV-4 and HVS which 
inefficiently phosphorylate deoxycytidine (Kit , 1985a) (Table 1).
These ranges of specificity extend to the affinity of different TKs 
for nucleoside analogues such as acyclovir (ACV), which, in a 
phosphorylated form, inhibit the DNA replicative cycle of specific 
herpesviruses (Collins, 1983; Elion, 1983; Kit et al.. 1987a,b)(Table
1). This has led to the development of antiviral therapies based on the 
application of nucleoside analogues to infected hosts. Preferential 
uptake of the drug by herpesvirus-infected cells and the inability of 
cellular TK to phosphorylate such analogues protects uninfected cells 
from the harmful effects of the activated analogue. The effectiveness 
of the phosphorylated analogue in inhibiting viral replication and 
killing infected cells is subject to one or more of the following 
occurring - i) competition with dTTP for incorporation into DNA (Coen 
and Schaffer, 1980) , ii) inhibition of the virus-specified DNA
polymerase (Furman et a!.', 1984), iii) incorporation into replicating 
DNA such that its stability and/or function are affected (Mancini et 
al., 1983), iv) induction of unbalanced nucleotide pools through
allosteric effects on ribonucleotide reductase and/or dCMP aminase or, 
v) inhibition of viral replication or infectivity through interference 
with envelope glycoprotein synthesis (Olofsson et al.. 1985).
The ultimate target of most anti herpetic drugs is the virus 
specified DNA polymerase - the role of TK is limited to the activation
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of the analogue. Thus the effectiveness of antivirals depends not only 
on the substrate specificity of the herpesvirus TK but also on the 
substrate specificity of the DNA polymerase, the specifity of cellular 
enzymes required to convert the mono-phosphorylated analogue to its di- 
and tri-phosphorylated form, and on the requirement that the analogue 
should be effective at a dose level which is not toxic to uninfected 
cells in vivo. An experimentally useful outcome of the broader 
specificity of herpesvirus TKs is that it enables in vitro selection 
of TK+ or TK" viruses from a mixed background in either TK" or TK+ host 
cells depending on the virus type and the analogue used.
The HSV-1, HSV-2 and VZV TKs are multifunctional in that they have a 
thymidylate kinase activity in addition to TK activity phosphorylating 
thymidine monophosphate to thymidine diphosphate ( Chen and Prusoff, 
1978; Fyfe, 1982). In HSV-1 these two catalytic activities are thought 
to share a common or at least overlapping site within the enzyme (Chen 
et al.. 1979).
A functional TK gene is not essential for viral growth in vitro 
with the exception of cells cultured in serum-starved conditions 
(Jamieson et al.. 1974). This implies that herpesvirus TK activity may 
play a particularly important role in the infection of resting or 
terminally differentiated cells in vivo such as neural cells - the 
site of latency for neurotropic herpesviruses. However, TK gene 
function also seems to be important in the infection of dividing cells 
in vivo in that it has been linked to herpesvirus virulence since TK" 
mutants are often attenuated in vivo (Kit et al.. 1983b, 1985a,b). A 
link between TK activity and neurovirulence has been established for 
HSV-1 TK in a mouse model (Field and Wildy, 1978). Although TK gene 
expression has been regarded as a requirement for viral latency 
(Tenser and Dunstan, 1979), TK-deficient mutants capable of
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establishing a latent infection in animal models have recently been 
isolated (Coen et al.. 1989; Efstathiou et al.. 1989; Meigner et al..
1988; Tenser et al, 1989 ). It seems that the extent to which
decreased TK expression affects latency may depend not only on the 
genetic background of the mutant virus but also on the animal model 
used (Coen et al.. 1989).
The mapping of genes encoding herpesvirus TKs has been approached 
from several experimental angles including i) amplification of TK DNA 
by polymerase chain reaction using primers derived from conserved 
sequence regions of characterised TK genes (Nunberg et al.. 1989) ,
ii) analysis of intertypic HSV-l/HSV-2 recombinants (Halliburton et 
al.. 1980), and iii) marker rescue of the TK function (Bello et al..
1987; Stow et al.. 1978). The most common approach has been the
transfection of fragments of herpesvirus DNA into TK" cells followed 
by the analysis of the ability of these fragments to biochemically 
transform transfected cells from a TK" phenotype to a TK+ phenotype 
(McDougall et al.. 1980; Otsuka et al.. 1981; Robertson and Whalley, 
1988; Sawyer et al.. 1986; Wigler et al.. 1977 ). Despite TK
expression in lytic infection being dependent on expression of 
immediate early functions, expression of TK in transfected fragments 
tends to be constitutive. In HSV-1 for example, the TK gene is 
regulated as an early gene during productive viral infection, its 
expression dependent on expression of immediate early gene products, in 
particular ICP4 and ICPO (Gelman and Silverstein, 1985). Nonetheless, 
fragments of HSV DNA containing an intact TK gene are capable of 
transforming TK" cells to a TK+ phenotype on transfection with the 
integrated TK gene expressed in the absence of immediate early HSV 
gene products. Superinfection with HSV-1 does, however, increase the 
level of TK transcription and translation 5-20 fold suggesting that
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certain regulatory controls are maintained (Kit and Dubbs, 1977 ).
The nucleotide sequences of the TK genes of a variety of 
herpesviruses have been published including EHV-1 (Robertson and 
Whalley, 1988), PRV (Kit, 1985b), VZV (Davison and Scott, 1986), BHV-1 
(Kit, 1985a; Mittal and Field, 1989), BHV-2 (Sheppard and May, 1989), 
HSV-1 (McKnight, 1980; Wagner et al., 1981), HSV-2 ( Kit et al., 1983a; 
Swain and Galloway, 1983), FHV (Nunberg et al.. 1989), MarHV (Otsuka 
and Kit, 1984), MDV (Scott et al., 1989), HVT (Martin et al.. 1989;
Scott, et al.. 1989 ), EBV (Baer et al., 1984), and HVS (Honess et al., 
1989a). We utilised transfection analysis in conjunction with Southern 
analysis to map the EHV-4 TK gene . The nucleotide sequence of the EHV- 
4 TK gene and flanking genes was then determined and the predicted 
protein products compared to those encoded by the gene homologues in 
other herpesvirus (Nicolson et al.. 1990b).
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MATERIALS AND METHODS
1. Materials
1) Cells
A BHK TK“ cell line was kindly provided by the Beatson Institute for 
Cancer Research, Glasgow.
2) Tissue culture
Special liquid medium was obtained from Flow Laboratories and 
bromodeoxyuridine and DMSO from Sigma. All other media supplements, 
including HAT supplement, and trypsin-versene were supplied by Gibco- 
BRL. A CellPhect kit used in transfections was supplied by Pharmacia.
2. Methods
1) Tissue Culture
BHK TK“ cells were propagated in Special Liquid Medium supplemented 
with L- glutamine (2mM), penicillin (2000IU/ml), streptomycin 
(2mg/ml), and 10% foetal calf serum. Bromodeoxyuridine (Brdll), a 
nucleotide analogue phosphorylated by cellular TK and thus toxic to TK+ 
cells, was added at 25ug/ml to eliminate spontaneous TK+ revertants 
in cell culture. This media is referred to as 10% SLM/BrdU. Cells were 
propagated in 175cm^ flasks in 15ml 10% SLM/BrdU at 37°C. Confluent 
monolayers were detached from the flask by the addition of trypsin- 
versene. Cells were pelleted, resuspended in 10% SLM and transferred to 
fresh 175 cm^ flasks at a density of 5x10^ to 1x10^ cells per flask.
2) Cell Stocks
Cells recovered from a confluent 125cm^ flask were pelleted and 
resuspended in 4ml 10% special liquid medium, 0.5ml foetal calf serum, 
and 0.5ml DMSO. Cell suspensions were transferred to 2cm plastic vials 
and stored in the vapour phase of a liquid nitrogen tank for 12-24 
hours. Vials were then immersed in liquid nitrogen and stored until
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required. Cell lines were recovered by retrieval of appropriate vials 
from the liquid nitrogen store and rapid thawing of frozen cells at
37°C. Thawed cells were added slowly to 8ml 10% SLM, spun, and 
resuspended in fresh medium.
3) Southern hybridisation
0.5 ug aliquots of recombinant plasmid DNAs were digested to 
completion with appropriate restriction enzymes to release fragments of 
interest. Reaction products were electrophoresed through 0.75% agarose 
and transferred to a Gene Screen membrane (New England Nuclear, 
Dupont) . Membranes were baked for 2 hours at 80°C, prehybridised 
overnight at 42°C in 45% formamide, 4.2x SSC, 4.2x Denhardts solution, 
8% dextran sulphate, 0.04M NaPPi , 80ug/ml salmon sperm DNA, 0.08% 
SDS and hybridised for a similar period following the addition of
2x10^ cpm of denatured, ^P-labelled EHV-1 DNA. The blot was washed in
2xSSC,0.1% SDS at 65°C, dried and exposed overnight.
4) Construction of recombinant plasmids
Recombinant plasmids were constructed by subcloning EHV-4 
fragments into Bluescript M13+ by standard techniques ( Maniatis et 
al.. 1982; Chapter 2 ). 'First generation' plasmids pBSBCIO and pBSCS6 
were constructed by isolating restriction fragments of C and subcloning 
these in a Bluescript vector cleaved at appropriate sites within the
multicloning site (MCS). A series of second and third generation 
plasmids pBSSB4, pBSSS4, pBSRX3, pBSRS3, and pBSMS2 were derived by 
digestion of parental plasmids with an appropriate enzyme followed by 
religation as outlined in Figure 2.
TK-deleted plasmids were constructed by deletion of a central 
portion of cloned EHV-4 DNA by restriction endonuclease digestion. 
Cleavage overhangs were filled in using T4 pol ( for 3' overhangs ) or 
Klenow enzyme (for 5' overhangs) and plasmids religated at the site of
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deletion (Fig. 3).
5) Transfections
Recombinant plasmids were transfected into monolayer BHK TK" cells 
by a modification of the technique of Graham and van der Eb (1973). An 
appropriate amount of plasmid DNA (0.2-20 ug) was prepared in 120 ul of 
sterile water and mixed with Buffer A (0.5M CaC^, 0.1M HEPES ) of a 
CellPhect transfection kit . After a 10 minute incubation at room 
temperature, 120ul of Buffer B (0.28M NaCl, 0.05M HEPES, 0.75mM 
NaH2P04, 0.75mM Na2HP04) was added while vortexing the solution. The 
precipitate was left at room temperature for 15 minutes prior to its 
addition to 3ml 10%SLM covering a semi-confluent monolayer culture of 
BHK TK" cells (seeded at 10^ cells/cm^ 24 hours earlier). Following a 
20-24 hour incubation at 37°C, the medium was decanted from the flasks 
and the cell layer washed twice with unsupplemented special liquid 
medium. Cells were incubated in 10% SLM for a further 24 hours and 
thereafter in HAT-supplemented medium ( Hypoxanthine 10"^M, 
Aminopterin 4 x 10'^M, Thymidine 1.6 x 10"^M in SLM). Flasks were 
screened for colonies derived from cells surviving selection within 2 
weeks of transfection.
6) Exo III Deletions
Exonuclease III deletion of plasmids pBSRX2 and pBSRS3 was performed 
in order to generate deletions in EHV-4 DNA proximal to one of the 
BSM13+ sequencing primer sites. A commercially available sequencing 
primer could then be utilised to read the sequence of several deleted 
inserts thus generating more sequence data per primer than the 
alternative approach involving synthesis of custom primers every 200- 
300bp into a sequence. The protocol used was a modified version of that 
described by Henikoff (1984).
25ug of plasmid DNA was digested with two carefully selected enzymes
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cleaving within the BS multi cloning site but not within insert EHV-4 
DNA, one enzyme generating a 5' overhang proximal to target DNA and the 
other a 3' overhang at a site close to the first enzyme but nearer the 
BS T7 or T3 promoter. Plasmid pBSRS3 was digested with SstI and BamHI 
to produce deletions from the EcoRV terminus of the EHV-4 insert and 
plasmid pBSRX2 with Kpnl and Xhol to produce deletions from the Xhol 
terminus of the insert (Fig. 4). In theory, Exo III should delete from 
the 5' overhang into insert DNA but should be prevented from deleting 
into plasmid DNA, thus destroying essential sequencing primer sites, by 
the 3' overhang. Linearised plasmid DNA was phenol extracted, 
chloroform extracted, precipitated, and dried. The pellet was 
resuspended in 120ul ExoIII buffer (66mM Tris-HCl (pH8); 0.66mM MgC^). 
A 30ul aliquot was incubated with 200 units of ExoIII at 32°C and 2.5ul 
aliquots removed into 7.5ul SI mix (0.04M KOAc; 0.07M NaCl; 7% 
glycerol; 0.02M ZnSO^; 60 units SI nuclease ) at 2 minute intervals. 
The mixes were incubated at room temperature for 30 minutes, mixed with 
lul SI stop (0.3M Tris-OH; 0.05M EDTA), and incubated 10 minutes at 
70°C. Mixes were cooled to 37°C and lul Klenow mix (0.02M Tris-HCl;
0.09M MgClg; 3 units Klenow fragment ) added. Following a 5 minute 
incubation lul of dNTPs (0.125mM dATP, dCTP, dGTP, dTTP) was added to 
promote a filling-in reaction at each of the plasmid termini. 40ul 
ligation mix (l/8th volume lOxligase buffer ; 25U T4 DNA ligase) was 
added to each aliquot and the reaction mix incubated overnight at room 
temperature. Competent E. Coli JM101 or JM109 were transformed with the 
products of selected ExoIII incubation time points and screened for 
inserts with suitable size deletions. Selected recombinant inserts were 
then sequenced using a primer proximal to the restriction sites used in 
the deletion process.
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7) Sequencing
Sequencing of RX2 and flanking DNA was performed using single 
stranded pBSRX2 DNA and pBSRX2-derived Exo Ill-deleted plasmids as 
template and Bluescript-derived and custom-made oligonucleotides as 
primers in a Sanger dideoxy sequencing strategy ( Sanger et al♦, 
1977)(Fig. 7b).
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RESULTS
1. Localisation of the EHV-4 TK gene
s
1) Southern hybridisation
The EHV-4 genome is a double stranded DNA molecule of 144 kbp, 
composed of a long (L) and short component (S), the latter bounded by 
a set of inverted repeats. Given the HSV-1 TK gene map position of 
approximately 0.3 (P isomer)(Holland et al.. 1984b) and evidence for 
colinearity of the I|_ isomer with EHV-1 (Davison and Wilkie, 1983), 
and of EHV-1 with EHV-4 (Cullinane et al.. 1988), the EHV-4 TK 
gene was expected to map at around 0.5 map units.
In a series of Southern hybridisations EHV-4 BamHl fragments mapping 
between 0.39 and 0.62 map units, BamHI Q, M, C, and F, were hybridised 
initially to an HSV-1 TK DNA probe - a 2kbp PvuII fragment of BamHI P 
(strain CL101). No hybridisation was detected at the stringency used 
(2xSSC) presumably due to a lack of sufficient DNA homology between 
HSV-1 and EHV-4 across this region of the genome (data unshown). At 
that time the EHV-1 TK gene had been mapped to a 5.35 kbp BamHI/Clal 
fragment mapping at the left end of EHV-1 BamHI B (Fig. 5a). This 
fragment, later found to include the entire TK gene and flanking 
sequence (Robertson and Whalley, 1988), was used as a hybridisation 
probe. Hybridisation to EHV-4 DNA was confined to the BamHI C fragment 
mapping between 0.43 and 0.53 . Southern analysis of subfragments of C 
indicated the region of crosshybridisation mapped to the right hand end 
of C: the probe hybridised to a lOkbp Clal/BamHl fragment (BC10) and to 
three Smal subfragments mapping between 0.48 and 0.53 (Fig. 6). Since 
the precise position of the EHV-1 TK gene within the probe fragment was 
unknown at this time, more accurate mapping of the EHV-4 TK gene by 
Southern analysis was not possible.
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2) Transfection Analyses
In order to confirm correct mapping of the EHV-4 TK gene and to 
determine more sensitively its position within BamHI C prior to 
sequence analysis a crude transfection assay was employed. Fragments of 
EHV-4 DNA encoding a functional TK gene should, on transfection, be 
capable of inducing biochemical transformation of TK" cells to a TK+ 
phenotype. Transfection of 8ug of recombinant plasmid pUC 9:C of 
the EHV-4 BamHI library resulted in the transformation of BHK TK- 
cells to a TK+ phenotype confirming the presence of a functional TK 
gene within EHV-4 C (Table 2). As positive controls plasmids 
containing the HSV-1 and EHV-1 TK genes, pTK (HSV-1 CL101 BamHI P in 
pAT153) and pBSBC5 (EHV-1 HVS25 5.35kbp BamHI/Clal fragment of BamHI B 
in BSM13+), were transfected into cells under identical conditions. 
Both plasmids exhibited a significantly greater transformation 
efficiency than pUC9:C. The negative control BamHI A of EHV-1 in pBR322 
induced no TK" to TK+ transformation. In order to more accurately map 
the gene the ability of subfragments of EHV-4 BamHI C to biochemically 
transform TK" cells was investigated.
A partial restriction map of BamHI C was determined by restriction 
analysis of C (Table 3). Suitable restriction sites for subcloning of 
the hybridising region of C were identified and a family of recombinant 
Bluescript plasmids constructed containing EHV-4 fragments of 2kbp to 
lOkbp in size (Table 3; Fig. 2).
Transfection of plasmids pBSBCIO, pBSCS6 , pBSSS4, pBSRS3, and pBSRX2 
into TK" cells resulted in biochemical transformation of a small 
proportion of the transfected cell population (Tables 3,4,5). This 
mapped the TK gene to a 2kbp EcoRV/XhoI fragment, RX2, of approximate 
genome map position 0.48 (Table 3).
Plasmid pBSSB4, which contains EHV-4 DNA mapping outwith the RX2
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region did not induce biochemical transformation of cells. One TK+ 
colony was detected in pBSMS2-transfected cultures. However, the 
transformed TK+ colony was not tested for the presence of integrated 
MS2 DNA in cytoplasmic DNA and it is possible the colony was a 
spontaneous revertant.
Having localised the EHV-4 TK gene to a 2kbp fragment sequence 
analysis was performed to establish the precise position and coding 
potential of the gene.
2. Sequence Analysis of EHV-4 C Fragment RX2 and Flanking DNA
The nucleotide sequence of RX2 and adjoining DNA was determined 
according to the strategy outlined in Fig. 7 and is detailed in Fig. 8 . 
A typical autoradiograph of a sequence gel is shown in Figure 9. The 
position of three major open reading frames (ORF), two complete and 
one partial, are indicated in a VAX analysis of potential start and 
stop codons within all six frames (Fig. 7c). One ORF was mapped to 
the lower strand (0RF1: bp 934-119) and two to the upper strand 
(0RF2:bp 949-2004 and 0RF3: 2225-2400) (Figs. 7,8).
0RF1 encodes a 272 amino acid polypeptide with 36% identity to the 
predicted products of genes UL24 of HSV-1 (McGeoch et al.. 1988a) and 
35 of VZV (Davison and Scott, 1986). A search for potential 
regulatory elements immediately upstream of 0RF1 revealed no elements 
of identical sequence to the consensus TTATA (Corden et al.. 1980 )
element. Potential TTATA boxes map at bp 1034-1029 (TAAATT) and bp 
1166-1171 (TAATTA) . Two potential polyadenylation signals are located 
at the 3' end of the gene - AATAAA which spans the termination codon 
TAA, and ATTAAA located lObp downstream of the end of the coding region 
of the gene (Birnstiel et al.. 1985; Proudfoot and Brownlee, 1976). 
Since the initiation Met codon of 0RF1 lies only 15 bp upstream of the
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first Met codon of 0RF2, the 5' regulatory and N-terminal coding
regions of the 0RF2 gene and gene UL24 homologue overlap.
0RF2 is the only intact open reading frame within RX2, the
smallest tested fragment with TK-transforming activity. It encodes a 
352 amino acid product which shares 36% identity with the HSV-1 TK gene 
product. TATA box homologues (Corden et al.. 1980), TTATA and TATTAA, 
are located 85 and 305 bp upstream of the initial methionine codon of 
0RF1 (at 865bp and 645bp in Fig. 8). A potential RNA Polymerase
initiation site (Corden et al.. 1980) is located 22 bp downstream of 
the TTATA motif, within the sequence TAC (bp 886-888). The initial Met
codon of most viral and eukaryotic genes is the first 'in frame' ATG
from the RNA initiation site and resides within the consensus sequence 
(A/G)CCATGG (Kozak, 1984, 1986), the most strongly conserved feature of 
which is a purine at position -3. The predicted EHV-4 TK initiation
codon is positioned at bp 949-951 within the sequence GTAATGG. The
coding region of the gene commences at bp 949 and extends to a TGA 
termination codon at bp 2005 .
The G/C content of the coding region of the EHV-4 TK gene is 52% as 
compared to 65% in HSV-1 (Wagner et al.. 1981 ). This difference in G/C 
contents is reflected in the distribution of codon usage within the two 
genes: G/C frequency in the third codon position of amino acids
specified by any third position base is significantly higher in the 
HSV-1 TK gene (80%) than in the EHV-4 TK (45%) or UL24 (44%) genes and 
may represent differential adaptation to the overall G/C contents of 
the two viral genomes (Tables 6,7). A Poly A signal, AATAAA (Proudfoot 
and Brownlee, 1976), is positioned 42 base pairs downstream of the
termination codon.
0RF3 extends for 2565 bp and encodes the EHV-4 gH gene (Chapter 4).
A 5 amino acid sequence encoded upstream of UL24 with 100% identity to 
the opening 5 amino acids of the EHV-1 UL25 homologue may correspond to 
the N-terminal coding region of an EHV-4 UL25 homologue (Fig.7).
3. Transfection of ExoIII-deleted RX2 and RS3 DNA into
TK- cells and Generation of TK- plasmid constructs.
A series of plasmids derived by deletion of pBSRX2 or pBSRS3 were 
analysed for their TK-transformation activity by DNA mediated transfer 
into TK" cells. Deletion mutants investigated included pBSDl, 
pBSD2, pBSD3, pBSD4, pBSD5, and pBSMS2 the EHV-4 inserts of which 
extend from bp 257 ,515, 703, 942, 983, and 966 respectively through 
to the Sail site, and pBSD6 which comprises bp 181-1714 (Fig. 10) .
A further two deleted constructs were created by the production of 
Smal-BstEII and Smal-BstXI internal deletions within fragments RX2 or 
RS3 of EHV-4 cloned into Bluescript M13+ or pUC9 (Fig. 3).
The results of transfections with these constructs are outlined in 
Table 5. Constructs pBSRX2, pBSDl, pBSD2, pBSD3,and pBSD4 efficiently
transformed cells in comparison to pBSMS2 , pBSD5, pBSME, and pPRSMB . 
Several points can be inferred from these data with the caveat that a 
limited number of transfections were performed . The first is that the 
internal Smal-BstEII and Smal-BstXI deletions apparently render the DNA 
incapable of TK-transformation. Presumably a TK transcript is 
inititiated at the intact Met codon but is truncated . Since the 
deletion spans the sites essential for nucleotide binding and 
nucleoside binding a functional TK would not be expressed as evidenced 
by the transfection results. Other points can be made with regard to 
the possible location of the promoter of the EHV-4 TK gene. Comparison 
of the number of HAT-resistant colonies produced on transfection with 
plasmids pBSD2, pBSD3, pBSMS2, and pBSD5 to that of undeleted pBSRX2 
indicated that pBSD2 and pBSD3 efficiently expressed TK in transfected 
cells suggesting that the TK promoter was intact in these constructs 
and thus maps downstream of bp 703 - the 5' limit of D3 (Fig. 10) . Of 
the two potential TATA boxes with a good fit to the consensus TATA
69
sequence, only T2 at bp 861-865 lies downstream of bp703 (Fig. 8). I 
therefore tentatively suggest that the EHV-4 TK promoter TATA box spans 
bp 861-865. Two GC rich boxes located approximately 50 and 105 bp 
upstream of this TATA box may be the EHV-4 equivalent of the GC rich 
boxes which are intrinsic components of the distal promoter elements of 
the HSV-1 TK gene (Jones et al.. 1985). GC boxes have also been located 
within the upstream region of the HSV-2 (Swain and Galloway, 1983) and 
marmoset herpesvirus (Otsuka and Kit, 1984) TK genes . The CAAT box of 
the HSV-1 promoter is located asymetrically between the two GC boxes 
in an inverted orientation (McKnight and Kingsbury, 1982). Putative 
EHV-4 CAAT boxes exist in both orientations within the DNA sequence 
between the GC boxes : CCAATT at 781-786 and TGAATT at 788-783.
4. Analysis of the Predicted Protein Products of 0RF1 and 0RF2
1) EHV-4 UL24 gene homologue protein product
Gene homologues of HSV-1 gene UL24 (McGeoch et al.. 1988a) have been 
identified in HSV-2 (Kit et al.. 1983a; Swain and Galloway, 1983), EHV- 
1 (Robertson and Whalley, 1988), MDV (Scott, 1989), HVT (Jacobson et 
al.. 1989b), HCMV (Jacobson et al.. 1989b), EBV (Baer et al.. 1984),
and HVS (Jacobson et al.. 1989b).. The degree of identity of the 
products of these genes to the predicted EHV-4 UL24 gene homologue 
product is detailed in Table 8 . Identities were of the order of 20% 
with beta- and gammaherpesvirus UL24-encoded proteins and of 30 to 40% 
with non-equine alphaherpesvirus UL24-encoded proteins. The EHV-4 and 
EHV-1 proteins exhibited 83% amino acid identity.
Alignment of these UL24 gene sequences indicates five regions of 
conserved sequence within the N-terminal and central portion of the 
protein (Fig. 11). 100% conservation of cysteine residues at two
positions (II and III) suggests these might be involved in disulphide
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bond formation. The functional significance of these domains has yet to 
be determined. As yet all that is known of the UL24 gene product 
function is its importance in HSV-1 for viral growth in vitro (Jacobson 
et al.. 1989b) : amino acid changes , particularly within the more
strongly conserved domains of the protein, often result in a virus 
mutant with a small plaque phenotype. The predicted EHV-4 UL24 product 
exhibits a particularly high degree of conservation with the EHV-1 UL24 
product across the N-terminal two thirds of the polypeptide, to the 
level of 94% . In contrast, identity within the C-terminal third is 
only 53%. This suggests that the N-terminal domain may be constrained 
in its sequence by functional requirements. The extreme N-terminal 
sequence may incur additional constraints due to the overlap of its 
coding sequence with the TK gene promoter region or, as in HSV-1, TK 
coding sequence.
2) EHV-4 TK gene protein product
The translated product of the EHV-4 TK gene is a 352 amino acid 
protein of predicted molecular weight 38800. The TK of EHV-1 has been 
identified as a dimer of approximate molecular weight 80 000 (Allen et 
al., 1979). Comparisons of its predicted amino acid sequence to that 
of other herpesvirus TKs indicated identities of 16 and 18% with 
gammaherpesvirus TKs and 29-47% with non-equine alphaherpesviruses. The 
degree of identity of the EHV-4 and EHV-1 TKs was 89% (Table 8 ).
A multiple alignment of all herpesvirus TK sequences reported to 
date and of the EHV-4 TK is presented in Figure 12. A particularly 
divergent region within herpesvirus TKs corresponds to the extreme N- 
terminal portion of the protein as defined as the part of the protein 
N-terminal to the first region of strong conservation between all 
herpesvirus TKs. In the case of the EBV and HVS TKs which, at 607 and 
527 amino acids in length are considerably larger than the other
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enzymes , the bulk of the extra amino acids are located N-terminal to 
this conserved site. The corresponding region of the HSV-1 TK 
polypeptide (amino acids 1-45) is non-essential for thymidine 
phosphorylating activity (Halpern and Smiley, 1984; Haarr and Flatmark,
1987) although it affects enzyme stability.
Multiple alignments (reviewed in Honess et al. (1989a), Mittal and 
Field (1989), Robertson and Whalley (1988), Scott et al. (1989)) have 
highlighted several regions of conserved sequence. Analysis of the 
degree of identity of the EHV-4 TK with other herpesvirus TKs using 
limits defined by the position of the most N-terminal and C-terminal 
conserved regions indicated higher identities. This was particularly 
noticeable in the case of the two gammaherpesvirus TKs since these 
limits eliminate inclusion of the additional N-terminal portion of 
these polypeptides in the comparison (Table 8).
The limits of the conserved regions of thymidine kinases quoted in 
the literature varies since different groups use different criteria for 
conservation. For the purposes of this thesis six conserved regions 
are designated A-F in Figure 12. The most N-terminal of these conserved 
regions , A, shares identity with a sequence domain within many 
nucleotide binding proteins and has been proposed to form part of a 
nucleotide binding site (Gentry, 1985; Otsuka and Kit, 1984) (Fig. 
13a). Residues which are critical to HSV-1 nucleotide binding activity 
and which seem to be particularly well conserved between herpesvirus 
TKs correspond to Gly56, Gly5g, Gly61, Lys62 and Thr63 (Liu and 
Summers, 1988) . Substitution of valine for glycine at positions 56, 
59, and 61 and substitution of isoleucine for lysine 62 abolishes 
enzyme activity in mutant HSV-1 TKs. Substitution of Thrg3 with 
alanine dramatically reduces enzyme activity. However, substitution 
with a serine residue results in a functional enzyme although its
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kinetic properties differ from those of the wild type enzyme (Liu and
Summers, 1988) (Table 9). This suggests that a hydroxyl group might be 
involved in the transfer of the phosphoryl group of the phosphate 
donor. The presence of only GXXGXGKT and GXXGXGKS motifs within the 
nucleotide binding domain of the alphaherpesviruses is consistent with 
the apparent restriction on residues which can be tolerated at 
positions equivalent to HSV-1 amino acid 63 within a functional 
herpesvirus TK. The predicted EHV-4 TK nucleotide binding domain is of 
the form GXXGXGKS in common with those of the EHV-1, PRV, FHV and MarHV 
TKs. The glycine residues Tie within a flexible part of the 
polypeptide which changes conformation on binding ATP to allow a 
stretch of alpha helix following the GXXGXGK(S/T) motif to enfold the
ATP molecule within a cleft in the enzyme (Fry et al.. 1986; Pai et 
al.. 1977). The lysine residue following GXXGXG is conserved and may
interact with the alpha phosphate of the phosphate donor in order to 
neutralise its charge (Pai et al.. 1977). In adenylate kinase other 
basic amino acid residues could not substitute for lysine (Kamps and 
Sefton, 1986) and it is interesting that lysine is 100% conserved
throughout the virus TKs outlined in Fig. 13a . The stretch of
hydrophobic residues N-terminal to the GXXGXGK(S/T) motif of region A 
may, as in adenylate kinase, form a hydrophobic pocket which binds the 
aromatic ring of the phosphate donor ( Fry et al.. 1986).
Region C corresponds to the putative nucleoside binding site (Fig. 
13b). This region of the polypeptide is of particular interest in that 
its amino acid sequence may determine the substrate specificity of the 
enzyme which may in turn affect the sensitivity of the viral 
reproductive cycle to nucleotide analogues. Sequence analysis of HSV-1 
mutants with altered substrate specificity has indicated that residues 
Alal68 anc* Argi76 play a direct role in substrate binding since
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viruses specifying Thr ^ g and Gln^g are BVdU and ACV resistant 
respectively (Darby et al., 1986; Larder et al.. 1983) (Table 9). 
The TKs of EHV-1, EHV-4, BHV-2, MarHV, FHV, HSV-2 and VZV possess a 
serine at a position corresponding to HSV-1 Alajgg and in those viral 
TKs tested , including HSV-2 and EHV-1, resistance to BVdU- and IVdU- 
induced inhibition of viral replication tends to be greater than that 
of wild type HSV-1 which is consistent with the analysis of the HSV-1 
BVdU resistant mutant (De Clerq, 1982; Kit et al.. 1987a,b). Resistance 
to the effect of BVdU in these viruses is thought to be a reduced 
efficiency of binding of monophosphorylated analogue rather than a 
reduced binding affinity for the nonphosphorylated analogue since the 
mutant Ala-Thr TK of HSV-1 and the wild type HSV-2 and EHV-1 TKs 
efficiently catalyse the first phosphorylation step (Darby et al., 
1986; De Clerq, 1982; Fyfe et al., 1983; Kit et al., 1987a). This
suggests that a change of residue may confer different binding activity 
for the substrate of the thymidylate kinase-catalysed step without 
changing affinity of the enzyme for the substrate of the thymidine 
kinase function.
Other mutations may, however , affect both TK and thymidylate kinase 
activity, indirectly through tertiary structure alteration, or directly 
since in HSV-1 at least, the thymidine kinase and thymidylate functions 
are thought to overlap and may even be specified by the same site. 
Thus, the DRH motif of the nucleoside binding site may be involved in 
both nucleoside and nucleotide binding (Robertson and Whalley, 1988)
An involvement in nucleotide binding has been implied due to the 
observation that the aspartate residue within DRH is the only one 
conserved throughout the herpesvirus TKs and evidence for a role for 
aspartate residues in binding nucleotide cosubstrates in a range of 
enzymes (Dever et al.. 1987; Fry et al.. 1986) . The DRH Asp residue
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may be critical for the binding of GTP as a donor in addition to ATP 
(Folkers and Trumpp, 1987). The Arg residue of the DRH motif within 
VZV has been implicated in substrate binding since VZV TK mutants with 
changes at this residue no longer bind acyclovir (Sawyer et al.,
1988).
The only information on the functional activity of region D is that 
deletion of the valine residue within sequence NLV of BHV-1 TK results 
in BVdU resistance (Mittal and Field, 1989).
Region E may be involved in movement towards region A in the 
presence of substrate (Pai et al.. 1977) and Arg residues might be 
important in this interaction since ACV resistance is conferred to 
HSV-2 by the substitution of Arg223 with His (Kit et al.. 1987d) (Table 
9).
Region F possesses weak similarity to a region towards the C- 
terminus of adenylate kinase, human thymidine kinase and pox virus TK 
across the region corresponding to KRL through to CRD in HSV-1 TK. 
Apart from the nucleotide binding site this is the only part of the 
non-herpesvirus enzymes to show similarity in primary amino acid 
sequence to herpesvirus TKs although overall similarities in secondary 
structure throughout the proteins have been predicted (Folkers and 
Trumpp, 1987).
The precise role of the other conserved regions of the 
herpesvirus thymidine kinases with respect to the structural and 
functional integrity of the protein remains to be determined.
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Figure 3.1 Schematic outline of the thymidine kinase and 
thymidylate kinase activities of multifunctional herpesvirus 
thymidine kinases (adapted from Robertson and VJhalley (1988)) .
Ficture 3.2 Production of recombinant plasmids used in 
transfections and as sequencing templates.
a) 'First generation' plasmids pBSBCIO and pBSCS6 were 
constructed by isolating restriction fragments of C and 
subcloning these in . a Bluescript vector cleaved at 
appropriate sites within the multicloning site.
b) 'Second and third generation' plasmids pBSSB4, pBSSS4, 
pBSRX2 r pBSRS3,and pBSMS2 were derived from plasmids 
pBSBCIO, pBSCS6, and pBSRS3 by digestion of parental 
plasmids with an appropriate enzyme followed by religation 
of the vector at the site of the deletion in EHV-4 DNA.
Figure 3.2
Production of Recombinant Constructs
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TK-Deleted Constructs
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Figure 3.3 Strategies utilised in the production of two TK- 
deleted constructs, pBRX.ME (a) and pPRS.MB (b) . See text for 
details.
Figure 3.4
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Figure 3.4 Schematic diagram indicating the BSM13+ MCS 
restriction enzyme sites utilised in the production of sets of 
ExoIII-deleted constructs derived from plasmids pBSRX2 and 
pBSRS3.
Figure 3.5 a) BamHI restriction map of EHV-1 (strain 
HVS25; Whalley et al. . 1981; Robertson and Whalley, 1988) 
with expansion of BamHI B to show the position of the 
5.35kbp TK DNA probe utilised in Southern hybridisations,
b) BamHI restriction map of EHV-4 (strain 1942; Cullinane 
et al.. 1988) presented in such a way that the EHV-1 and 
EHV-4 genomes align in terms of map units. On the basis of 
colinearity of the EHV-1 and EHV-4 UL components the EHV-4 
TK gene would be expected to map within BamHI C .
Figure 3.5
Map Position of EHV-1 TK DNA Probe
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Figure 3.6 Southern hybridisation of an EHV-1 TK probe, a 
5.35kbp BamHI/Clal fragment of EHV-1 BamHI B, to EHV-4 
BamHI library constructs comprising EHV-4 BamHI M, Q, C, 
and F fragments cloned in pUC 9.
a) 0.8% agarose gel : (1) Hindlll size markers (32P- 
labelled) (2) BamHI digest of pUC9:M (3) BamHI digest of 
pUC9:Q (4) BamHI digest of pUC9:C (5) BamHI digest of 
pUC9:F (6) BamHI/Clal digest of pUC9:C (7) BamHI/Smal 
digest of pUC9:C. Approx. 0.5ug DNA loaded per lane with 
the exception of lane (4) to which O.lug DNA was added.
b) Autoradiograph showing hybridisation of the EHV-1 TK DNA 
probe to a Southern blot of the above gel : (1) Hindlll 
size markers (32P-labelled) (2) BamHI digest of pUC9:M 
(3) BamHI digest of pUC9:Q (4) BamHI digest of pUC9:C 
(5) BamHI digest of pUC9:F (6) Hindlll size markers 
(32P-labelled) (7) BamHI/Smal digest of pUC9:C (8) 
BamHI/Clal digest of pUC9:C.
c) Clal and Smal restriction map of EHV-4 BamHI C. The 
EHV-1 TK probe hybridised to the rightward lOkbp Clal/BamHI 
fragment and to three rightward Smal/Smal or . Smal/BamHI 
fragments.
Figure 3.6 
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Figure 3.7 Sequence analysis of RX2 and flanking DNA.
a) Localisation of two major ORF , a UL24 gene homologue 
and the TK gene, within RX2. A further partial ORF was 
identified as the N-terminal coding region of the gH gene 
of EHV-4. Transcriptional direction is indicated by arrows. 
Numbering corresponds to that used in Figure 3.8.
b) Sequencing strategy utilised. Arrows indicate regions 
sequenced using individual custom-made primers or BS 
primers (with ExoIII-deleted EHV-4 DNA) . The arrow 
direction indicates whether data was obtained for the upper 
or lower strands.
c) VAX analysis of the coding potential of the sequence. 
Potential ORFs are indicated by boxes. As shown in a) two 
major and one minor ORF were detected.
Figure 3.7 
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Figure 3.8 Nucleotide sequence analysis of RX2 and 
flanking DNA and predicted amino acid sequences of the 
products of the UL24 gene homologue and of the thymidine 
kinase gene. The predicted N-terminal amino acid sequence 
of the gH gene homologue is also indicated. Putative TATA 
boxes (T), polyadenylation signals (PS), and 
transcriptional start sites (R) are underlined as are the 
EcoRV and Xhol restriction site termini of RX2.
Figure 3.8
Nucleotide Sequence Analysis of 2400bp of EHV-4 BamHI C
(P S -U L 2 4 )  (P S - U L 2 4 ) *  K
CACATACTCTGCCATCTCGGCTACTACTATAAGGCCTTTAGCTTCGATCTTGGTGTATACTTGCGTGTAGGCGCGCTAACAAAAAAGGGGCAGCAGTCIITAAIGTCACGGGCTrriATI 120
EcoRV
TTGGGGCAAATAGGGATGCCACCCAGGCAAGGGGGTTTGCGAGCGATATAGTCGCCGGTTGATATCCCACAGCGGCGTTAGTGGTGTTTGCTTGGGCCGTCGCCGAAAACAAACTCGCAA 2 4 0  
P A F L S A V W A L P N A L S I T A P Q Y G V A A N T T N A Q A T A S F L S A V
CGGCAGCAGTCGCTGCAGGTTTAGCTTGCGTTATAGGTTGAATAGACCCAGTAGTAGTTTTGGCTCTAAAAGCTTTGGAATTTGTTCTTCGCGTAACACATCGCCTTCTAGTTGATCTCT 3 6 0  
A A  T A A P K A Q T I P Q I S G T T T K A R F A K S N T R R T V C R R R T S R E
CAGAAATGGGAGGGGAGTATTCCGCTAGGCGTGATATAGTGCAAGATAGCACAGCTGCGTTGCTATACACTACCTGTGGCGATAAACGCGTTACCCTCAACACCCGCATTCCTCGTTGAG 4 8 0  
S I  P P S Y E A L R S I  T C S L V A A N S Y V V Q P S L R T V R L V R M G R Q A
CTACAAACACTAACACCGGTGCTAGTAAAATTTCACCGCTTCCCGGAGGCAAGGTTTTGGCTAGCAACCTACATGAGTCGTGAAGCTGTCGCATACCCCCCTTCCGTTGTAAATTTTTAC 6 0 0  
V F V L V P A L L I E G S G P P L T K A L L R C S D H L Q R M G G K R Q L N K S
TAGCGGTGTTCATATTTTTTGAGAAGCGACACGTTTTTAGTTCTATTAAGATGCAGACCCCTTTGGCGTCAGAGCCATGCCCAAATTGCACTGTACATACACAATCTGGGCGCCGCTGTC 7 2 0  
A T N M N K S F R C T K L E I L I C V G K A D S G H G F Q V T C V C D P R R Q G
CGAGGTTGACCTCAAAGGCTAGAGACACGCCCATAGCCGTTTTAAGAGTTTCCGCTGGCACCAATTCACTAAAAAGGGGAGCAAGCCGCGCTCCGTACACTCCATTCTTCTTGGCGCTTG 8 4 0
l n v e f a l s v g m a t k l t e a p v l e s f L p a l r a g y v g n k k a s a
(T -T K )  ( R -T K )  (O R F2 : T K ) M A A C
CCAAATCTTGAACCATTGCGTTATAGAAGCGGTTGTGGCACCGTATACCCGCTCTGAGTCTGCTTCTAGCGGTGAGACGCTGTTTACGTTTCATCTCCACAGGCAGTAATGGCTGCTTGC 9 6 0  
L D Q V M A N Y F R N H C R I G A R L R S R A T L R Q K R K M  (0R F1  : U L24 h o m o lo g u e )
V P P  G E A P R S A S G T P T R R Q V T  I V R  I  Y L D G V Y G  I  G K S T T  G R V  
GTACCCCCGGGAGAAGCTCCACGAAGCGCCAGCGGAACGCCCACCCGGCGGCAAGTAACAATAGTTAGAATTTACCTCGATGGAGTTTATGGCATCGGTAAGAGCACGACGGGACGAGTT 1 0 8 0
M A S A A S G G S P T L Y F P E P M A Y W R T L F E T D V I S G I Y D T Q N R K  
ATGGCATCGGCTGCTAGCGGAGGAAGTCCAACTCTATACTTTCCAGAGCCTATGGCGTACTGGCGGACTCTTTTTGAAACGGACGTAATTAGTGGTATTTACGACACCCAAAACCGGAAA 1 2 0 0
Q Q G N L A V D D A A L I T A H  Y Q S R F T T P Y L I L H D H T C T L F G G N S  
CAGCAGGGAAATTTGGCCGTTGATGACGCGGCATTAATAACTGCGCATTACCAAAGCCGCTTTACCACGCCCTACCTGATACTCCACGATCACACTTGTACGTTGTTTGGGGGAAACAGC 1 3 2 0
L Q R G T Q P D L T L V F D R H P V A S T V C F P A A R Y L L G D M S M C A L M  
CTACAGCGTGGAACACAACCGGACCrGACCCTTGTGTrTGACCGCCACCCGGTCGCCTCTACCGTATGCrTTCCAGCAGCCCGCTACCTACTCGGTGACATGTCAATGTGCGCGCTAATG 1 4 4 0
A M V A T L P R E P Q G G N I  V V T T L N V E E H  I R R L R T R A R  I G E Q  I D 
GCTATGGTTGCTACTCTACCAAGAGAACCCCAGGGTGGTAACATTGTGGTTACCACCCTAAATGTAGAGGAGCATATACGGAGACTGCGTACGCGGGCTAGAATAGGAGAACAAATTGAC 1 5 6 0
I T L I A T L R N V Y F M L V N T C H F L R S G R V W R D G W G E L P T S C G A  
ATTACGCTGATTGCTACATTGCGAAATGTGTACTTTATGCTAGTTAATACATGTCACTTTTTGCGCTCTGGGCGAGTTTGGCGCGACGGTTGGGGTGAGCTACCCACTTCCTGTGGGGCT 1 6 8 0
Y K H R A T Q M D A F Q E  R V S P E L G D T L F A L F K T Q E L L D D  R G V I L  
TATAAGCATCGCGCCACACAGATGGACGCCTTCCAAGAGCGCGTTTCACCGGAGCTGGGCGACACTCTGTTTGCCCTGTTTAAAACTCAAGAACTGCTAGACGATCGCGGTGTAATATTG 1 8 0 0
E V H A W A L D A L H L .  K L R N L N V F S A D L S G T P R Q C A A V V E S L L P  
GAAGTTCACGCTTGGGCGTTGGACGCGCTTATGCTAAAACTGCGTAACCTGAATGTTTTCAGTGCCGATTTAAGTGGTACACCGCGACAATGTGCAGCTGTTGTAGAGTCTTTGCTGCCA 1 9 2 0
L M S S T L S D F D S  A S A L E R A A R T F N A E M G V *  
CTTATGAGCAGCACCTTATCAGATTTTGATTCCGCCTCTGCTTTAGAGCGGGCGGCACGCACCTTTAACGCGGAGATGGGCGTCTGAAGCTATATGTAATGTTTGTTGTGCCAATGCCAA 2 0 4 0
(P S -T K )  (P S -T K )
AATTGTGAAATAAAGATTCATTTGCCAATATCCATCATAGCGCCTTGTGTGTTTCGTGTGTAAACTTCCAGTTTCTAGTTTGGGGATATATAAGCCGTTGTGCTCTTAAATCATTTAGTA 2 1 6 0
X h o l (T -g H )  (ORF 3 : g H )  M S Q P Y L K I A I L V A A T  I V S A
CAGCGCGGCCGAGATACTCGAGGTATCCAGTGGTTGTATATTGGGAATAAATACTGCTGCGATTATGTCACAACCGTATCTAAAAATAGCTATCTTAGTGGCCGCTACTATTGTGTCTGC 2 2 8 0
I P V W T T P V S  T S P P Q Q T K L H Y V G N G T U V H N N T F N V T R Y D R I  
GATTCCCGTTTGGACAACACCGGTTTCAACTTCACCACCCCAACAAACAAAATTGCACTATGTGGGAAATGGTACCTGGGTACACAACAATACATTCAACGTAACCAGGTATGACAGGAT 2 4 0 0
Figure 3.9 Autoradiograph of sequence analysis of EHV-4 C 
using custom-made primers. Reaction mixes were loaded 
in order A,C,G,T from left to right. The gel was run at 
2000V/cm for 3.5 hours to elucidate sequence unreadable in 
a previous 2.0 hour run. Thus the sequences shown below 
commence approximately 70bp 3' of the primer sites.
Lanes 1-4: Primer UPSBS bp 390-374 (lower strand); Template 
pBSCS6.
Lanes 5-8: Primer LN5 bp 1329-1345 (upper strand); Template 
pBSRX2.
Lanes 9-12: Primer LN8 bp 1391-1375 (lower . strand);
Template pBSRX2.
Lanes 13-16: Primer LNC bp 1064-1047 (lower strand);
Template pBSRX2.
Figure 3.9
Autoradiograph of TK-Seouencing Reactions
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Figure 3.10 EHV-4 DNAs cloned in BSM13+ or pUC vectors 
which were analysed for their capacity to induce TK- to TK+ 
transformation within BHK TK- cells (see Table 3.5).
a) Schematic representation of EHV-4 RS3 DNA indicating 
restriction sites used in deletion procedures, the position 
of the TK gene (black box), and the position of putative 
TK TATA boxes (T1 and T2). Numbering corresponds to that 
utilised in Figure 3.8. Deletions produced within RX2 and 
RS3 by ExoIII digestion are represented below.
b) Deletions produced within RX2 and RS3 by restriction 
endonuclease digestion (see Figure 3.3).
Ficrure 3.10
KX2- and RS3-Deleted DNAs
CO £1
Ficrure 3.11
Alignment of the Predicted Products of Herpesvirus 
UL24 Gene Homologues
EHV-4 . . . . . . . . . . . . . . . . . . . . . . . . . . MCRKQRLTARSRLRAGIRCHNRFYNAMVQDLASAKKNGVYG--ARLAPLFSELVPAETLKT
EHV-1 . . . . . . . . . . . . . . . . . . . . . . . . . . MKRRQRLTARSRLRAGIRCHNRFYNAMV3DLASAKRNGVYG- -ERLAPLFSELVPAETLKT
VZV . . . . . . . . . . . . . . . . . . . . . . . . . . MSASRIRAKCFRL--GQRCHTRFYDVLKKDIDNVRRGFADAFNPRLAKLLS-PLSHVDVQR
HSV-1 . . . . . . . . . . . . . . . . . . . . . . . . . MAARTRSLVERRRVLMAGVRSHTRFYKAL-AEEVREFHATKICG- -TLLTLLSGSLQGRSVFE
HSV-2 . . . . . . . . . . . . . . . . . MARTGRRAAVGRPARTSSLTERRRVLLAGVRSHTRFYKAF-AREVREFNATRICG--TLLTLMSGSLQGRSLFE
MDV MSSEMPLPTTIVAPTCSMGEKNVLKRYRRQVSSTRNFKRHVNTNVLRKRRLAAGWRCHDRFYKRLYAEAMCLG9QVYDWPGRSFAKIFGKVMVLDVFKQ
HVT ........ MPSTRRSKCKPRICYGNAGLAGNCLRGKHAGNHLMAGLLIGAGVRGHNRFYKKLAAENFDQSSAGNTV-GRTLQKILSKILPSELLKG
HCMV . . . . . . . . . . . . . . . . . . MPSGRGDDADSTGNALRRLPHVRKRIGKRKHLDIYRRLLRV-FPSFVALN.. RLLGGLF. . . . PPELQ
EBV . ............... MDPTRGLCALSTHDLAKFHSLPPARKAAGKRAHLRCYSKLLSLXSWEQLA....... SFLSLPPGPTFT
HVS . . . . . . . . . . . . . . . . . . . . MLSVIKQRDKEVLAHLPNKRKIAGNKAHLETYKKLAKYTVSASI F. ....... KFLSISHPCPLR
Cons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . rl-AG-R-H-RfY--l. . . . . . . . . . . . 1 --1 -S......
it***************
I
EHV-4 AMGVSLAFEVNLGQRRPDCVCTV- - -QFGHGSDAKGVCI LIEUaCRFSWMJTASKNL QRKGGM^QLHDSCRLLAKTL-PPGSGE ILLA-PV
EHV-1 ALGVSLAFEVNLGQRRPDCVCTV---QFGKGSDAKGVCILIEUCTCRFSKNMNTASKNL QRKGGMRPVHDSCRLLARTL-PPGSGEIVLA-PV
VZV AVRISMSFEVNLGRRRPDCVCII— QTESSGAGKTVCFIVELKSCRFSANIHTPTICYH QFCEGMRQLRDT-MALIKETTPTGSDEIMVT-PL
HSV-1 ATRVTLICEVDLGPRRPDCICVF— EFANDICTLGGVCVIIELKTCKYISSGDTASKRE QRATGMKQLRHSLKLLQSLA-PPGDKIVYLC-PV
HSV-2 ATRVTLICEVDLGPRRPDCICVF— EFANDKFLGGVCVILELICTCKSISSGDTASKRE QRTTGMKQLRHSLKLLQ
MDV LTD FRLVFEVHLERRRPDCICMFKLPRDLWEVGCDGVCVILELKTCKFSRNLKTRSKHE QRLTGIKQLLDSKSLIGQIA-PQGSDCIVIC-PM
HVT ASAFRLAFEVDLGRRRPDCICMFTLSGGLLVEGCNNVCVIIELKTCRFYRNLKTASKNE QRATGTKQLLESKTLIERMA-PRGSDHTIIC-PV
HCMV KYRRRLFIEVRLSRRIPDCVLVFL-PPDSGSRGIVYCYVIEF1CT-TYSDADDQSVRWHATHSLQYAEGLRQLKGALVDFDFLRLPRGGGQVWSWPS
EBV D— FRLFFEVTLGRRIADCVWAL..... QPYPRCYIVEFICTAMS-NTANPQSVTRKA— -QRLEGTAQLCDCANFLRTSCPPVLGSQGLEVLAA
HVS AICT-RLFFEVSLGNRIADCVMLTS.... CGETRICYVIELKTCMTSN--LDISDIRKS-- QRSQGLCQLADTVNFIHNYA-PLG-RQAWTVLPI
Cons a— -L-fEV-LG-RrPDCvcx......... vC-iiELKTC.... t-Sk..... QR-G-QL-ds-ll P-G..... P-
***************** ********************* ************************ **
II III IV
EHV-4 LVFVAQRGMRVLRVTRLSPQWYS— NAAVLSCTISRLAEYSPPI— SERSTRRRCVTRRTNSKAFRAICTTTGSI CPI TQAKPAATAAVASLFSATAQ
EHV-1 LVFVAQRGMRVLRVTRLSPQWYS- -NAAVLSCTISRLAEYAPPV- - -SAKSTRRRCVAKGTKAKAFSTKAAAEPVPSITPACPSAAAAWSLFPAAVP
VZV LVFVSQRGLNLLQVTRLPPKVIHG-NLVMLASHLENVAEYTPPIR-SVRERRRLC-KKKIHVCSLAKKRAKSCHRSALTKFEENAACGVDLPLRRPS
HSV-1 LVFVAQRTLRVSRVTRLVPQKVSG-NITAWRMLQSLSTYTVPIEPRTQRARRRRG--GAARGSASRPKRSH- - - -SGARDPPESAARQLPPADQTPT
HSV-2
MDV LVFVARRKLSVLHVMCLK--KRHIVTDFHRLCSILATASDYKARITDTHKILKRHNTNTIHIQRRSGKASANVTDLRNHIACN1CTATLSFSNNQERT"
HVT LVFVARRGLWIRSTPLK- -KKAICTDFHRLASM4YLRSEYRLYDSGMCKPMRKICHRNKRTVSTVRRMRCGISDTGVLPIEKQTMDARGKDCGTSGIE
HCMV LVFFQQKADRPSFYRAFRSGRFDLCTDSVLDYLGRRCDESVAHL-- -LAATRRRLLRTARGKRAALPRARASAVAGGRGGDNARRGLARGRAHGPGAQT
EBV LVFKNQRSLRTLQVEFPALGQtCTLPTSTTGLLNLLSRWaDGAL RARLDRPRPTAQGHRPRTHVGPKPSQLTARVPRSARAGRAGGRKGQVGAVG
HVS LIFKSQKTLKTLHIETPKFPVNLTHTSEEKLSCFLWSRADVEIRKKIHLAPKPKRI FkUDSLLDSTSTEHSAYRQKL IERNKKKCFTLQNQTSKFRDRP
Cons LVFv-qr-l--l-vt-l........ I..... y-....... r..................... a--. . . . . .
*****************
EHV-4 ANTTNAAVGYQPATISLANPLA1WASL FAPK 
EHV-1 ANTTNAAAVHQPVAVSHVNPLAWAASLFSPK 
VZV LGACGGILQSITGMFSHG*
HSV-1 STEGGGVLKRIAALFCVPVATKTKPRAASE 
HSV-2
MDV GGTAMRNMANIIARLVQRP*
HVT GEPIMQRMRNIISHLSRRH*
HCMV VSASGAQGSGSQGADLLRGSRRARVRGGGAVEPAVRARRRTVAADAATTTVSSAFFVPRDRRGRSFCRPTRSL 
EBV QVCPGAQK*
HVS NKKSMDQLRARQANARPCKKKQHNNKRLRNNRKHGGKVSRLTTTTSFSSEAAFSNYPVSTHKL
Figure 3.11 Alignment of the predicted amino acid sequences 
of the HSV-1 UL24-specified polypeptide and its counterpart in 
other herpesviruses. Data obtained from Robertson and Whalley, 
1988 (EHV-1), Davison and Scott, 1986 (VZV) , McGeoch et al. .
1988a (HSV-1), Scott, 1989 (MDV and HVT) , and Jacobson et al.. 
1989b. A consensus sequence line is detailed in which 
residues conserved in 6 to 8 polypeptides are presented in 
lower case, those conserved in 8-10 in upper case.
Ficrure 3.12
Alignment of the Predicted Amino Acid Sequences of
Herpesvirus Thymidine Kinases
EBV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . m a g f p g k e a g p p g g w r k
HVS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . m t g r g q p
EBV c q e d e s p e n e r h e n f y a e i d d f a p s v l t p t g s d s g a g e e d d d g l y q v p t h
HVS p k k n d t y d y p r k q p p k n g s y d n y d y p t s t k t r s t n k q r k d s n y p p r e t  i f
EBV w p p l m a p t g l s g e r v p c r t q a a v t s n t g n s p g s r h t s c p f t l p r g a q p p a
HVS e p d l a a d p i y s v p r p p s r v p h k l v k v n y k s n l v p i  t a s n s v s e l .......
EBV p a h q k p t a p t p k p r s r e c g p s k t p d p f s w f r k t t s c t e g g a d s t s r s f m y
HVS  - - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
EBV q k g f e e g l a g l g l d d k s d c e s e d e s n f r r p s s - - h s a l k q k x g g k ......
HVS I s l h d e t q v t e c v e a p l i a k s p d i t v y e k m f s v r p k h t l t k l e g k q k m f t
HSV-1.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . m a s y p c h q h a s a f d q a a r s r g h n n
HSV-2.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . m a s h a g q q h a p a f g q - a a r a s g p t -
EBV g k p s g l f e h l a a h g r e f s k t s k h a a q l k r l s g s v m n v l n l d d a q d t r q a k
HVS r k k k g s f v k i g s n m l e f g e s l k s k l h n d s k k s p . . . . . . . . . . . . . . . . . . . . . . . .
EHV-4 in a a c v p p g e a p r s a s g t p t r r q v t i v r i y I d g v y g i g k s t t g r v m a s a a •
EHV-1 m a a r v p s g e a r r s a s g a p v r r q v t i v r i y I d g v y g i g k s t t g r v in a s a a •
PRV . . . . . . . . . . . . . . . . . . . . . .  m r i I r i y I d g a y g t g k s t t a r v m -a ----
BHV-1 . . . . . . . . . . . . . . . . . . . . . . m a e p a r a l  r v v r i y l d g a h g  I g k t t t g r a  I a a a s -
BHV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .m s r l l r v y v d g p h g l g k t t a a s r l a s - - -
MarHV . . . . . . . . . . . . . . . . . . . . . . m s g t a g t s r i l r v y l d g p h g v g k s t t a e a l v a r c e
FHV . . . . . . . m a s g t i p v q n e e i  i k s q v n t v r i y i d g a y g i g k s l t a k y l v r a d e
HSV-1 r r t a l r p r r q q k a t e v r l e q k m p t l  I r v y i d g p h g m g k t t t t q l  I v a  - I g
HSV-2 g r a a s r p s h r q g a s e a r g d p e l p t l l r v y i d g p h g v g k t t t s a q l m e a l g
VZV . . . . . . . . . . . . . . . . . . . m s t d k t d v k m g v l r i y l d g a y g i g k t t a a e e f l h h f a
MOV . . . . . . . . . . . . . . . . . . . . . . m a s q m t s a q l i r v y l d g s m g i g k t s m l n e i p t h s -
HVT . . . . . . . . . . . . . . . . . . . . . . m a l p r r p p t l t r v y l d g p f g i g k t s i l n a m p d h t -
EBV a q r k e s m r v p i v t h l t n h v p v i k p a c s l f l e g a p g v g k t t m l n h l k a - - -
HVS d e p d g l v h v p v h l l y p p k h q d p v p a f f i f l e g s i g v g k t t l l k s m n g i - -
Cons  R i T l  D G - • G - G H  t t - - - - I . . . . . . .
★★★★★★★★★★★★★★★ft*************
A
E H V -4 s gg s P t1y fP e Pm a yw r t1fe td V i s g i y d tq n r kq qgn 1a V d d a a Iita
E H V -1 s gg s P tIyfP e Pm a yw r tIfe a d V is g i Y dtqn r kq qgd Ia a d d a a s ita
PRV Igg--a Iy vPe Pm a yw r tIfd td tV a g i y d a qt r kq ngs Is e e d a a IV ta
BH V -1 t a ge gV I ffPe Pm a yw r tmfgtd a Is g i I a a s a r c a a a s h gs a r a r r a ga
B H V -2 e r gd -a i y t Pe Pm s yw s ga ge d d IV a r V y ta q h r m d r ge i d a r e a a gV V I
M arH V P r r P i r s m Iq e Pm a yw r s tfa s d a i te i y d tq h r Id s n e i ta a e a g a fm t
FHV n r Pgyty y fp e Pm Iyw r S Ife td V V gg i Y a V q d r k r r ge Is a e d a a y i t a
H S V -1 s r d d -iV y v p e Pmtyu r V Iga s e t i a n iy ttq h r Id q ge i s a gd a a V V ID t
H S V -2 P r d n - i V y v p e Pmtywq V Iga s e tItn i y n tq h r Id r ge i s a g e a a V V IDt
VZV i tP n r i I i i ge P Is yw r n Ia ge d a i c g i y gtqt r r I n gd V s P e d a q r I t a
MDV t mgV P vIk V f e Pm k yw r - y y f t d IV ttV n dtc d r r r  r ge fs Ifq s s m i V t
HVT P d ga P i I kV ye Pmkyw r - c q s td I V V a a n e tPe r r r g ga I s r f q s d m i m a
EBV V fgd It i V V p e Pm r ywth V y-e n a i ka m h kn V t r a r  h g r ---e d t s a e V I
HVS Iggkn V Ia fh e P i a ywtd V f-s n s Ie e V y kItIP a k v g r --- t s n s a k I I
Cons --g - - - Iy - p EP M - Y u r - If - - d - - - - i y * tq - R - - - G - - s - - d a a - - - a
B
E H V -4 h y q s r f t t p y I i 1 h d h t - - c t 1 f g g n s 1 q r g t  qp d  I t t V f d r h
E H V -1 h y q s r f t t p y I i I h d h t - - f g I f g g d s I q r g t  r p d  I t V V f d r h
PRV - - q t r P P s r  r r t c c V h t r 1 V p I f g P a V e g p P e ID t V V f d r h
BH V -1 P r r r g r g g p g c V I P g q V r g p V I n f a r a r V r  a  a a P P g P a P 9 g t V t I V f d r h
B H V -2 g a q I t m s t p  y V a I n g t i a - - p h i g e e - - - ... P s P g n a t  P P d t i I i f d r h
M arH V s I q I h m g t p  y a I I e e a m r - - p h V g r e 1 a e p d  d - n g p I P q r r  d f V t V V d r h
FHV h yq a r f a a p y I I I - - h s r l s t i t g y qkV V C B ­ - - - - - - e  h P d V t I i i d r h
HS V -1 s a q i t m g m p y a V t d a V I a - - p h i g g e a g s S ' - h a P P P a I t I i f d r h
H S V -2 s a q i t ID s t p y a a t d a V I a - - p h i g g e a V g p q a P P P a I t I V f d r h
VZV h f q s I f c s P h a i m h a k i s a 1 ID d t s t s d I V q V n k e p y k i m I s d r h
MDV a I q s k f a d p y I V f h e r I s s kC h r i t g t r g  n P s I i I i I d r h
HVT s i q a r f a d p y t I f h e r I s s kc r g k i e i c d  t P a i i I ID I d r h
EBV a c qm k f t t p f r V I a s r k r s I I V t e s g a r s V a  p I  d c w i I h d r h
HVS a c q I k f a s p i I a I k t a t d r t s s pkn s I I s s  d m u V m f d r h
Cons - - Q - - f - - P y - - I - - - - - - - - - - g - - - - - -  -  - - - - - - - -  - p d  -  t  I  -  f  D R H * * * * * * * * * * * * * * * * * * *
Figure 3.12 (Cont.)
EHV-4 p v a s t v c f  p a a r y l  t g d m s m c a l m a m v a t  I p r e p q g g n i  v v t t  I n v e - e h  
EHV-1 p v a s a v c f p a a r y l i g d m s m c a l i a m v a t l p r e p q g g n i v v t t l n v d - e h  
PRV p v a a t v c f  a v a r f  i v g d i  s a a a f v p w r p r c p g s p p  - r q p g g g  I a g p g r a p
BHV-1 p v a a c l c y p f a r y c l  r e i  n a e d l  I m l a a a m p p e a p g a n l v v c t  I p p a - e q
BHV-2 p t a s l  I c y p l a r y l t r c l p i e s v l s l  i  a l  i p p t p p g t n l  i I g t a p a e - d h
MarHV a v a s m v c y p l a r f m m g c v s  I r s v a s  I i s h  I p p p l p g t n l v v a s  I d f r  - e h
FHV p l a s l v c f p l a r y f v g d m t l g s v l s l m a t l p r e p p g g n l v v t t l n i e - e h
HSV-1 p i a a l l c y p a a r y l m g s m t p q a v l a f v a l i p p t l p g t n i v l g a l p e d r - h  
HSV-2 p i a s l l c y p a a r y l n g s m t p q a v l a f v a l m p p t a p g t n l v l g v l p e a - e h  
VZV p i a s t i c f p l s r y l v g d m s p a a l p g l l f t l p a e p p g t n l v v c t v s l p s - h
MDV p i s a t v c f p i a r h l t g d c s l e m l  i s m i  i r l p q e p p g c n l v i v d l h d e k e h
HVT p v a a i  I c f p i t r y l l g e y s l e m l i s s i  i r l p l e s p g c n l t v t i  I p d e k e h
EBV I I s a s v v f p l m l  I r s q l  I s y s d f i q v l a t f t a d - p g d t i v w m k l n v e - e n
HVS p l s a t v v f p y m h f q n g f l s f s h l  i q l w s s f k a s - r g d n i  i  I I n l n s q - e n
Cons P • a a ■ v C  f  P ■ a R y I • g • ■ s • • ■ I - - - - a - I P - e p p G - N l v v - -  I - - - - e h
★★ft****************************
C D
EHV-4 i r  r  I r  t  r  a r  i  g e q • i  d i t  I i  a t  I r  n v y  f  m I v n t  c h f  I r  s g r  .............................
EHV-1 v r r l r t r a r i g e q - i d m k l i a t l r n v y s m l a n t s n f l r s g r .................. ....
PRV a a - p a a r a r a g e h - v d a r l  I t a l  r n v y a m l v n t s r y l s s g r ..............................
BHV-1 q r r l a a r a r p g d r - a d a g f l v a v r n a y a l l v n t c a f l r a g g d g a ..................
BHV-2 I s r l v a r g p p g e l  - p d a r m l  r  a i  r y v y a  I l a n t v k y l q s g g ...............................
MarHV a a r l r a r a p p g e r - l d l t m m a a i r n a y a m l a n t s r y l l s g g ..............................
FHV I k r l r g r s r t g e q - i d m k l i h a l r n v y m m l v h t k k f l t k n t - - - - - - - -
HSV-1 i d r  l a k r q r p g e r  - I d l a m l a a i  r r v y g  I l a n t v r y l q g g g  - - -
HSV-2 a d r  l a r r q r p g e r  - I d l a m l s a i  r r v y d l  l a n t v r y l q r g g ......................... -
VZV I s r v s k r a r p g e t - v n l p f v m v l r n v y i m l i n t i i f l k t n n - - - - - - - -
MDV v s r l s s r n r t g e k - t d l l m l r a l n a v y s c l v d t i m y a n h i c p y s k d - - -
HVT v n r i  c s r d r p g e t - a d r n m l  r t  I n a v y a s l v d t v k y a n l  t c p y e k e  - - -
EBV m r r l k k r g r k h e s g l d a g y l k s v n d a y h a v y c a w l l t q y f a p e d i v k v c
HVS I k r v k k r n r k e e k s v s i e h i r l l n n c y h a v y c a w l l v q n f t p e e i v e v c
Cons - - R l - - R - R p G E - - - D - - - l - a l r n v Y - m L v n T - - y l - - g ..................................
E
EHV-4 - - - - v w r d g w g - e l p t s c g a y k h r a t q m d a f q e r v  - - s p e l g d t  I f a  I f k
EHV-1 - - - - v w r d g w g - e l p l s c e t y k h r a t q m d a f q e r e - - s p e l s d t l f a m f k
PRV - -■ - - r w r d d w g  - r a p r f d q t t r d c  I a I n e l c  - - r p r d d p e  I q d t  I f g a y k
BHV-1 t a g t r w s g r t q m h w p r s - q t p v v m n a k c a g - - - - - - - - a g l r d t l f a a l k
BHV-2 -s h r  a d I g s e p p r  I p I a p • p e i  g d p n n ------------
MarHV - - - - d w r r d w g - s l p v f k p s a f v a r a a k t a y t l p l r d e p g l a d t l f a a l k
FHV -s w r  d g h g k I k i  f  s h y e r  n r  I v  e t  t  i  v s d • • • s t  e s d I c d t  I f  s v  f  k
HSV-1 - - - - s w r e d w g - q l s g a a v p p q g a e p q s n a g p r ..................... p h i g d t l f t l f r
HSV-2 - - - - r w r e d w  g - r  I t  g v a a a  t  ■ r p d p e d g a g s ......................I p r i e d t l f a l f r
V ZV  ...................... n h a g « n - t l s f c n d v f k q k l q k s e c i - - k l r e v p g i e d t l f a v l k
MDV - - - - e w e s e w l - d l p w f d t s l a t t f i n e p r t - d y r g s r v s l h h t l l a i f k
HVT - - - - s w e m e w l - g l p w f e e s l l e e f i s r p r p v i c s r t r m p l d r t l l a i f k
EBV a g I t  t  i  t  t  v c h q s h t  p i  i r  s g v a e k I y • k n s i  f  s v I k e v i  q p f  r  a d a v • ■
HVS f n a k h i t d l s s - s k p s f l a k h v s t e d m l k s s i f n t w i e m t k a h r d s c t - -
Cons .................W r - - w g - - l p .............................................................................................p - l - d t l f a - f k
F
EHV-4 t q e l  I d d r g v i  l - e v h a w a l d a l m l k l r n l n v f s a d l s g - t p r q c a a v v e
EHV-1 t p e l  I d d r g v i  l - e v h a w a l d a l m l k l r n l s v f c a d l s g - t p r q c a a t v e
PRV a p e l c d r r g r p l - e v h a w a m d a l v a k l l p l r v s t v d l - g p s p r v c a r p w r
BHV-1 c r  e I y p g  g g t  g I p a  v h  a u a  I d a  I a g r  1 a a I e v f  v I d v s  - a a p d a  c a a a v I
BHV-2 .................p g g h n ............................... t l l a l .............................................. i h g a g - a t r g c a a m t s
MarHV v p e f  I d a r  g y p r  • a a h a « t  I d i I a n r  i  r  a I r  v y  t  I d I t  g ■ p p e a c a a a f  r
FHV a r e l s d q n g d l  I - d m h a w v l d g l e m t  I q n l q i  f t  I n l e g  - t p d e c a a a  I g
HSV-1 a p e l  l a p n g d l y - n v f a w a l d v l a k r l r p m h v f i  I d y d q - s p a g c r d a l  I
HSV-2 v p e l  l a p n g d l y - h i f a w v l d v l a d r l  I p m h l f v l d y d q - s p v g c r d a l  I
VZV I p e l c g e f g n i l - p l w a w g m e t l s n c s r s m s p f v l s l e q - t p q h a a q e l k
MDV r r e l c a e d g s l s - t t h a w i  I w g l  I m k l r n i n v e r f n i t g l s t t k c v e s f m
HVT r k e l c s e n g e l l - t q y s w i l w g l l t k l h t i n v e l f d i s g m s r r e c a s a i m
EBV l l e v c l a f t r t l ................................ a y l q f v l v d l s e f q d d l p g c w t e i y m q a l k
HVS I m e c l  I t f c k e l .................e k v q l  i h v n v s p f t d d i p g l w a s i y t s i  r r
Cons -  p  E I  ■ -  -  ■ g  -  ■ I  -  -  •  h  a  w -  I  d  •  L •  •  •  I  -  •  I  •  v  f -  -  d  I  ■ g  -  -  p  -  -  c  a  -  a  ■ -
F
Figure 3.12 (Cont.)
EHV-A s l l p l m - s s t l s d f d s a s a l e r a a r t f n a e m g v *
EHV-1 s l i p l m - s s t l s d s e s a s s l e r a a r t f n a e m g v *
PRV r  g a r  r  r  *
BHV-1 d m r p a m - q a a c a d g a a g a t l a t l a r q f a l e m a g e a t a g p r g l *
BHV-2 w t l d l l a d r l r s m n m f t w t t a r p r s l c g s d e e l a p l d a v h r d p k t r i s s  
MarHV r l c a g l v l t e g s h p g a l c e l k r a a a a y a r e m s v v g s r e p t t a e v e s a *  
FHV a l r q d m d m t f i a a c d m h r i s e a l t i y h *
HSV-1 q l t s g m v q t h v t t p g s i p t i c d l a r t f a r e m g e a n *
HSV-2 r l t a g m i p t r v t t a g s i a e i r d l a r t f a r e v g g v *
VZV t l  I p q m t p a n m s s g a w n i  I k e l v n a v q d n t s *
MDV d t m s e r l v t h m s w n d a f e i e a d v l - a y n k e m a m *
HVT h t m p e r l s t  l a s w n d l c e l e d d v i  - s y n k g m c n e v g a s r *
EBV n p a i r s q f f - - d w a g l - - - - s k v i s d f e r g n r d *
HVS n s a i k p n r v - - n n l a l  e d l a r t f n s q *
Cons - - - - - - - - - - - -  . . . . . . . . . . . .
EHV-A (352)
EHV-1 (352)
PRV (295)
BHV-1 (357)
BHV-2 (306)
MarHV (360)
FHV (3AA)
HSV-1 (376)
HSV-2 (375)
VZV (3A1)
MDV (3A3)
HVT (350)
EBV (607)
HVS (527)
Figure 3.12 Alignment of the predicted amino acid sequences 
of the thymidine kinases of 14 herpesviruses. Data obtained 
from Robertson and Whalley, 1988 (EHV-1), Kit, 1985b (PRV) , 
Mittal and Field, 1989 and Kit, 1985a (BHV-1) , Sheppard and 
May, 1989 (BHV-2), Otsuka and Kit, 1984 and Scott et al. , 1989 
(MarHV), Nunberg et al.. 1989 (FHV) , McGeoch et al., 1988a 
(HSV-1), Kit et al. . 1983a (HSV-2), Davison and Scott, 1986 
(VZV) , Scott et al., 1989 (MDV and HVT), Baer et al., 1984
(EBV), and Honess et al.. 1989a (HVS). A consensus sequence 
line is detailed in which residues conserved in 7 to 11 
polypeptides are presented in lower case, those conserved in 
in 12 to 14 herpesvirus TKs in upper case. Six regions of 
conservation of sequence referred to in the text are denoted 
by asterisks and the letters A-F.
Figure 3.13 Alignment of the putative nucleotide and 
nucleoside binding domains of herpesvirus thymidine 
kinases .
a) Conservation of sequence within the putative nucleotide 
binding domain of thymidine kinases of herpesviruses, 
vaccinia virus (Hruby et al.. 1983), and humans (Bradshaw 
and Deininger, 1984) and of two ATP-binding enzymes, 
adenylate kinase (Heil et al.. 1974) and bovine ATPase 
(Walker et al., 1982). Consensus lines are detailed for 
herpesvirus TK sequences and for all enzyme sequences 
presented.
b) Conservation of sequence within the putative nucleoside 
binding domain of herpesvirus thymidine kinases.
In the consensus lines of a) and b) capital letters 
indicate 100% conserved residues, small letters indicate 
70-99% conservation.
Figure 3.13
Conservation of Sequence within the Putative Nucleotide 
and Nucleoside binding Sites of Thymidine Kinases
EHV-4 R I Y L D G V Y G I G K S T T (27-41)
EHV-1 R I Y L D G V Y G I G K S T T (27-41)
PRV R I Y L D G A Y G T G K S T T ( 5-19)
BHV-1 R I Y L D G A H G L G K T T T (12-26)
BHV-2 R V Y V D G P H G L G K T T A ( 6-20)
FHV R I Y I D G A Y G I G K S L T (22-36)
MarHV R V Y L D G P H G V G K S T T (12-26)
H S V - 1 R V Y I D G P H G M G K T T T (51-65)
HSV-2 R V Y I D G P H G V G K T T T (51-65)
VZV R I Y L D G A Y G I G K T T A (14-28)
EBV S L F L E G A P G V G K T T M (286-300)
HVS F I F L E G S I G V G K T T L (211-225)
MDV R V Y L D G S M G I G K T S M (12-26)
HVT R V Y L D G P F G I G K T S I (12-26)
Cons (HV) r - y - d G - - G - G K - t -
VV - I - I - G P M F S G K S T E ( 9-20)
Human TK - I - L - G P M F s G K S T E ( 24-35 )
Bov.ATPase K I G L F G G A G V G K T V F (151-165)
A d . K i n a s e K I I F V V G G P G s G K G T Q (10-25)
Cons (all) - - - - - G - - 9 - G K - t -
EHV-4 D R H P V A S T V C F P A A R Y L L G D M (138-158)
E H V - 1 D R H P V A S A V c F P A A R Y L I G D M ( 138- 1 58)
PRV D R H P V A A T V c F A V A R F I V G D I (108-128)
BHV-1 D R H P V A A C L c Y P F A R Y C L R E I (132-152)
BHV-2 D R H P T A S L L c Y P L A R Y L T R C L (115-135)
FHV D R H P L A S L V c F P L A R Y F V G D M (134-154)
M a r H V D R H A V A S M V c Y P L A R F M M G C V (130-150)
HSV-1 D R H P I A A L L c Y P A A R Y L M G S M (162-182)
HSV-2 D R H P I A S L L c Y P A A R Y L M G S M (163-183)
VZV D R H P I A S T I c F P L S R Y L V G D M ( 1 29- 149)
EBV D R H L L S A S V V F P L M L L R S Q L L (392-412)
HVS D R H P L S A T V V F P Y M H F Q N G F L (315-335)
M D V D R H P I S A T V c F P I A R H L T G D C (121-141)
HVT D R H P V A A I L c F P I T R Y L L G E Y (121-141)
Cons D R H P - a - - - c - P - a r - - - 9 - -
Table 3.1
Substrate Specificities of Herpesvirus Thymidine Kinases
Herpesvi rus dCyd kinase 
activity
donor 
ATP CTP
Nucleoside 
BVDU araT
analogues 
DHPG A C V
alpha
HSV-1 + + + + + + +
HSV-2 + + + + + + +
EHV-1 + + + + + + +
VZV + + + + + na +
MarHV + + + + + + +
PRV - + + + + - -
BHV-1 - + + + + - -
EHV-3 - + + na + n a n a
HVT - + + na na n a +
g a m m a
BHV-4 - + + + -  + - -
HVS - + na + n a n a -
EBV + + + n a + n a n a
Table 3.1 Specificity of herpesvirus thymidine kinases for 
nucleoside substrates and phosphate donors. Data compiled from 
Kit, 1985a, and Scott et al.. 1989. Unavailable data are 
represented by ' na'.
Table 3.2
Transfection of HSV-1. EHV-1. and EHV-4 TK DNAs into TK- Cells
Construct ug DNA
HAT-resistant 
colony count
HSV-1 pTK 4 >1000
EHV-1 pBSBC5 9 >100
EHV-1 pBR:BamHI A 10 0
EHV-4 pUC9:BamHI C 8 8
Table 3.2 Transfection of HSV-1 and EHV-1 TK DNAs , EHV-1 
BamHI A, and EHV-4 BamHI C into BHK TK- cells. The final 
column details the number of HAT-resistant colonies induced by- 
transfection of the constructs into 5xl05 TK- cells. These 
results suggested that EHV-4 BamHI C might encode a functional 
TK activity.
Table 3.3 The TK-transforming capacity of several regions 
of BamHI C was assessed by monitoring the ability of 
recombinant constructs to induce a TK+ phenotype on 
transfection into BHK TK- cells. Derivation of the 
constructs is detailed in Figure 3.2 and in the text. 
Fragments MS2 cloned in construct pBSMS2 is entered as (-) 
since on one occasion a TK+ colony was detected in the 
post-transfection screening process (see text).
Table 3.3
TK-Transformina Activity of Recombinant Plasmids
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Table 3.4
Transfection of Sub fragments of EHV-4 BamHI C into TK- Cells
Construct ug DNA
HAT-resistant 
colony count
pBSBCIO 20 8
pBSCS6 20 8
pBSSS4 20 40
pBSSB4 20 0
pBSRS3 20 90
Table 3.4 Transfection of restricted regions of EHV-4 BamHI 
C into BHK TK- cells. A TK+ phenotype was evident within a 
proportion of TK- cells transfected with constructs containing 
fragments BC10, CS6, SS4, and RS3 of EHV-4 C. These data 
mapped the EHV-4 TK gene to the 3kbp EcoRV/Sall fragment of C.
Table 3.5
Transfection of RX2 and Deleted DNAs into TK- Cells
Construct limits (bp) ug DNA
HAT-resistant 
colony count
pBSRX2 181-3107 2 14, 5, 15
pBSDl 257-3107 2 11, 6 , 11
pBSD2 533-3107 2 18, 4, -
pBSD3 703-3107 2 41, 25, 29
pBSD4 942-3107 2 6 , 4, 3
pBSMS2 966-3107 2 0 , 1, o
pBSD5 981-3107 2 0 , 0 , 0
pBSD6 181-1714 2 0 , 0
pBSME 181-966:1488-2181 2 0 , 0
pBSMB 181-966:1694-3107 2 0 , 0
Table 3.5 Transfection of recombinant constructs containing 
deletions within RX2 or RS3 of BamHI C as detailed in Figure 
3.10. TK+ colonies were evident in cultures transfected with 
pBSRX2 and pBSRS3 constructs with deletions spanning the 5' 
761 bp (181 to 942, Figure 3.10). With the exception of 1 HAT- 
resistant colony in the pBSMS2-transfected cultures (see text) 
no HAT-resistant colonies were observed in transfections with 
other deleted DNAs including pBSME and pBSMB.
Table 3.6
Codon Usage of EHV-4 UL24 gene Homolocrue
2nd
1st\.
I \
A
(22%)
C
(31%)
G
(21%)
T
(26%) 3rd Residue f (%)
A Lys 12 Thr 2 Arg 7 I le 5 A (30%) Ala 36 (13.2)
Asn 8 Thr 4 Ser 4 I le 1 C (20%) Arg 26 ( 9.5)
(29%) Lys 3 Thr 6 Arg 3 Met 6 G (24%) Asn 12 ( 4.4)
Asn 4 Thr 9 Ser 3 I le 3 T (26%) Asp 4 ( 1.5)
Cys 8 ( 2.9)
C Gin 8 Pro 4 Arg 4 Leu 7 A Gin 12 ( 4.4)
His 2 Pro 3 Arg 4 Leu 4 C Glu 7 ( 2.6)
(23%) Gin 4 Pro 3 Arg 5 Leu 0 G Gly 15 ( 5.5)
Hi s 1 Pro 4 Arg 3 Leu 5 T His 3 ( 1.1)
I le 9 ( 3.3)
G Glu 5 Ala 8 Gly 6 Val 4 A Leu 27 ( 9.9)
Asp 2 Ala 10 Gly 2 Val 2 C Lys 15 ( 5.5)
(30%) Glu 2 Ala 8 Gly 4 Val 11 G Met 6 ( 2.2)
Asp 2 Ala 10 Gly 3 Val 3 T Phe 9 ( 3.3)
Pro 14 ( 5.1)
T End 1 Ser 4 End 0 Leu 5 A Ser 22 ( 8.1)
Tyr 2 Ser 3 Cys 3 Phe 2 C Thr 21 ( 7.7)
(18%) End 0 Ser 3 T rp 1 Leu 6 G T rp 1 ( 0.4)
Tyr 3 Ser 5 Cys 5 Phe 7 T Tyr 5 ( 1.8)
Val 20 ( 7.3)
Table 3.6 Codon usage of the EHV-4 UL24 gene homologue and 
amino acid frequencies within its predicted product. The 
frequencies of each base within codon positions 1,2, and 3 are 
presented as percentages.
Table 3.7
Codon Usage of EHV-4 TK gene
2nd A C G T
i 1st\1 \ (23%) (26%) (22%) (29%) 3rd Residue f (%)
A Lys 3 Thr 6 Arg 4 lie 6 A (24%) Ala 35 ( 9.9)
Asn 5 Thr 9 Ser 8 lie 1 C (24%) Arg 28 ( 7.9)
(25%) Lys 2 Thr 8 Arg 0 Met 12 G (24%) Asn 10 ( 2.8)
Asn 5 Thr 8 Ser 4 I le 7 T (28%) Asp
Cys
19
7
(
(
5.4)
2.0)
C Gin 8 Pro 6 Arg 5 Leu 10 A Gin 13 ( 3.7)
His 5 Pro 5 Arg 9 Leu 3 C Glu 15 ( 4.2)
(26%) Gin 5 Pro 5 Arg 7 Leu 11 G Gly 25 ( 7.1)
His 3 Pro 1 Arg 3 Leu 4 T His
H e
8
14
(
(
2.3)
4.0)
G Glu 6 Ala 5 Gly 10 Val 7 A Leu 39 (11.0)
Asp 12 Ala 9 Gly 3 Val 2 C Lys 5 ( 1.4)
(33%) Glu 9 Ala 8 Gly 3 Val 3 G Met 12 ( 3.4)
Asp 7 Ala 13 Gly 9 Val 12 T Phe
Pro
14
17
(
(
4.0)
4.8)
T End 0 Ser 3 End 1 Leu 4 A Ser 22 ( 6.2)
Tyr 8 Ser 2 Cys 3 Phe 2 C Thr 31 ( 8.8)
(16%) End 0 Ser 1 T rp 4 Leu 7 G T rp 4 ( 1.1)
Tyr 2 Ser 4 Cys 4 Phe 12 T Tyr
Val
10
24
(
(
2.8)
6.8)
Table 3.7 Codon usage of the EHV-4 TK and amino acid 
frequencies within its predicted product. The frequencies of 
each base within codon positions 1,2, and 3 are presented as 
percentages.
Table 3.8
Identity of the EHV-4 UL24 and TK Gene Products 
with Counterparts in Other Herpesviruses
UL24
(Entire)
TK
(Entire)
TK
(Restricted)
EHV-1 83 89 90 (27-326)
PRV 42 47 ( 5-295)
BHV-1 37 40 (12-321)
BHV-2 29 31 (6-262)
MarHV 36 40 (12-320)
FHV 47 51 (22-323)
HSV-1 36 36 38 (51-346)
HSV-2 18 35 37 (50-345)
VZV 37 35 40 (14-316)
MDV 29 34 37 (12-317)
HVT 31 33 35 (12-318)
HCMV 23
EBV 23 18 25 (286-586)
HVS 21 16 25 (211-509)
Table 3.8 Percentage identities exhibited by counterparts of 
the EHV-4 UL24 and TK gene products in a variety of 
herpesviruses. The entire UL24 and TK gene products are 
compared in columns 1 and 2. The final column details 
comparison of amino acids 27-326 of the EHV-4 TK polypeptide 
with the equivalent region within other TKs (as indicated by 
residue numbers in brackets) . This part of the TK polypeptide 
corresponds to the most conserved or 'core' region of the 
polypeptide commencing at residue 1 of the nucleotide binding 
domain and terminating at a position equivalent to the final 
residue of the PRV TK polypeptide.
Table 3.9 The effect on TK activity of substitution of 
specific amino acids within the HSV-1 and HSV-2 TK 
polypeptides. Abbreviations used are as follows - ns 
(nucleoside), nt (nucleotide), and wt (wild-type).
Table 3.9
Analysis of HSV-1 and HSV-2 TK mutants
DISCUSSION
The TK gene of EHV-4 maps at around 0.48 map units within the long 
component of the genome. Similar map positions have been reported for 
the TK genes of other alphaherpesviruses including HSV-1 in its II 
isomeric form. The TK gene lies within a region of the herpesvirus 
genome conserved in gene order such that the genes UL24 homologue-TK-gH 
are arranged in conserved relative transcriptional sense. However, the 
position of this block of genes within the genome varies between 
alpha-, beta-, and gamma herpesviruses and a TK gene is notably absent 
from this gene block in the betaherpesvirus HCMV genome. Thus in 
alphaherpesviruses (I|_ isomer HSV), with the exception of MDV which 
lacks a UL24 homologue, the gene block is positioned in the central 
region of the long component of the genomes, and in EBV it maps around 
30kbp from the left genome terminus. Within the alphaherpesvirus group 
the fine gene arrangement differs slightly thus in HSV-1 the N-terminal 
coding regions and 5' regulatory regions of the UL24 and TK genes 
overlap whereas in EHV-4 the overlap is between the N-terminal coding 
region of one gene and the 5' regulatory region of the other gene.
Translation of the HSV-1 TK gene is unusual in that in addition to 
the 5' terminal Met codon, internal Met codons are used . by the 
ribosomal translational apparatus as initiation codons giving rise to 
variant sized transcripts and intact and truncated TK proteins (Marsden 
et al.. 1983). A similar translational pattern has not been reported 
for any other herpesvirus TKs.
It is evident from the comparative analyses of the TKs encoded by 
different herpesviruses that the gene has evolved from a common 
progenitor gene. Robertson and Whalley (1988) have proposed that the 
gene may have been acquired from a cellular thymidylate kinase gene and 
that thymidine kinase activity evolved at a later stage. Honess and
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coworkers (1989a) have proposed a tentative evolutionary divergence 
scheme on the basis of the comparative analyses of all herpesvirus TK
sequences. Their tree clearly separates the EBV and HVS sequences from
that of the alphaherpesviruses. In this scheme EHV-1 TK is most closely
related to that of VZV (Chapter 1, Fig. 3).
The thymidylate kinase activity of EHV-1 , at least with respect to 
BVdl) and IVdU monophosphate substrates, is significantly lower than 
that of HSV-1 (Kit et al.. 1987a,b). The poor affinity of TKs for these
analogues has been attributed to the presence of a serine residue at a
position corresponding to Ala^gg in HSV-1. Since the EHV-4 TK 
possesses a serine and not an alanine at this position it might be 
expected to exhibit similar monophosphate substrate binding
characteristics to those of EHV-1. Thus it would be predicted that
EHV-4 would exhibit resistance to BVdU and IVdU.
On the basis of the study of the affinity of HSV-1 TK mutants for
thymidine and other nucleoside substrates Darby et al (1986) have
proposed that the HSV-1 TK active site is composed of three distinct 
regions of polypeptide - region A, region C, and Cys 336 - arranged to
form overlapping nucleoside and nucleotide binding sites . The cysteine
residue at 336 in HSV-1 is critical for HSV-1 TK nucleoside and 
nucleotide binding since substitution with tyrosine alters affinity for 
both substrate and cosubstrate and is thus proposed to interact with 
both nucleotide and nucleoside binding sites (Darby et al., 1986).
Although it is conserved in most of the herpesvirus TKs including EHV- 
4 TK, at position 315, it is not present in HVS or VZV . Despite the 
100% conservation of a cysteine residue within the putative 
nucleoside binding site (Fig. 13b) of alpha and beta herpesviruses, 
the residue can, in HSV-1 at least, be substituted with other side 
chains with little effect on enzyme activity (Table 9). This ruled out
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a role for HSV-1 Cysjyj in disulphide bond formation with Cys33g 
(Inglis and Darby, 1987).
The interest in herpesvirus TK genes is directed, in the main part, 
towards the following - i) use of the gene in genetic manipulation 
either as a target insertion site in herpesviral genomes or as a 
cotransfectable phenotypic marker (Shih et al.. 1985), ii)
investigation of the role of TK in virulence and latency, and iii) 
analysis of TK nucleoside specificity and its exploitation in antiviral 
drug development. Our interest in the EHV-4 TK gene is directed to its
potential as a target site for insertion of foreign genes into the EHV-
4 genome. It is possible that, as in other herpesviruses, inactivation 
of the TK gene might lead to viral attenuation. An EHV-1 TK" mutant 
produced by Cornick and coworkers (1990) was found to be attenuated in 
equines. However, the mutant was selected under pressure in the 
presence of nucleoside analogues, a strategy which induces multiple 
mutations within the genome. Thus, it cannot be concluded that
attenuation was a direct consequence of mutations within the TK gene. 
Definitive analysis of the role of the TK gene in EHV pathogenicity 
will require the production of mutants with defined mutations solely 
within the TK gene .
The determination of the precise genomic position of the EHV-4 TK 
gene is a prerequisite to the production, by recombinant DNA 
techniques, of such mutants. As a preliminary step towards the 
construction of recombinant TK" viruses, we have constructed two EHV-4 
TK-deletion plasmids. These could be co-transfected into cells with 
wild type EHV-4 and progeny recombinant TK" virus isolated. Studies 
on the growth characteristics and latency capacity of such mutants 
should lead to a greater understanding of the role of thymidine kinase, 
if any, in equine herpesvirus pathogenesis.
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CHAPTER 4
NUCLEOTIDE SEQUENCE OF THE EHV-4 gH GENE
INTRODUCTION
As detailed in the general introduction, map positions have been 
reported for the six major glycoproteins of EHV-1 (Allen and Yeargan , 
1987). A candidate for a glycoprotein gene not mapped in that study is 
a homologue of HSV-1 gH. Glycoprotein H is one of only two 
glycoproteins , the other being gB, encoded throughout members of all 
three subgroups, alpha , beta, and gamma, of the herpesvirus family 
(Baer et al.. 1984; Cranage et al.. 1988; Gompels and Minson, 1986; 
Gompels et al.. 1988b; Heineman et al.. 1988; McGeoch and Davison, 
1986; Oba and Hutt-Fletcher, 1988). A gH gene homologue has been mapped 
to the EHV-1 genome by sequence analysis but its protein product has 
yet to be identified (Robertson and Whalley, 1988; Robertson et al., 
1991).
The gH-type proteins of VZV (gpIII), HSV-1 (gH), EBV (gp85), and 
HCMV (gp86) are important in mediating virus infectivity since 
antibodies against gH can neutralise infectivity independent of 
complement (Buckmaster et al.. 1984; Cranage et al., 1988; Forghani et 
al.. 1984; Gompels and Minson, 1986; Gretch et al.. 1988; Grose et
al., 1983; Keller et al.. 1984, 1987; Montalvo and Grose, 1986; Oba and
Hutt-Fletcher, 1988; Rasmussen et al.. 1984; Strnad et al., 1982).
Unlike gB, gC, and gD, gH of HSV-1 is apparently not. involved in 
adsorption of the virion to cellular receptors (Kuhn et al., 1990). 
Accordingly, the neutralising effect of HSV-1, and also of EBV, anti-gH 
antibody appears to occur at some stage after adsorption of virions to 
the host cell membrane indicating a role for gH in penetration events 
(Fuller et al.. 1989; Miller and Hutt-Fletcher, 1988) . HSV-1 and VZV 
anti-gH antibody inhibits plaque formation in infected monolayer
cultures (Buckmaster et al., 1984; Gompels and Minson, 1986; Grose et
al., 1983; Keller et al.. 1987) and a monoclonal antibody to HSV-1 gH
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inhibits syncitium formation in HSV-1 syncitial strain infected cells 
(Gompels and Minson, 1986). Thus, it seems the gH-type glycoprotein may 
play a role in membrane fusion events of both the virion-host cell and 
intercellular type thus being important for initial penetration into 
target cells and for cell-to-cell spread of the virus.
Analysis of the target glycoproteins of antibodies raised against 
whole herpesvirus virions has revealed that the gH-type protein of 
alpha-, beta- and gammaherpesviruses is low in abundance, 
immunoreactivity, or both since few antibodies are directed to this 
glycoprotein (reviewed in Gompels et al.. 1988b). However, as stated 
above, monoclonal antibodies with a gH target tend to neutralise viral 
infectivity in the absence of complement and , in HSV-1 at least, gH is 
essential for viral replication (Desai et. al, 1988; McGeoch and
Davison, 1986). Taken with the observation that gH is specified within 
all herpesviruses investigated to date, this indicates an important, if 
not critical, role for this glycoprotein in the herpesvirus life cycle.
In HSV-1, VZV, and EBV , the gH gene is located within part of the 
genome of conserved genetic organisation with gene order UL24-TK-gH- 
UL21-UL20-major capsid protein (MCP) gene . In HCMV, the gene 
arrangement differs : the gH gene maps proximal to the UL24 gene but is 
separated by 10 genes from the MCP gene and no TK function is encoded 
in its vicinity (Chee et al.. 1990).
Southern hybridisation and sequencing studies have indicated that the 
UL24-gH-TK-x-x-MCP gene block is located at a col inear position within 
a wide range of alpha- and gammaherpesviruses (Davison and Wilkie, 
1983; Davison and Taylor, 1987; Gompels et al.. 1988a ; Cull inane et 
al., 1988 ). Thus in HVS (Gompels et al.. 1988b), EHV-1 (Robertson and 
Whalley, 1988), and PRV and BHV-1 (Petrovskis et al., 1988), the gH 
gene homologue is located within the central region of the UL
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component and is positioned immediately downstream of the thymidine 
kinase gene. Having previously located the thymidine kinase gene of 
EHV-4 by virtue of colinearity of the EHV-4, EHV-1 and HSV-1 genomes 
(Nicolson et al.. 1990b) we sequenced downstream of this gene in 
order to search for an open reading frame with the capacity to encode a 
glycoprotein H homologue. In this chapter the nucleotide sequence of 
the EHV-4 gH gene homologue is reported and its predicted amino acid 
sequence compared to that of other herpesvirus gH-type proteins as 
presented in Nicolson et al.. 1990a.
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RESULTS
1. Nucleotide Sequence of EHV-4 genome - map units 0.49-0.51 
The EHV-4 strain 1942 thymidine kinase (TK) gene maps within a 2kbp 
EcoRV/XhoI subfragment of the Bam HI C fragment in the long unique 
component of the genome at approximate map position 0.48 as reported in 
the previous chapter (Nicol son et al.. 1990b). Thi s corresponds to a 
position just upstream of the rightward Xhol site of BamHI C as
represented in Figure la. The nucleotide sequence of 2.88kbp of DNA 
immediately downstream of the TK gene , determined according to the 
strategy outlined in Figure lc, is detailed in Figure 2 . A typical
sequence gel autoradiograph is presented in Figure 3 . 9 Analysis of
potential open reading frames (ORF) within all six frames (Fig. lb) 
revealed a major open reading frame of 2565 base pairs, in 
transcriptional sense left to right, positioned 170bp downstream of the 
putative polyadenylation signal of the TK gene (AATAAA bp 9-14, Fig. 
2). This ORF is predicted to encode a polypeptide possessing features 
characteristic of a membrane glycoprotein . Comparison of the predicted 
protein sequence of the gene to that of published herpesvirus 
glycoprotein sequences indicated similarity to the glycoprotein H of 
HSV-1 and to its homologue within other alpha, beta and gamma 
herpesviruses. The gene is thus hereafter identified as the EHV-4 gH 
gene pending identification of its protein product and review of equine 
herpesvirus glycoprotein gene and gene product nomenclature.
The DNA sequence upstream and downstream of this open reading frame
was searched for putative gene control elements. Several TATA box 
homologues - consensus sequence TATA(^j)A(^) (Corden et al., 1980) -
are located upstream of the initiation codon. Two sequences with a 
particularly good fit to the consensus sequence are located at 
positions 87-93 (TATATAA) and 157-162 (TATATT). The polyadenylation
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signal AAUAAA (Proudfoot and Brownlee, 1976) is not specified within 3' 
non-coding DNA proximal to the termination codon, TAA, at bp 2750. 
However, the minor polyadenylation signals AUUAAA and AGUAAA (Birnstiel 
et a!., 1985) are specified within the extreme 3' terminal coding
region of the gene. The sequence, TGTGTTGT (2770-2777) shares
homology with the consensus element of McLauchlan et aT. (1985),
YGTGTTYY, often present 24-30 bp downstream of the polyadenylation 
signal element of HSV and mammalian mRNAs, and is located at an 
appropriate distance from the ATTAAA element at 2737-2742. However, 
since consensus sequence elements may occur fortuitously within DNA, we 
cannot rule out the possibility that the EHV-4 gH transcript is 
terminated considerably downstream of the gene,, and that it may encode 
a contiguous gene.
The modified scanning hypothesis of translation (Kozak, 1984, 1986)
proposes that the initiation codon of a transcript is the first ATG
downstream of the mRNA start site which is accessible to the ribosomal
translational apparatus. The ATG at bp 185-187, within the sequence 
CGATTATGT, is the first ATG downstream of the in-frame stop codon at 
bpl16-118. Although the local sequence of this codon is only 
moderately homologous to Kozak's consensus sequence, CC(^q )CCATGG, it 
does retain the purine at position -3, the most highly conserved 
feature of the 5' flanking sequence of the initiation codon of 
eukaryotic mRNAs. Assignment of this codon as the initiation codon of 
the gH gene is supported by the potential of the DNA immediately 
downstream to encode a functional signal peptide domain.
The gene has a GC content of 45% which contrasts with the 67% GC 
content of the HSV-1 gH (McGeoch and Davison, 1986). Each of the 61 
amino acid-specifying codons is used to encode the EHV-4 gH (Table 1)
with no preference for codons with a third position G or C. In the
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HSV-1 gH gene there is a clear bias towards codons possessing a 3' G or
C. This difference in the codon usage profiles of the two genes
reflects the difference in the overall %GC content of the genes and,
presumably, of the two viral genomes.
2. The EHV-4 gH Polypeptide 
The EHV-4 gH gene encodes a protein 855 amino acids in length with a 
predicted molecular weight of 94 100. The predicted polypeptide has 
the potential to exhibit the following structural features 
characteristic of membrane glycoproteins as depicted in Figure 3 -
i) N-terminal signal sequence peptide - an N-terminal signal sequence 
is required for the targetting of membrane proteins to the endoplasmic 
reticulum, where the signal peptide is cleaved and the nascent protein 
undergoes processing (Walter and Lingappa, 1986). Signal sequences are 
characterised by an N-terminal basic region (n), a hydrophobic core (h) 
and a polar C-terminal region (c) followed by a signal peptidase 
cleavage site, usually near a predicted beta turn (Perlman and
Halvorson, 1983; von Heijne, 1983). An N-terminal domain of hydrophobic 
character is evident from a hydropathic plot of the EHV-4 gH in which 
the local hydrophilicity of each residue is plotted (Fig. 4) (Hopp and 
Woods, 1981). Residues Tyr(5) to Ala(14) are predominantly hydrophobic 
in character and are likely to constitute the h region of the gH signal 
sequence. Application of the eukaryotic weight matrix developed by 
von Heijne (1986) for the prediction of signal sequence cleavage sites 
indicates that A1a(19) is the most probable terminal residue of the 
signal peptide . The predicted molecular weight of gH after cleavage 
of the signal peptide is 92130.
ii) Hydrophilic external domain - in membrane glycoproteins this major 
domain projects from the virion envelope or infected cell plasma
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membrane and comprises the glycosylated portion of the polypeptide. It 
is therefore usual to find potential N-linked glycosylation sites (N-X- 
S/T) within this domain. Residues 20-816 may constitute the external 
domain of EHV-4 gH. Within this region there are 11 putative N-linked 
glycosylation sites, seven of which are located within the N-terminal 
half of the polypeptide and four in the C-terminal half (Fig. 3). Due 
to its exposure on the virion or cell surface this part of the protein 
is likely to contain the major antigenic determinants of gH with 
respect to the host humoral immune response and, in this case, possibly 
one or more complement-independent neutralisation epitopes as in the 
HSV-1, VZV, EBV, and HCMV gH-type polypeptides. Prediction of parts 
of the polypeptide which may be exposed on the surface of the native 
protein is aided by the analysis of the local hydropathic character of 
each residue and by prediction of the secondary structure of the 
protein using algorithms such as those of Hopp and Woods (1981), Chou 
and Fasman ( 1978) and Kyte and Doolittle (1982). Such analyses were 
applied to the EHV-4 gH using VAX and Microgenie software (Devereux et 
al.. 1984; Queen and Korn, 1984) (Figures 4-6).
The region of maximum hydrophilicity in a hydropathic plot often 
corresponds to an antigenic determinant (Hopp and Woods, 1981 ). The
hydrophilic peak of the EHV-4 gH plot occurs at amino acids 759-763
(Fig. 4), within a region of the polypeptide predicted to adopt an
alpha helical conformation. We might therefore expect an epitope to map
to this portion of gH given that it is likely to be oriented on the 
surface of the protein in an aqueous environment. Other algorithms 
result in a different position for the hydrophilic peak (Fig. 5) 
although, in gross terms the plots are similar. In terms of gross 
antigenicity, analyses predict that the N-terminal and central regions 
of the glycoprotein are more immunogenic than the C-terminal region
85
with amino acids 20-200 and 300-500 possessing the highest scores in 
surface accessibility and antigenicity predictions (Fig. 6b,c).
The HSV-1 gH extracellular domain has a potential membrane 
associated region located close to the transmembrane domain sequence 
(Gompels and Minson, 1986) , amino acids 780-803 , which contains
charged residues but which is enriched in hydrophobic residues. EBV 
gp85 also has a potential membrane-associated region spanning amino 
acids 538-554 (Heineman et al.. 1988). With the exception of the 
transmembrane domain and signal peptide no other regions of significant 
enrichment of hydrophobic residues were identified in EHV-4 gH.
iii) Hydrophobic transmembrane domain - a characteristic feature of 
membrane glycoproteins is the existence of a stretch of around 20 or 
more hydrophobic amino acids towards the C terminus within which polar 
amino acids such as Ser and Thr may be tolerated but not charged 
residues such as Arg or Glu (Wiley, 1985). This has been hypothesised 
to constitute the membrane spanning portion of the glycoprotein and may 
consist of one or more alpha helical loops traversing the virion 
envelope or infected cell membrane. Amino acids 817-836 of the EHV-4 gH 
are enriched in hydrophobic residues (Fig. 4) and are predicted to 
constitute the gH transmembrane domain comprising a single traverse 
of the membrane.
iv) Cytoplasmic domain - the proposed cytoplasmic domain of EHV-4 gH, 
stretches from amino acids 837-855 .Residues are largely hydrophilic 
in character and the domain possesses an overall charge of -1. A 
proposed function of this domain is to anchor the transmembrane domain 
within the lipid bilayer and thus to fix the C-terminal end of the 
glycoprotein to the membrane.
Comparison of the predicted EHV-4 gH polypeptide to other gH-type 
glycoproteins revealed identities of 85%, 32%, 26%, 18%, and 17% with
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the gH-type glycoproteins of EHV-1, VZV, HSV-1, HCMV, and HVS 
respectively . Dot matrix comparisons of EHV-4 gH with the gH-type 
glycoproteins of HSV-1 , VZV, HCMV, and EBV are presented in Figure 7. 
The C-terminal region of the protein is clearly conserved to a greater 
degree than the N-terminal region. Previous comparison of the amino 
acid sequence of the gH proteins of alpha, beta and gamma 
herpesviruses by Gompels et al. (1988b) and Cranage et al. (1988) had
demonstrated the greater conservation of sequence in the C-terminal 
region of the protein and highlighted several features of the gH 
protein conserved throughout the herpesvirus family - i) an unusually 
short cytoplasmic domain of 14 or 15 amino acids in alphaherpesviruses 
and of 7 or 8 amino acids in beta and gammaherpesviruses, ii) four 
conserved cysteine residues at similar positions relative to the 
putative transmembrane domain and within conserved local sequence, and
iii) a conserved glycosylation site sequence NGTV 13-18 amino acids N- 
terminal to the transmembrane domain.
EHV-4 gH exhibits all the above features as shown in an alignment of 
herpesvirus gH-type glycoproteins reported to date (Fig. 8 ): the
proposed cytoplasmic domain is under 20 amino acids in length, the four 
conserved cysteines are present at positions 556, 591, 663 and 716, and 
the C-terminal glycosylation site is located within the sequence NGTV 
(amino acids 796-799) which is positioned 19 amino acids N-terminal to 
the putative EHV-4 transmembrane domain. A further site of cysteine 
conservation between the EHV-4 and HSV-1 gHs occurs within the N- 
terminal portion of the protein within the conserved sequence GCD 
(amino acids 245-247 in EHV-4 , 257-259 in HSV-1 ). The Cys residues 
at 737 and 740 in the EHV-4 gH occur at sites of cysteine conservation 
throughout most herpesvirus gHs, with the exception of HSV-1. It is 
clear from the multiple alignment that conservation of sequence is
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limited to two parts of the polypeptide - a short domain of limited 
conservation within the N-terminal half of the protein and a larger 
domain commencing at the first site of cysteine conservation and ending 
at the conserved C-terminal NGTV sequence. Between these conserved 
regions there is no apparent identity between the beta/gammaherpesvirus 
gH group and the alphaherpesvirus gH group and intergroup alignment is 
arbritary. Of the 11 putative glycosylation sites of EHV-4 gH and the 
7 of HSV-1, only three are conserved, one within the N-terminal 
portion and two within the C-terminal portion. Conservation of N-X-S/T 
sites throughout the gHs is apparent only at two sites within the 
conserved C-terminal domain with a further site of conservation within 
only beta and gammaherpesvirus gHs.
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Figure 4.1
Localisation of the EHV-4 gH Gene Homolocrue
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Figure 4.1 a) BamHI restriction map of EHV-4 genome (1942 
strain: Cullinane et al.. 1988) with expansion of BamHI C
showing positions of Xhol and Sail restriction sites, b) 
Analysis of potential open reading frames within a 2.88 kbp 
region of BamHI C. The major open reading frame was identified 
as a gH gene homologue. c) Sequencing strategy.
Figure 4.2 Nucleotide sequence of 2.88 kbp EHV-4 DNA 
mapping immediately downstream of the TK gene. The 
predicted amino acid sequence of the product of a major 
open reading frame, EHV-4 gH, is indicated below the coding 
sequence. Putative polyadenylation signals (PS) and TATA 
(T) boxes are underlined as are potential N-linked 
glycosylation sites within the gH polypeptide.
Figure 4.2
Nucleotide Seguence of the EHV-4 gH Gene Homologue
( P S -T K )  (P S -T K )  (T -g H )
AATTGTGAAATAAAGATTCATTTGCCAATATCCATCATAGCCCCTTGTGTGTTTCGTGTGTAAACTTCCAGTTTCTAGTTTGGGGATATATAAGCCGTTGTGCTCTTAMTCATTTAGTA 1 2 0
( T - g H )
CAGCGCGGCCGAGATACTCGAGGTATCCAGTGGTTGTATATTGGGAATAAATACTGCTGCGATTATGTCACAACCGTATCTAAAAATAGCTATCTTAGTGGCCGCTACTATTGTGTCTGC 2 4 0
E H V -4  gH P o ly p e p t id e  M S Q P Y L K I A I L V A A T  I V S A
GATTCCCGTTTGGACAACACCGGTTTCAACTTCACCACCCCAACAAACAAAATTGCACTATGTGGGAAATGGTACCTGGGTACACAACAATACATTCAACGTAACCAGGTATGACAGGAT 3 6 0  
I P V W T T P V S T S P P Q Q T K L H Y V G  H G T W V H H N T F N V T R Y D R I
AACCATGGAACCAGTTTATAATAACAATTTATCCTCTACTACCTTTTTTGTTGCTATATCGGAGAGAAATTTTCGCACGGTTAACACTCCACTTGGAGCGTCCGTATTTTGGATTTTAAA 4 8 0  
T M E P V Y M N  H L S S T T F F V A I S E  R N F R T V N T P L G A S V F W I  L K
AAGCGCTCTTAATCCTCCCAAACACCAACCCTGTATAGCTAATGTGCCAGAACCCGGTGACCCACGCGGACCGTGCGTCAACTCAACTGTGAGTCTATTTTTTAATGACAATTTGGAGCC 6 0 0  
S A L N P P K H Q P C I A N V P E P G D P R G P C V  N  S T V S L F F N D N L E P
GTTTTTAATGACAAAAAATCTTTTGGAGTTTGAAGTATTGCCCGACAACTACATAACCGGATGGACGTTTGAGCGGTCTAAAACTGTGGCTACGAAAGGCAACCCGGTTGGAGTGGTTCT 7 2 0  
F L M T K N L L E F E .  V L P D N Y I T G U T F E R S K T V A T K G N P V G V V L
CTCCCCTCCCCGAACAAGTCCGGATGTAAATAACACCATAAGAGATGATGGCACCCCTAAACAGCACTTGAGCATTATAGACGAACATACTACGTTCGTGCTCGACCTGCAAAATTTTAC 8 4 0  
S P P R T S P O V  N N T I R D D G T P K Q H L  S I  I D E H T T F V L D L Q  M F T
AAAAACTTTAACTTATATAAGCCCATTTGCTGCGGTGTGGCCAATAACAGCCTTTCATGCCGGAATTACAGTAATGGGGTGTGACACAACTCAGGCGATTGCGTACCTCGGCAATGGGTT 9 6 0  
K T  L T Y  I  S P F A A V W P  I T A F H A G I  T V M G C D T T Q A  I  A Y L G N G F
TATGGGTTTGCAAATAAGCTCGGTAAACAATCCACCGCTGGAGATGATTGTTGCACCAAATGACGTCCGTGCTCGGATAGTTAACCGCCTTCCCCCAAGACGTCGACTTGAGCCACCCGG 1 0 8 0  
M G L Q I S S V N N P P L E H I V A P N D V R A R I V N R L P P R R R L E P P G
GCCATATGCAGGACCTATCTACAAGGTGTACGTACTCAGTGATGGAAATTTTTACTTGGGTCATGGCATGAGCAAGATTTCTAGGGAGGTTGCCGCGTACCCAGAAGAGAGTTTGGACTA 1 2 0 0  
P Y A G P I Y K V Y V L S D G N F Y L G H G M S K I S R E V A A Y P E E S L D Y
CCGCTACCACTTATCGCTTGCCAACCTTGATACTCTGGCTATGTTGGCAGAACTTTCTTCCGGTAAGAGCAAGGATGTGAGCTATTACTTGTATCGCATAATTGCGAGGCTGGCCGTAGC 1 3 2 0  
R Y H L S L A N L D T L A M L A E L S S G K S K D V S Y Y L Y R I I A R L A V A
AACGTTTTCCCTTGCAGAAGTTATACGCCTGAGTGACTATATGCTCCTTCAAGAGGCCATCGACGTGGATATAAACCTCCGCCTAATTGTACCTCTAGTGATGAAGTACGCCGCTGGGGG 1 4 4 0  
T F S L A E V I  R L S D Y M L L Q E A I D V D  I N L R L  I V P L V M K Y A A G G
AACGGCAGATAGCTCGTACACATCCTCGGACGTAGCTATGGACCAATTCGAGGTGGCTCAAGCCCAGATTGAGAAGATAGTAGCCGATATAAATATCGAAAATGAATTGCGCAAACCTAT 1 5 6 0  
T A O S S Y T S S D V A M D Q F E V A Q A Q  I  E K I  V A D I  N I  E N E L R K  P M
GTACGAGCACCGCTCATTATTGAAAAGCGTGTACGCTTATTCTAGAAAGCCGCTACCAAACGCGGTAAGCTTTGCTAACCGGCTCATCACGGCTATGTATAAAGAAGCAATTAAGGACAG 1 6 8 0  
Y E  H R  S L L K S V Y A Y S R K P L P N A V S F A N R L  I T A M Y K E A  I K D R
AATTACGTGGAACTCTACGATGCGAGAGGTGTTATTTTTTGCGGTTGGTGCTGCTGCAGGTTCGCATGTTATCCTCACGGATGGGCCAGATCTCGGTTTACATGCCCACAAAGATTCTTC 1 8 0 0  
I  T W N S T M R E V L F F A V G A A A G S H V I L T D G P D L G L H A H K D S S
GATGTTTCTATCTCTTAACCGCAACATACTCTTGTTGTGTACGGCCATGTGTACGGCGTCGCATGCCGTGTCCGCAGGAGTAAAACTAGAGGAAGTTATGGCTGGCCTTATTGCCGGGGG 1 9 2 0  
M F  L S  L N R N  I  L L L C T A M C T A S H A V S A G V K L E E ' V H A G L  I  A G G
TGTACAATTTAGCCTCCTAGAAGTATTTAGTCCATGTATGGCGTCTGCTCGATTTGACCTGGCCGAAGAAGAGCATGTGCTAGATCTACTGTCCGTTATCCCACCTCGCCTGTACACCGA 2 0 4 0  
V Q  F S L L E V F S P C H A S A R F D L A E  E E  H V L D  L L S V  I P P R  L Y  T D
CTTAAACACTGGCTTGGAGGACGACGGAACCACCATCCATTCATACGGACGGTCTGCTAACGGAATTTTAAACTCTCGAATCGCATATAACTTTGATGCTGTTCGTGTATTTACTCCAGA 2 1 6 0  
L N T G  L E D D G T T I H S Y G - R S A N G I L N S R I A Y N F D A V R V F T P E
GTTGGCCTCATGCAGCACTAAACTACCAAAAGTTTTGGTAGTGCTACCCTTAGCATCAAACCGAAGCTACGTTATAACTCGTACTGCGCCCAATATAGGTTTAACTTACTCTCTTGATGG 2 2 8 0  
L A S C S T K L P K V L V V L P L A S  M R S  Y V I T R T A P N I G L T Y S L D  G
GGTAAATATAGCAAAGCCTATAGTCATCAGTTACATCACTTATGGAAATTGTCAAGTTTCGAGAGCTACAATCAGGTCAGTTTACTTGGACCATCCGGGCCACACCCAGTCGTGCGTATA 2 4 0 0  
V N I A K P I V I S Y I T Y G N C Q V S R A T I R S V Y L D H P G H T Q S C V Y
TTGCGGGAGTGTGTTTATGCGGTATATGGCATCCGGAGCAATTATGGATTTGATATACATAGATGACAAAGATGTAGAGTTGCAACTGGTAGCAGGGGAAAACTCAACTATTCCAGCCTT 2 5 2 0  
C G S V F M R Y M A S G A I M D L I Y I D D K D V E L Q L V A G  E R S T  I  P A F
TAACCCAAAGCTGTATACGCCCAGCATGAATGCTCTTTTAATGTTTCCAAACGGAACAGTAACCCTAATGTCTGCATTTGCATCCTACTCAGCTTTTAAAATTCCCAGTACTTATCTGTG 2 6 4 0  
N P  K L Y T P S M N A L L M F P  N G T V T L M S A F A S  Y S A F K I  P S T Y L W
(PS-gH)
GGCTTCTATTGGGGGTTTGTTGCTGGCTATTCTGATTTTATATGTAATCGTTAAAATGTTATGTGGTGGTGTAATTAATAATGACTATAGTTTGTTATTAAACTCTGAGTAAACACAAAC 2 7 6 0  
A S I G G l l  L A I L I L Y V I V K M L C G G V I N N D Y S L  L L W S E *
(PS-gH)
AATGTCTAGTGTGTTGTATTGCGTGTAAACAGTATACGAGTGAACATTTATACGTAAAATGGTTAAATTTTATTTTCGCTATAAACGGGAATGCGGCGGCGAGGGCTGCTGCGGCGGCGA 2 8 8 0
Figure 4.3
Putative Structural Domains within the EHV-4 gH Polypeptide
SIGNAL PEPTIDE EXTRACELLULAR DOMAIN
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Figure 4.3 Predicted distribution of four structural domains 
within EHV-4 gH on the basis of analyses of local hydrophobicity 
scores along the polypeptide (Hopp and Woods, 1981).
Figure 4.4
Hydropathic Plot of the EHV-4 aH Polypeptide
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Figure 4.4 Hopp and Woods (1981) hydropathic plot comprising 
analysis of the local hydrophilicity of each residue of the EHV- 
4 gH polypeptide using a six amino acid window. Positive values 
indicate a local hydrophilic environment: negative values a
local hydrophobic environment.
Figure 4.5
Secondary Structure Analysis of EHV-4 gH
Figure 4.5 Hydropathic and secondary structure analyses of 
EHV-4 gH using algorithms available on VAX software (Devereux 
et al.; 1984).
Figure 4.6 Analysis of EHV-4 gH using VAX software 
(Devereux et al.. 1984). Overlaid on Chou-Fasman secondary 
structure predictions (a)) are motifs indicating regions of 
the polypeptide with high b) surface accessibility, and c) 
antigenicity scores.
Figure 4.6
Schematic Predictions of EHV-4 gH Secondary
Structure. Surface Accessibility, and Antigenicity.
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Figure 4.7
Dot Matrix Plots of Herpesvirus gH Polypeptides
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Figure 4.7 Comparison of EHV-4 gH with its counterparts in 
HSV-1 (McGeoch and Davison, 1986) , VZV (Keller et al. . 1987) ,
and EBV (Heineman et al. . 1988) by dot matrix analyses. 
Parameters used were a 30 amino acid window and a stringency 
of 53%.
Figure 4.8
Multiple Alignment of Herpesvirus gH-tvpe Polypeptides
EHV-4 MSQPYLKIAILVAATIVSAIPVWTTPVSTSPPQQTKLHYVGNGTWVHNNT--FNVTRYDRITMEPVYN NNLSSTTFFVAIS--ERNFRT-VNT---
HSV-1 MGNGLWFVGVIILGVAWGQVHDUTEQTDPWFLDGLGMDRMYWRDTNTGRLWLPNTPDPQKPPRGFLAPPDELNLTTASLPLLRUYEERFCFVLVTTAEFP 
VZV ....... MFALVLAVVILPLWTTANKSYVTPTPATRSIGHMSALLREYSDRNMSLKLEAFYPTGF--DEELIKSLHWGNDRKHVFLV--1VKVNPTTH
HCMV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MR
HVS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M
EBV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cons  --wt — . . . . . . . . . . . . . . . . . . . . . . . n .... .......... -...... -......... -.......
EHV-4 PLGASVFWILKSAL NPPKHQPCIANVPEPGDPRGPCVNSTVSLFFNDNLEPFLMTKNLLEFEVLPDNYITGWTFERSKTVATKGNPVGVVLSPPRTS
HSV-1 RDPGQLLYIPKTYLL-GRPPNASLPAPTTVEPTAQPPPSVAPLKGLLHNPAASVLLRSRAWVTFSAVPDP--EALTFPRGDNVATASHPSGPRDTPPPR- 
VZV EGDVGLVIFPK-YLLSPYHFKAEHRAPFPAGRFGFLSHPVTPDVS-FFDSSFAPYLTTQHLVAFTTFPPNPL-VWHLERAETAATAERPFGVSLLPARPT
HCMV PGLPPYLTVFTVYLLSHLPSQ-RYGADAASEALDPHAFHLLLNTYGRPIRFLIRFLRENTTQCTYNSSLRNSTV-VRENAISFNFFQSYNQYYVFHMPRC 
HVS TlLQLFLVFLNILEALCDYQLPKPRINKPPAEERLKLRNGYNTTLIEFDDGVQSFNLNUTKIIEHIPHDELIEL-WREANVTEPLVNTLLKRSDTYRPET
EBV ................ MQLLCVFCLVLLUEVGAASLSEVKLHLDIEGHASHYTIPUTELMAKVPGLSP-EALUREANVTEDLASMLNRYKL IYKTSG
Cons  I —  k - y l l  —  p a e...... v .... l - f ..... f l  —  t —  f  —  pd— e—  r E i— t-ata--p-g-- I-p-p--
EHV-4 PDVNNTIRDDGTPKQHLSIIDEHTTF--VLDLQNFTKTLTYISPFAAVWPITAFHAGITVMGCDTTQAIAYLGNGF. . . . . . . . . . . . .. .. . .. ..
HSV-1 PPV-GARRHPTTELDITHLHNASTTWLATRGLLRSPGRYVYFSPSASTWPVGIWTTGELVLGCDAALVRARYGREF. . . . . . . . . . . . . . . . . . . . .
VZV VPK-NTILE-HKAHFATWDALARHTFFSAEAIITNSTLRIHVPLFGSVWPIRYUATGSVLLTSDSGRVEVNIGVGF. . . . . . . . . . . . . . . . . . . . .
HCMV LFAGPLAEQFLNQVDLTETLERYQQRLNTYALVSKDLASYRSFSQQLKAQDSLGQQPTTVPPPIDLSIPHVWMPPQTTPHDUKGSHTTSGLHRPHFNQTC
HVS NVH-IPGHGNSYACALPYWSYTIDQUEDNKTTGYLGNFGIPSKTVLNEFF--YDFQYVYTNRQFYTEATYVLNCLIG.. . . . . . . . . . . . . . . . . . . .
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EHV-4 MLAELSSGKSKDVSYYLYRIIARLAVATFSLAEVIRLSDYMLLQEAIDVDINLRLIVPLVMKYAAGGTADSSYTSSDVAMDQFEVAQAQIE-KIVADINI
HSV-1 GDAGAEQGPRPPLF URLTGLLATSGFAFVNAAHANGAVCLSDLLGFLAHSRALAGLAARGAAGCAADSVFFNVSVL-DPTARLQLEARLQHLVAEIL
VZV MTTKADQHDINEESYYH-- IAAR IATSIFALSEMGRTTEYFLLDEIVDVQYQLKFLNYI LMRIGAGAHPNTISGTSDLIFADPS-QLHDELSLLFGQVKP
HCMV DFLDAALDFNYLDLSALLRNSFHRYAVDVLKSGRCQMLDRRTVEMAFAYALALFAAARQEEAGTEISIPRALDRQAALLQI QEFMITCLSQTPPR
HVS EIIETPPLTFIKM-LQDEMFTIEIRDGCNINNIVNPKTFLFAFKAVVAHFLVIDSLRTQQHILLNCFANYMSELEFLRKLMES--CFEFFEFDFPYTVIE
EBV RAVTMTAASYARYVLQKLVLL-EMKGGCRE-PELDTETLTTMFEVSVAFFKVGHAVGETGNGCVDLRWLAICSFFELTVLKD11GICYGATVKGMQSYGLE
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CMV TTLLLYPTAVDLAKRALWTPDQITDITSLVRLVYILSKQNQQHLIPQWALRQIADFALQLHKTHLASFLSAFARQELYLMGSLVHSM LVHTT....
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Figure 4.8 (cont.)
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Figure 4.8 Multiple alignment of the predicted product of the 
HSV-1 gH gene (McGeoch and Davison, 1986) and its counterpart 
in EHV-4, VZV (Keller et al. . 1987), HCMV (Cranage et al., 
1988), HVS (Gompels et al.. 1988b), and EBV (Baer et al., 
1984). A consensus line is detailed in which residues 
conserved in 3 or 4 'gH's are represented by lower case, 
residues conserved in 5 or 6 'gH's by upper case.
Table 4.1
Codon Usage of EHV-4 gH Gene Homolocrue
2nd
1st\
\
A
(26%)
C
(27%)
G
(15%)
T
(32%) 3rd Residue f (%)
A Lys 19 Thr 13 Arg 6 lie 23 A (25%) Ala 72 ( 8.4)
Asn 26 Thr 12 Ser 14 lie 13 C (23%) Arg 37 ( 4.3)
(30%) Lys 10 Thr 13 Arg 5 Met 25 G (22%) Asn 50 ( 5.8)
Asn 24 Thr 20 Ser 10 H e  22 T (30%) Asp 39 ( 4.6)
Cys 11 ( 1.3)
C Gin 12 Pro 22 Arg 6 Leu 13 A Gin 16 ( 1.9)
His 8 Pro 13 Arg 11 Leu 11 C Glu 34 ( 4.0)
(19%) Gin 4 Pro 9 Arg 5 Leu 13 G Gly 46 ( 5.4)
His 9 Pro 8 Arg 4 Leu 14 T His 17 ( 2.0)
H e 58 ( 6.8)
G Glu 15 Ala 17 Gly 16 Val 25 A Leu 92 (10.8)
Asp 21 Ala 17 Gly 7 Val 3 C Lys 29 ( 3.4)
(30%) Glu 19 Ala 12 Gly 10 Val 20 G Met 25 ( 2.9)
Asp 18 Ala 26 Gly 13 Val 21 T Phe 32 ( 3.7)
Pro 52 ( 6.1)
T End 0 Ser 11 End 0 Leu 18 A Ser 71 ( 8.3)
Tyr 21 Ser 10 Cys 4 Phe 3 C Thr 58 ( 6.8)
(21%) End 0 Ser 10 Trp 7 Leu 23 G T rp 7 ( 0.8)
Tyr 19 Ser 16 Cys 7 Phe 29 T Tyr 40 ( 4.7)
Val 69 ( 8.1)
T^KLe 4.1 Codon usage of the EHV-4 gH gene homologue and 
amino acid frequencies within its predicted product. The 
frequencies of each base within codon positions 1,2, and 3 are 
presented as percentages.
DISCUSSION
The gH gene of EHV-4 maps immediately downstream of the TK gene and 
specifies a protein product of 855 amino acids in length. On the basis 
of sequence data , the EHV-1 gH mRNA transcript termination is 
signalled by a standard AATAAA polyadenylation signal sited 
approximately 80 bp downstream of the termination codon (Robertson et 
al., 1991). A consensus polyadenylation signal is not located at a
corresponding position within EHV-4 although a match to the less 
common ATTAAA polyadenylation signal occurs within the extreme 3' end 
of the coding region of the EHV-4 gH gene. It is possible, therefore, 
that the fine details of transcription of the EHV-1 and EHV-4 gH genes 
differ.
With the exception of pseudorabies virus gH which is only 686 amino 
acids in length (Petrovskis et al.. 1988), the gHs of alpha
herpesviruses tend to be larger than their beta and gamma herpesvirus 
counterparts ranging from 838 (HSV-1) to 882 (BHV-1) as compared to 
706-743 for the EBV, HVS and HCMV gH-type polypeptides. It has been 
hypothesised that this length difference is a consequence of expansion 
of the N-terminal region of alphaherpesvirus 'gH's and/or a 
contraction of beta/gamma herpesvirus 'gH's (Gompels et al.. 1988b). At 
855 amino acids in length the EHV-4 gH is of comparable size to most of 
the alphaherpesvirus gHs and is only 7 amino acids longer than the 
EHV-1 gH . The predicted amino acid sequence of the EHV-4 gH 
shares identity with the gH-type glycoproteins of EHV-1, HSV-1, VZV 
(gplll), HCMV (gp86), HVS, and EBV (gp85). The identity is greater 
with the 'gH's of other members of the alphaherpesvirus subgroup - 85%
with EHV-1, 26% with HSV-1 and 32% with VZV - than with those of 
members of the beta and gamma subgroups - 17% with HCMV and 18% with 
HVS and EBV. That the gH of EHV-4 is more closely related to VZV gplll
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than to HSV-1 gH is consistent with the phylogenetic tree of 
herpesvirus evolution constructed by Whalley et al. (1989) on the basis 
of the relatedness of the gB glycoproteins of several alpha, beta and 
gamma herpesviruses (Chapter 1; Fig. 3c). Conservation in N-terminal 
region of gH-type proteins tends to be limited to gH proteins from 
the same herpesvirus subgroup whereas conservation in C-terminal 
region extends across 'gH's of different subgroups.
The strong conservation of gH throughout the three herpesvirus 
subgroups implies it has an essential function and that functional 
constraints have restricted the divergence of its C-terminal primary 
amino acid sequence in the course of herpesvirus evolution. The 
strong conservation of cysteine residues throughout the alpha, beta and 
gamma herpesvirus gHs investigated implies some degree of conservation 
of the secondary and tertiary structure of these proteins presumably 
involving disulphide bonding (Gompels et al., 1988b) which is essential 
to this/these conserved function(s).
A tryptophan residue at 232 in EHV-4 gH coaligns with of the
HSV-1 gH which is the site of a ts mutation which renders progeny virus 
noninfectious (Desai et al.. 1988). This Trp residue is conserved in 
other alphaherpesvirus gHs including EHV-4 and EHV-1 . Due to the 
divergence of N-terminal beta/gammaherpesvirus gH sequences it is not 
possible to speculate whether a Trp residue might be critical for 
beta/gammaherpesvirus gH function : alignment of beta/gammaherpesvirus 
gHs with alphaherpesvirus gHs across this region of the polypeptide is 
arbitrary. If a functionally important Trp is conserved in 
beta/gammaherpesvirus gHs it is clearly not situated within a block of 
conserved residues.
From studies on other herpesvirus gHs glycosylation includes 
complex and high-mannose N-linked oligosaccharide chains ( Edson and
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Thorley-Lawson, 1983; Strnad et al., 1983). Comparison of the apparent 
molecular weight of mature gH as isolated from virion extracts to the 
unglycosylated molecular weight predicted from the amino acid sequence 
indicates that glycosylation is not as extensive as that for gC-type 
glycoproteins. For example the apparent molecular weight of HSV-1 gH is 
110 kDa (Showalter et al.. 1981; Buckmaster et al.. 1984) whereas that 
predicted for the amino acid sequence minus signal sequence is 88.5 
kDa (McGeoch and Davison, 1986).
It remains to be determined whether the native, processed EHV-4 gH 
corresponds to any of the previously reported EHV-4 glycoproteins. The 
only feasible candidate is a 138K protein identified in EHV-4 (Meredith 
et al.. 1989). It is possible that, as is the case with gH of HSV-1, 
EHV-4 gH is undetectable by SDS-PAGE due to low abundance within the 
virion envelope and low incorporation of radioactively labelled sugars 
such as N-acetylglucosamine .
Several approaches could be utilised to identify the protein 
product of the gH gene . Antibodies generated against a peptide 
sequence derived from the predicted gH protein product could be used 
to immunoprecipitate the protein from an EHV-4 protein preparation. 
Alternatively antibodies raised against a suspected EHV-4 gH protein 
could be tested for their ability to immunoprecipitate an in vitro 
translation product from mRNA selected by the gH ORF DNA. The former 
technique was successfully used to confirm identity of the VZV gpIII 
gene product (Keller et al., 1987) and of the EBV BXLF2 product (Oba 
and Hutt-Fletcher, 1988). The latter technique produced evidence 
linking EBV gene BXLF2 with protein gp85 ( Heineman et al.. 1988; Seibl 
and Wolf, 1985). A further technique utilised was the transfection of 
the gH ORF into cells and testing of the expressed protein for 
reactivity with a monoclonal antibody against the suspected protein
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product (Heineman et al., 1988). It is anticipated that application of 
such techniques to the investigation of the EHV-4 gH gene product 
should lead to the detection of a novel EHV-4 glycoprotein in infected 
cell extracts.
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CHAPTER 5
DIRECT REPEAT ELEMENTS AND PUTATIVE ORIGIN 
DNA REPLICATION OF EHV-4
INTRODUCTION
The genomes of different types of herpesvirus are distinct from each 
other in terms of size, base composition, repeat element distribution, 
coding characteristics, and cis-acting element distribution. Nucleotide 
sequence analysis of non-coding DNA immediately downstream of the EHV-4 
gH gene revealed two features identified in the genomes of other
sequenced herpesviruses : direct repeat elements and a putative origin 
of replication.
Alphaherpesvirus genomes possess regions of short direct repeats 
arranged in tandem at apparently random positions throughout the genome 
in addition to major repeat elements the arrangement of which 
determines herpesvirus genome classification (Chapter 1). The most
thorough mapping of direct repeat elements exists for the completely 
sequenced HSV-1, VZV, and EBV genomes ( Baer et al., 1984 ; Davison and 
Scott, 1986; McGeoch et al.. 1988a ) with the caveat that some elements 
may have deleted on cloning (Straus et al.. 1983). It has been
hypothesised that the elements are parasitic sequences which have 
accumulated, possibly by recombination, in coding and non-coding 
regions of the genome where their presence does not cause a selective 
disadvantage to the virus (Davison and Scott, 1986). The only reported 
functions for a set of such repeats in non-coding DNA of 
alphaherpesviruses are site-specific recombination (Chou and Roizman, 
1985) and a role in maturation of unit sized genomic DNA (Hammerschmidt
et al, 1988). Direct repeat regions within HCMV and EBV have been
associated with enhancer activity ( Sugden and Warren, 1989; Weston, 
1988). However, no enhancer activity has been reported within 
alphaherpesviruses . The only published EHV-4 minor direct repeat 
element is a region of 31 direct repeats of an 8bp sequence which has 
been mapped to the TR$ component of the genome (Cull inane et al..
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1988).
Herpesvirus origins of replication are sites within the genome at 
which DNA replication is initiated. These origins are, like cleavage 
and packaging signals and regulatory elements such as promoters and 
enhancers, crs-acting elements the distribution of which varies 
between different herpesvirus genomes . The number and approximate 
sites of the origins of HSV-1 was originally determined by electron
microscopy studies of replicating viral DNA (Friedmann et al, 1977,
Hirsch et al.. 1977) and by analysis of the genetic composition of 
replicative defective genomes (Vlazny and Frenkel, 1981). Fine mapping 
of the origins was subsequently determined by the analysis of the 
capacity of genomic fragments to support replication of plasmids in 
cells permissive for viral replication (Stow, 1982). This technique has 
become a standard approach to mapping novel functional herpesvirus 
origins of DNA replication.
The replication origins of five herpesviruses have been 
characterised and sequenced. These include the following - EHV-1 ori$ 
(Baumann et al.. 1989), HSV-1 ori$ (Stow, 1982; Stow and McMonagle, 
1983), HSV-1 ori^ (Gray and Kaerner, 1984; Weller et al., 1985 ),
HSV-2 ori$ (Whitton and Clements, 1984), HSV-2 ori^ (Lockshon and 
Galloway, 1986), VZV ori$ (Stow and Davison, 1986), and EBV ori-P 
(Baer et al.. 1984; Yates et al.. 1984). The origins located within the 
S components of HSV-1, HSV-2, and VZV are positioned within the 
inverted repeats and are thus present in two copies per genome. All 
herpesvirus origins of replication reported to date exhibit dyad 
symmetry. However, the internal structure of the alphaherpesvirus and 
gammaherpesvirus origins differ.
Alphaherpesvirus origins are characterised by a palindromic 
sequence element of variable length the central region of which is rich
94
in A/T residues. To the left of the poly A/T tract is a conserved 
sequence element CGTTCGCAC, termed site I, which is located either 
completely or partially within the palindrome (EHV-1 ori$, HSV-1 and 
HSV-2 oris and ori^ or outwith the palindrome (VZV ori5) (Baumann et 
al.. 1989; Stow and Davison, 1986; Weir and Stow, 1990). To the right, 
in all herpesvirus origins except VZV ori$, is a region of DNA, termed 
site II, which is complementary in sequence to site I. Mutational 
analyses and binding studies have revealed that site I is critical for 
origin activity while site II and the poly A tract contribute to the 
efficiency of origin activity ( Deb and Deb, 1989; Stow and Davison, 
1986; Weir and Stow, 1990). The conserved sequence, CGTTCGCAC of HSV-1 
origins of replication is directly involved in the binding of the 
product of gene UL9 of HSV-1 ( Olivo et al., 1988), termed the origin 
binding protein (OBP) (Elias et al., 1986 ). The OBP binds to the 
sequence 5'-GT(G/T)CG-3' which occurs within both strands of an 8bp 
binding domain in CGTTCGCAC (Koff and Tegtmeyer, 1988). Thus two OBP 
molecules bind asymmetrically to site I. This asymmetry of binding has 
been hypothesised to play a role in the uni-directionality of DNA 
replication possibly by restricting access of a multi-enzyme complex or 
melting events to one strand (Koff and Tegtmeyer, 1988). OBP molecules 
also associate with 5bp OBP-binding motifs within site II although 
binding affinity is significantly lower than that at site I.
In addition to a cis-acting origin of DNA replication, initiation 
and maintenance of DNA replication requires seven virus-specified 
products in HSV-1 including DNA polymerase and the major DNA binding 
protein (McGeoch et al.. 1988b; Olivo et al.. 1990; Wu et al.. 1988).
Although HSV-1 possess three origins of replication, genomes from which 
ori[_ and one copy of ori$ have been deleted are replication competent 
and specify biologically active progeny virions ( Longnecker and
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Roizman, 1986; Polvino-Bodnar et al., 1987).
Whereas the alphaherpesvirus origins of replication identified to 
date possess the discussed conserved features - poly A/T tract and
CGTTCGCAC - the gammaherpesvirus EBV origin of replication , ori-P ,
has neither of these features suggesting that different mechanisms may 
be active in the initiation of alpha and gammaherpesvirus DNA 
replication (Yates et al.. 1984). Two regions of the genome have been 
implicated in origin activity : a dyad symmetry element and, lkbp
upstream, a region of direct repeat elements which also act as a
transcriptional enhancer (Reisman and Sugden, 1986; Reisman et al.. 
1985).
This chapter presents the nucleotide sequence of 1725bp of DNA 
mapping downstream of the EHV-4 gH gene termination codon and compares 
features of this sequence to similar features in other 
alphaherpesviruses.
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RESULTS
1. Sequence Analysis of EHV-4 Genome. Map Units 0.51-0.52
The nucleotide sequence of the extreme right end of EHV-4 BamHI C , 
determined according to the strategy presented in Figure 1, is 
detailed in Figure 2. Analysis of the nucleotide sequence of EHV-4 DNA 
mapping immediately downstream of the EHV-4 gH gene revealed three 
features of interest - i) a region of tandemly repeated direct repeat 
elements, ii) a putative origin of DNA replication, and iii) an open 
reading frame (Fig. 1). Sequence analysis of a limited region of the 
repeat region is presented in Figure 3.
1) EHV-4 direct repeat elements
The region of direct repeat elements maps 101 bp downstream of the 
gH termination codon and spans 423 base pairs (bp 2853 to 3275, Fig.
2). It comprises 20 complete repeat elements and a 3' terminal partial 
repeat sequence. The complete elements range in size from 15 to 24bp 
and possess a conserved 15bp G/C rich core sequence -GCGGCGGCGAGGGCT - 
flanked by variable numbers of 5' GCG elements and 3' GCT elements such 
that the consensus repeat sequence is of the form - (GCG)j _ 
3GCGGCGAGG(GCT)i_3 (Table 1). The %GC of the repeat region is 86.3% . 
In contrast, the %GC of the coding region of the gH gene is 45%.
A region of direct repeats is located at a similar position within 
the EHV-1 genome although the size and sequence of the elements is 
distinct . The repeat region is shorter than that of EHV-4 comprising 
two repeats of a 32bp element and a single 20 bp partial repeat 
(Robertson et al.. 1991). The EHV-1 and EHV-4 repeat elements are, 
however, related in sequence as shown in Table 1. The EHV-4 repeat 
element bears little homology with the 8bp repeat located in EHV-4 TR$ 
-GGAGGTGG- which is present in 31 complete copies and 1 partial copy 
with no variation repeat size (Cullinane et al.. 1988).
97
The EHV-4 repeat elements are stringent multiples of three in size. 
An analysis of potential open reading frames within this part of the 
EHV-4 genome indicated two potential ORFs of 153 and 173 amino acids 
(Fig. lb) spanning the repeats , 141 amino acids of which are encoded 
within the repeat region .
2) Putative EHV-4 origin of DNA replication
A putative EHV-4 origin of DNA replication was localised downstream 
of the repeat elements on the basis of similarity in sequence to that 
of reported HSV-1, HSV-2, VZV, and EHV-1 herpesvirus origins. The 
putative origin comprises an A/T rich region upstream of which is an 
llbp element - 5'-CGTTCGCACTT-3' - identical in sequence to an element 
conserved within all reported human herpesvirus origins and , across 
the 5' 9bp , to one within EHV-1 ori$ ( Baumann et al., 1989; Stow and 
Davison, 1986). A sequence element complementary to part of this 
conserved sequence, 5'-GTGCGAACG-3', is positioned downstream of the 
EHV-4 poly A tract. A hypothetical stem and loop structure can thus be 
deduced for the putative origin given the extent of base pairing which 
might occur between the complementary flanking elements and within the
A/T rich region . The hypothetical stem-and-loop structures of the
putative EHV-4 ori|_, HSV-1 ori$ , HSV-1 ori[_ , and EHV-1 ori$ are
presented in Figure 4. The EHV-4 palindrome differs from that of HSV-1 
ori[_ in two major characteristics - i) it is considerably shorter, and
ii) it possesses fewer potential intrastrand base pairing events. The 
EHV-4 ori|_ palindrome is thus apparently more similar in size to 
origins identified within the S components of herpesvirus genomes . It 
shares with EHV-1 ori$ its lower degree of palindrome perfection in 
terms of potential base-pairing events.
An alignment of all functionally characterised origins of
herpesvirus DNA replication and of the putative EHV-4 origin is
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indicated in Figure 5. The sequence of the GT(T/G)CG motifs of 
characterised origins are compared to that of EHV-1 and EHV-4 in Table
2. With the exception of the VZV ori$ , GT(T/G)CG motifs are present 
in both left and right arms of the palindrome. A difference in the 
second base exists within the motif in the right arm of the HSV-1 and 
HSV-2 ori$ and has been speculated to account for the much lower 
affinity of OBP for the right end of the HSV-1 palindrome (Elias and 
Lehman, 1988; Koff and Tegtmeyer, 1988). The putative OBP-binding sites 
of the EHV-4 origin possess the sequences 5'-GTTCG-3' (upper strand) 
and 5'-GTGCG-3' (lower strand ) (left arm), and 5'-GTGCG-3' (upper 
strand) and 5'-GTTCG-3' (lower strand) (right arm). These motifs are 
identical to those within the EHV-1 ori$ thus neither EHV origin has 
a non-consensus second base. The two flanking bases of the motif and 
the third position residue are both purines or pyrimidines (Koff and 
Tegtmeyer, 1988) . Since the 3rd position base and flanking residues 
are different in the upper and lower strand binding sites this may be 
an important determinant of the unidirectionally of DNA synthesis from 
the origin site. The putative EHV-4 ori[_ motifs are consistent with 
this observation : third base T is coupled to flanking CC and third
base G to flanking AA or GA.
3) Open reading frame
Analysis of the coding capacity of all six reading frames within DNA 
downstream of the gH gene indicated that the C-terminal coding region 
of a gene maps within the extreme right hand end of BamHI C (Fig. lb).
This gene, transcribed from right to left, maps from bp 3715 through to
the BamHI site at 4605 (Fig. 2 ) and presumably into the adjacent 
BamHI fragment, F. Analysis of the C-terminal 263 amino acids encoded 
by this open reading frame indicated sufficient similarity to the 
products of genes UL21 of HSV-1 and 38 of VZV to identify the EHV-4
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gene as a homologue of these genes. A comparison of the predicted 
protein products of these three genes is outlined in Figure 6 . The 
degrees of identity of the EHV-4 0RF3-specified C-terminal sequence 
with the corresponding regions of its HSV-1 and VZV counterparts are 
22% and 30% respectively.
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Figure 5.1 Positions of a direct repeat region, a putative 
origin of DNA replication, and a UL21 homologue within the 
right end of BamHI C.
a) BamHI restriction map of EHV-4 (strain 1942; Cullinane 
et al., 1988) with expansion of the sequenced region to 
show features of interest. The sequencing strategy is 
indicated below.
b) VAX analysis of potential ORF within all six reading 
frames.
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Figure 5.2
Nucleotide Sequence of EHV-4 DNA . Map Units 0.51-0.52
GGCTTCTATTGGGGGTTTGTTGCTGGCTATTCTGATTTTATATGTAATCGTTAAAATGTTATGTGGTGGTGTAATTAATAATGACTATAGTTTGTTATTAAACTCTGAGTAAACACAAAC 
A S I G G L L L A I  L I  L Y V I V K M L C G G V I N N D Y S L L L N S E *
AATGTCTAGTGTGTTGTATTGCGTGTAAACAGTATACGAGTGAACATTTATACGTAAAATGGTTAAATTTTATTTTCGCTATAAACGGGAATGCGGCGGCGAGGGCTGCTGCGGCGGCGA
C c________ ]  [_______ c _
GGGCTGCTGCGGCGGCGAGGGCTGCGGCGGCGGCGAGGGCTGCGGCGGCGGCGGCGAGGGCTGCGGCGGCGGCGGCGAGGGCTGCGGCGGCGGCGGCGAGGGCTGCGGCGGCGGCGGCGA 
 ] [____ a____ ] [_____ b______ ] [ d ]_[_ _ _____ d ] [_ _ _ _ _ _ _ d_______ ] [________ f__
GGGCTGCTGCGGCGGCGGCGAGGGCTGCTGCGGCGGCGGCGAGGGCTGCTGCGGCGGCGGCGAGGGCTGCTGCGGCGGCGGCGAGGGCTGCTGCGGCGGCGGCGAGGGCTGCTGCGGCGG 
 ] [_________ e ] t_________ e_________ ] [_________ e 3 [_________ e_________ ]_t_________ e_________ ] [______
CGGCGAGGGCTGCTGCGGCGGCGGCGAGGGCTGCTGCGGCGGCGGCGAGGGCTGCTGCTGCGGCGGCGGCGAGGGCTGCTGCTGCGGCGGCGGCGAGGGCTGCTGCGGCGGCGGCGAGGG 
 e ] [_________ e ] [__________ g ]  [__________ g___________ ] [_________ e 3 [_________ e
CTGCTGCGGCGGCGGCGAGGGCTGCTGCTGCGGCGTAAATGCAGCTATTCCACAGGCTCCCCGCTTAAATAGGAAAGGTGGGCGGGCGGTTTACTGGTAAATGTAGTTACGTAGCGHcti
 3 [__________ g___________ 31_____
TOrTGGTTACAATAATTATTATATATTATTAGCAATTGEIgCtfflreaSGGAATTGGTCCAATCAAATGGTTTAAAAACGGCCATGTGACATACAAACCAATCACAACACCTAGTATTGA
TTACTTATCAATAGGTTCCAAATCAATAATTTCGCCTAATGCGGGTTTGTACTACCTCCAGCTATCTTCCGTTGAAAATTACAACGGCATGGGGCGGTCGGGACACCACCATATATAAAT
ATCTCGCGCTTGCATTGTAGACCGCAAACTCACCTTTAATGTAGTAAATTTTACAACATTAAAATGTTATTCGCCTTAATAAAATTACAATACAGCGATGTAACTTCGGAGTTTTTATGC
U A
TCTGTTAACATGCACAGGTACACCACCACGCTTTAATCTCTCGCTGAGTAAGTAATATAAGTAGTATGCCCCCTTTCGGCTTAAGTCCAAATTATCAAATGCTGTTATTAAAGACACGTT 
R N V H V P V G G R K L R . E S L L Y Y L Y Y A G K R S L D L N D F A T  I L S V N
GAGAACTATGGCCACCGGCAAGCCGCTTCCCAGCATGCGACAGGCTGACTGTGCCGCCCCCCCGATACCTTCTTTGGCGTATAGCTTGTTTAGTACGCTTGCAATTTTAGCTTTAATTTC 
L V I A V P L G S G L M R C A S Q A A G G I G E K A Y L K N L V S A I  K A K I E
ATTTGATTCGTTGAAGGAACTAAGCCCCAACTCAACTCTGGTGGAGTTTGCAGCAAACTCGGCAAGTAGGTTAGCCTCTAGCTCCACAACTTCAGAAAAACTACCGTTTACTGGAGTGTT
N S E N F S S L G L E V R T S N A A F E A L L M A E L E V V E S F S G N V P T N
GGAGTGGGTATAGCGAACGATTATCTCGCATAGGTCTCCTAACATTGCACTTTCGCGTATTATTTCATTTACGGCATCGGCCACCAGGTGGGGGTCTGGTAACGGATCGCATGCGTCATG 
S H T Y R V  I I E C L D G L M A S E R I  I E N V A D A V L H P D P L P D C A D H
CACCGCTCCGATGTAGCTCTCGACCAGCTGTTCTAGGGATGCGTAGCAGTTGATTAGGTTCCACTTGTTTAGAATAAACTGGCAGAGTACAAATCGTTGTAGCGTGGTAATGCCCAGTTG 
V A G  I Y S E V L Q E L S A Y C N  I L N W K N L I  F Q C L V F R Q L T T  I G L Q
AGTAAGCTTTCCCCCAAAAAATCGCAGTTTTCCCTCATGGCCGTATACTGCTAAAACGGCATCAACAATGGTACTTCGCGCTTGGTTGAGGTGGTCATCCAAGCCCGGCCATGGTTCCTC
T L K G G F F R L K G E H G Y V A L V A D V I T S R A Q N L H D D L G P W P E E
AACCAAGATAATTTCATCGACCAGTTTGAATAGTAACTGTAGTGATTGTAACGATGCTCCACTTGCTGATTTGCTTGATGAGTTCCAGATGCTACAGGGTTTTGGAATAAGTCGCACCTG
V L I I E D V L K F L L Q L S Q L S A G S A S K S S S N W I S C P K P I L R V Q
CACAAAGTCGCTCACCACTGTTTTTCTAAGTGTGCGTTTGGATCC
V F D S V V T K R L T R K S G
Figure 5.2 Nucleotide sequence of 1965bp of EHV-4 DNA . The 
numbering system used in Chapter 4 has been adopted such that 
the C-terminal coding region of the gH gene homologue is 
numbered as before, terminating at bp 2749. Individual repeat 
elements are bracketed and letters a to g assigned in order of 
increasing size (see Table 1) . The conserved element CGTTCGCAC 
and its complement within the putative EHV-4 oriL are boxed. The • 
predicted C-terminal amino acid sequence of the product of the 
UL21 gene homologue is indicated below the nucleotide sequence.
2 7 6 0
2 8 8 0
3 0 0 0
3 1 2 0
3 2 4 0
3 3 6 0
3 4 8 0
3 6 0 0
3 7 2 0
3 8 4 0
3 9 6 0
4 0 8 0
4 2 0 0
4 3 2 0
4 4 4 0
4 5 6 0
4 6 0 5
Figure 5.3
Sequencing Reaction in Repeat Region
Figure— 5.3 Autoradiograph of sequencing reaction using
primer HL13 (bp 3467-3451) and denatured pBSSB4 as template.
Figure 5.4
Putative Stem-and-Loop Structures of HSV-1. EHV-1. 
and EHV-4 Origins of DNA Replication
A
r
c
A G C C G G T G G G C G T G G C C G C T A T T A T A A A A A A A G T G A G A A C G C G A A G C G T T C G C A C T T T G T C C T A A T A A T A T A  H S V - 1  ori‘L
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
T C G G C C A C C C G C A C C G G C G A T A A T A T T T T T T T C A C T C T T G C G C T T C G C A A G C G T G A A A C A G G A T T A T T A T A T 7 2 / 1 4 4
A
C
G
C.
G.
L  T T
T C G C A C T T  C G C C C A A T A T A  A H S V - 1  o r i .
I I I I I I I I I I I I I I I I I I I I
A G C G T G A A G C G G G T T A T A T  T 2 1 / 4 5
G A T A
C
A
C
C
C. C A  A T C A C  G
G T T C G C A C  C A A T A A T T T T A  E H V - 1  or i §
I I I I I I I I I I I I I I I I I I I A
C A A G C G T G  G T T A T T A A A A T  1 9 / 5 5
A A A A C A A C T
C
T
T
A
G G
C G T T C G C A C T T  G T T A C A A T A A T T A T  P u t a t i v e
I I (I I I I I I | (I II I I I I I I I | T E H V - 4  o r i L
G C A A G C G T  G G T T  A A G G T  T A T T  A A T  A 2 2 / 5 4
G A T
G
A
Figure 5.4 Potential base-pairing events within three 
functionally characterised origins of DNA replication - HSV-1 
oriL (Weller et al.. 1985), HSV-1 orig (Stow and McMonagle, 
1983) , EHV-1 orig (Baumann et al.. 1989) - and within a
putative EHV-4 origin . Figures assigned to each structure 
detail the number of potential base matches against the length 
of the palindrome. The position of the conserved sequence 
element CGTTCGCAC (TT) within each palindrome is indicated by 
underlining.
Figure 5.5
Alignment of A/T rich DNA and Flanking DNA
of Herpesvirus Origins of DNA Replication
EHV-4 o r i , G T A G C G T T C G C A C T T G G T T A C A A T A A T T A T T A T A T A T T A T T A - - G C A A T T G - G T G C G A A C G G G G A A
EHV-1 ori G G C C C G T T C G C A C C A A T C A C C A A T A A G T T T T A A T A A T A A T T A T T G C A A C A A A G T G C G A A C A C T A C G
HS V - 1 o r i , G A A G C G T T C G C A C T T T G T C C T A A T A A T  A T A T A T A T T A T T A G G A C A A A G T G C G A A C G C T T C G
HSV-2 ori G A A G C G T T C G C A C T T T G T C C T A A T A G T  A T A T A T A T T A T T A G G A C A A A G T G C G A A C G C T T C G
HSV-1 ori G A A G C G T T C G C A C T T C G T C C C A A T A T . . . . . A T A T A T A T T A T T A G G G C G A A G T G C G A G C A C T G G C
HSV-2 ori G A A G C G T T C G C A C T T C G T C C T A A T A G T  A T A T A T A T T A T T A G G G C A A A G T G C G A G C G C T G G C
VZV orig CCAC C G T T C G C A C T T T C T T T C T A T A T A T A T A T A T A A T A T A T A T A T A G A G A A A G A G A G A G A G T T T C T
Figure 5.5 Nucleotide sequence similarity of DNA spanning the 
conserved CGTTCGCAC (TT) element and A/T rich DNA within the 
following herpesvirus origins of replication - EHV-4 oriL 
(putative), EHV-1 orig (Baumann et al. . 1989), HSV-1 oriL
(Weller et al. . 1985) , HSV-2 oriL (Lockshon and Galloway, 1986), 
HSV-1 orig (Stow and McMonagle, 1983) , HSV-2 orig (Whitton and 
Clements, 1984), and VZV orig (Stow and Davison, 1986).
Figure 5.6
Alignment of the Predicted Products of HSV-1 UL21 
and its VZV and EHV-4 Counterparts
HSV-1 FELSYATTMHYRDWFYVrTORNRAYFVCGGCVYSVGRPCASQPGEIAKFGLVVRGTGFODRWANYVRSELRQRGLQDVRPIGEDEVFLDSVCLLNPNVSSEL-DVINTNDVEVLDECL
ii i i i i ii mi mi i i mini ini n ii n mill i 111 n i i ini i i
VZV ME FPYHSTVSYNGVT FYFNERATRAY FICGGCLISIPRKHG— GEIAKFGHWRGVGPGDRSVASYVRSELNRTGKTUWSSNNNCVFLDRVALLAAGSGAWRDLCGTFDVEVEDPTL
HSV-1 AEYCTSLRTSPGVLISGLRVRAQDRIIELFEHPTIVNVSSHFVYTPSPYVFALAQAHLPRLPSSLEALVSGLFDGIPAPRQPLDAHNPRTDWI-TGRRAPR....... PIAGSGA
I I II I I I  II I I I  I I I I I II II llll l l l l I I I  I III II I I
VZV ADYLVSLPVrHLTLVAGVDV-TRENKLKLFPTPTAINTTNGFMYVPNEASFSLVYMRMLELPESLQELVSGLFDGTPEIRDALHGSNDOElCTSI IVSRRAADWTEDVKADDVPI SGEPY
VZV SEKQPRRRKKSDHITLSNFVQIRTIPRV. . . . . . MJIWDPRHK-ATTHCIRA. . . . . LSCAVFFADEVIFKARKVJPGLEDELNEARETIYTAWAVYGERGELP-FFGHA- - - -
I II I III I II II I I I II I Mil I II II II II INI I I III
EHV-4 GSKRTL-RICTW SDFVCWRLIPKP..... CSIUNSSSKSAS-GASLQS. . . . . LflLLFKLVDEI ILVEEFVPGLDOHLNQARSTIVOAW-AVYGHEGKLR- F FQGK-—
II I I III I I I I II I I I  II I II I II
HSV-1 GSGGAGAKRATV-— SE FW/KHIDRVGPAGVSPAPPPNNTDSSSLVPGAGDSAPPGPTLREIUWFYAADRALEEPRADSGLTREE. . . . . . . VRAVRGFREQAVKLFGSAGAPR
I III I II I II II I II I II I
VZV SEKQPRRRKKSDHITLSNFVQIRTIPRV. . . . . . MDIUDPRHK-ATTHCIRA. . . . . LSCAVFFADEVI FKARKUPGLEDELNEARETIYTAWAVYGERGELP- FFGHA--
gsk rk--v S-FUQ-r-Ip- iwn—  sksa— ga. ...... L— f— De-i. . . . k£GL-d-ln-ar-ti--aV-AVyG--g-l— fFG...
VZV --YGRDLTSC--CRFVIVQYILSRWEAFNCYAVIEDLTRSYVNALPSD DDTDQVAQDLIRTIV-DTAHSLUEVGFIGTLAETLL-FLPIJQLPCYKETSHLAKKEGVRILRLAKTGVG
I Mil I II I llll I I II I I I I  II I I I
EHV-4 - - -LTQLGITTLQRFVLCQFILNKWNLINCYASLEQLVESYIGA—  - VH5ACDPLP-DPHLVADAVHEIIRESAMLGDLCEIIVRYTHSNTPVNGSFSEWELEANLLAEFAANS- -T
II II I I II I I I II I III I I I I I I II
HSV-1 AFIGAALGLSPLGKLAVYYYIIHRERRLSPFPALVRLVGRYTQ RHGLYVPRPDDPVL-ADAINC3.FRDALAAGTTAB3LLMFDLLPPKDVPVGSD\QADSTALLRFIE- S
I I  I I  I I  I I  I I II II III II I
VZV - -YGRDLTSC- -GRFVIVQYILSRUEAFNCYAVIEDLTRSYVNALPSD DDTDQVAGDLIRTIV-DTAMSLLREVGFI GH'LAETLL- FLPLPQLPCYKETSHLAKKEGVRILRLAIUGVG
 Lg-- Qrfv— q-Il--w—  ncya— e-L— sY— a... h-- p-p-c£r Iv-D— N— Re--- G-l-E.......... s-v-... II......
VZV LS-DTVPVDVSVTERHEYEISRYLDTLYSGDPCYNGAVRLCRLLGSSIPIALYYNTI SGfJAFEPYFAG RRYIAYLGALFFGRVHQTPFGDGtOCTQR* (541)
I I I II I II III I I I  II I II I I
EHV-4 RVELGLSSFNESNEIKAKIASV-LNKLYAKEGIGGAAQSACRMLGSGLPVAIVLNVSLITATONLD LSRKGAYYLYYLLSERLKRGGVPVHVNRA* ( ? )
I I I I  III I II I I  I I  I III I II II II I I
HSV-1 QR-LAVPGGVISPEHVAYLGAFL-SVLYAGRGRMSAATHTARLTGWSLVLAVGDVDRLSAFDRGAAGAASRTRAAGYLDVLLTVRLARSQHGQSV* (535)
II I I  I II I I II I II II I II I I I
VZV LS-DTVP\®VSVTERHEYEISRYLDTLYSGDPCYNGAVRLCRLLGSSIPIALYYNTISGNAFEPYFAG RRYIAYLGALFFGRVHQTPFGDGKKTQR* (541)
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Figure 5.6 Alignment of the predicted products of gene UL21 of 
HSV-1, gene 38 of VZV, and the rightward flanking gene of the 
EHV-4 gH gene homologue (C-terminal region only). A consensus 
line is presented below the alignment in which lower case 
represents residues conserved in two polypeptides and upper case 
residues conserved in all three.
Table 5.1
Repeat Elements of EHV-1 and EHV-4
S e q u e n c e S i z e Number D e s i g n a t i o n
GCGGCGGCGAGGGCT GCT 18 2 c
GCGGCGGCGAGGGCT 15 1 a
GCG GCGGCGGCGAGGGCT 18 1 b
EHV- 4  R e p e a t s GCGGCG GCGGCGGCGAGGGCT 21 3 d
GCGGCG GCGGCGGCGAGGGCT GCT 24 1 f
GCG GCGGCGGCGAGGGCT GCT 21 7 e
GCG GCGGCGGCGAGGGCT GCTGCT 24 2 g
GCG GCGGCGGCGAGGGCT GCT 21 2 e
GCG GCGGCGGCGAGGGCT GCTGCT 24 1 g
GCGGCG 6 1 p a r t i a l
EHV-1 R e p e a t s GCGGGAGCGAGGGCTGCTGCGGCGGCGGCGCG 32 2
GCGGGAGCGAGGGCTGCTGC 20 1 p a r t i a l
GCGGGAGCGAGGGCTGCT GCGGCGGCGGCGCG EHV-1 i n t a c t  r e p e a t
C o m p a r i son I I I !  I l l l l l l l l l l l  l l l l l l l l l l l l
GCGGCGGCGAGGGCTGCT GCGGCGGCGGCGGC EHV- 4  c , d  ( p a r t i a l )  r e p e a t s
Table 5.1 The nucleotide sequence, size, number, and order of 
repeat elements mapping downstream of the EHV-1 and EHV-4 gH 
gene homologues are indicated in the upper two sections of this 
table. The 'designation' column identifies repeat elements of 
EHV-4 as detailed in Figure 2. The third section details a 
comparison of the intact EHV-1 repeat element to two EHV-4 
elements, 'c' and part of 'd'.
Table 5.2
Binding Motifs within Herpesvirus Origins of DNA Replication
Left arm Right arm
E H V - 4  o r i
E H V - 1  o r i
HSV-1 ori
HSV-1 ori
HSV-2 ori
HSV-2 ori
VZV ori
C G T T C G C
A G T G C G A
C G T T C G C
G G T G C G A
C G T T C G C
A G T G C G A
C G T T C G C
A G T G C G A
C G T T C G C
A G T G C G A
C G T T C G C
A G T G C G A
C G T T C G C
A G T G C G A
G G T G C G A
C G T T C G C
A G T G C G A
T G T T C G C
A G T G C G A
T G C_ T C G C
A G T G C G A
C G T T C G C
A G T G C G A
C G C_ T C G C
A G T G C G A
C G T T C G C
Table 5.2 Nucleotide sequences of the asymmetric 5bp GT(G/T)CG 
binding motifs within the right and left arms of the palindromes 
of herpesvirus origins of replication . 5' and 3' flanking 
residues are indicated to the left and right of the 5bp motifs. 
Nucleotides which do not conform to consensus rules (see text) 
are underlined. Data from Koff and Tegtmeyer (1988) and Baumann 
et al. (1989).
DISCUSSION
Sequence analysis of 1855kbp of DNA immediately downstream of the 
EHV-4 gH gene indicated that EHV-4 encodes a gene homologue of genes 
UL21 of HSV-1 and 38 of VZV which are arranged in a similar genomic 
position , immediately proximal to the gH gene in tail-to-tail 
orientation. The function of the gene products of these genes is as 
yet unknown (Davison and Scott, 1986; McGeoch et al., 1988a).
Comparison of the protein coding capacity of the portion of BamHI C 
sequenced in this study - UL24 homologue-TK-gH-UL21 homologue - 
indicates conservation of this gene block the HSV-1, VZV, and EHV-4 
genomes.
Though gene arrangement might be conserved, the sequence analysis of 
EHV-4 revealed two elements - a region of direct repeats and a putative 
origin of replication - which are not located at a similar position
within the genomes of HSV-1 or VZV. The direct repeat elements are of
limited interest at present since there is little evidence as yet to 
suggest that any such elements have a functional role within
alphaherpesviruses. However, it is interesting that direct repeat 
elements have been located in juxtaposition to other herpesvirus 
origins of replication, such as VZV ori$. Analysis of the effect of 
repeat elements on HSV-1 ori-driven replication of plasmids in 
herpesvirus infected cells is in progress. It is possible the repeat 
elements might have an enhancer-type role in initiation of DNA
synthesis at the origin but this is extremely speculative.
Direct repeat regions in herpesvirus genomes often occur at regions 
of heterogeneity between different viral isolates, with different 
numbers of repeats present in distinct isolates. Allen et al. (1983a)
have reported that multiple passage of EHV-1 in non-equine cell lines 
leads to differences in genome size due to differences in the sizes of
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copies of short repeat sequences occurring at specific regions of the 
genome and Whalley and coworkers (1981) have reported that EHV-1 EcoRI 
fragments K and L are heterogeneous in size.
Of the full complement of minor repeat elements within VZV and 
HSV-1 none are conserved in position or, to a significantly high 
degree, in sequence. There is evidence for the existence of a direct 
repeat region in the genome of EHV-1 at a similar position to that of 
EHV-4. However, this region differs from that of EHV-4 in that the 
direct repeat elements are larger and present in only two copies and a 
partial. It is possible, however, that deletion of part of this region 
in EHV-1 and/or EHV-4 may have occurred during passaging of the virus 
in vitro or on cloning and propagation in E. coli. A region of tandem 
repeats has been reported downstream of the PRV gH gene though sequence 
data has not been published (Petrovskis et al.. 1988). Further PRV
repeat regions have been reported within the S component and adjacent 
to the gB gene homologue ( Simon et al.. 1989; Zhang and Leader, 1990). 
There is no evidence for repeats in the latter position in EHV-4, at 
least in EHV-4 strain 1942 (Riggio et al.. 1989). The only other 
reported EHV-4 tandem repeat element is an 8bp sequence - GGAGGTGG - 31 
copies of which are located within TR$ between gene homologues of HSV-1 
genes US9 and US10 . A region of direct repeats is located at a similar 
position within HSV-1 (McGeoch et al.. 1985) and PRV (Zhang and Leader, 
1990) but not within VZV (Davison, 1983). Given the number of repeats 
in HSV-1 and VZV it seems most likely that further sequence analysis 
of EHV-1 and EHV-4 will reveal further repeat regions especially within 
restriction fragments which are known to be heterogeneous.
The EHV-4 repeat elements were strict multiples of three in size 
which might imply constraints placed on their sequence by a protein 
coding function. Open reading frames spanning the repeat region were
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almost exclusively represented by repeating codons and thus it seems 
most unlikely that any of these are functional protein coding genes. 
Furthermore, given the extent of gene conservation between EHV-4 and 
HSV-1 and VZV reported in this thesis and that of Riggio (1990) a gene 
exclusive to EHV-4 at this position would seem unlikely. It seems 
more likely , particularly since repeats in noncoding DNA of VZV and 
HSV are often multiples of three in size, that repeat sizes are 
determined by mechanisms involved in their generation .
In view of the sequence similarity of the putative EHV-4 origin to 
those of human and EHV-1 origins it would appear to be an excellent 
candidate for an EHV-4 ori^ The only other origins of replication 
definitively mapped within the Uj_ component of alphaherpesvirus genomes 
are the o r ^  of-HSV-1 and of HSV-2. These are considerably larger than 
the putative EHV-4 ori|_ and are susceptible to deletion on cloning into
plasmids (Gray and Kaerner, 1984; Weller et al.. 1985). It seems likely
that the sequence presented in this thesis is the intact element since 
deletion of the HSV-1 oriL resu^ts in a l°ss of the polyA/T tract.
A continuing debate within research into DNA replication origins is 
whether the palindromic sequence of origins adopts an intrastrand base 
paired conformation. There is as yet no experimental evidence that 
cruciform or stem-and-loop origin structures exist in vivo. 
Furthermore, mutational studies have indicated that although the left 
arm of the palindrome is crucial for origin activity, the right arm can 
be deleted with little effect (Deb and Doelberg, 1988). It is
interesting that the EHV-1 0H 5 and our putative oriL possess fewer
intrastrand base pairing events than do the human herpesvirus origins 
indicating a perfect palindrome is not required for origin activity.
The HSV-1 ori’L maps in the intervening DNA between genes encoding 
UL29 and 30 which encode the major DNA binding protein and DNA
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polymerase respectively (McGeoch et al.. 1988a). Given the localisation 
of the origin and the function of the two flanking gene products in DNA 
replication it has been postulated that such an arrangement may be 
important to the regulation of initiation of DNA replication. The 
putative EHV-4 oriL mapping between gH and a gene of unknown function 
would seem to be removed from such control. A putative EHV-1 oriL 
sequence of very similar sequence to that of EHV-4 maps to a similar 
genomic position (Robertson et al.. 1991). Whether an origin maps 
between the DNA pol and DNA binding protein genes of EHV-1 or EHV-4 has 
yet to be inferred either indirectly by sequence analysis or directly, 
by functional studies. The existence of two origins of replication 
within PRV, one at the extreme left end of the long component, the 
other downstream of gH, has been reported ( Kupershmidt et al.. 1988;
Petrovskis et al.. 1988; Wu et al.. 1986a,b) but sequence or functional 
characterisation has yet to be published. It might be expected from the 
comparative sequence analyses of PRV and EHV sequence data generated by 
ourselves and others that, with the exception of the 0.1-0.4 m.u. 
inversion of PRV (Davison and Wilkie, 1983), the EHV and PRV genomes 
would be more similar in terms of genome layout of coding regions and 
cis-acting elements than the EHV and HSV or VZV genomes. Consequently, 
it may be that the internal Ul ori of PRV maps to a comparable position 
to that of EHV-1 and EHV-4 particularly in the light of the mapping of 
PRV tandem repeats at a similar position to those of EHV-1 and EHV-4 
(Petrovskis et al.. 1988).
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CHAPTER 6
SEQUENCE ANALYSIS OF EHV-4 gpl3 GENE 
AND FLANKING GENES
INTRODUCTION
Genes encoding glycoproteins with sequence similarity to HSV-1 
gC have been identified in several herpesviruses including HSV-2, VZV, 
PRV, BHV-1, MDV and EHV-1. Unlike gH and gB-type glycoproteins a gC- 
type glycoprotein seems to be specified only by alphaherpesviruses and 
not by beta and gammaherpesviruses, at least on current information.
The gC-type glycoproteins of HSV-1, MDV , and PRV are 
nonessential for viral replication in vitro yet gC- field isolates 
have not been isolated suggesting a critical role for gC in vivo 
(Churchill et al.. 1969; Holland et al.. 1984a; Mettenleiter et al., 
1988; Robbins et al.. 1986b). Functions assigned to the gC-type 
glycoproteins of herpesviruses include a role in pathogenicity (Kumel 
et al.. 1985; Mettenleiter et al.. 1988; Schreurs et al.. 1988), in
binding of complement factor C3b (Bielefeldt Ohmann and Babiuk, 1988; 
Smiley and Friedman, 1985), and in the mediation of adsorption of 
the virion to target cells (Kuhn et al.. 1990; Mettenleiter et al., 
1988; Okazaki et al.. 1987: Zuckermann et al.. 1989). Comparative
analysis of HSV-1 gC and PRV gIII has indicated that these 
glycoproteins might have diverse functional roles within their 
respective viral replicative cycles (Whealv et al.. 1989). In contrast, 
common functional roles have been reported for glycoproteins such as 
gH and gB which exhibit a greater degree of conservation in terms of 
amino acid sequence and representation in herpesviruses of different 
subgroups (Rauh and Mettenleiter, 1990) . An example of the diverse 
function of different 'gCs' is C3b binding activity which has only been 
demonstrated for HSV-1 gC and EHV-1 gpl3 presented on infected cell 
membranes and for HSV-2 gC in a purified form ( Bielefeldt Ohmann and 
Babiuk, 1988; Seidel-Dugan et al.. 1988). The MDV gC-type glycoprotein, 
A antigen or gp57-65, differs from other 'gCs' in that it is
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predominantly a secreted antigen and in this form may be involved in 
immunoevasion by protecting virus infected cells from attack through 
binding antibody (Isfort et al.. 1986, 1987). The gC-type glycoproteins 
of BHV-1 and HSV-1 seem to assemble into homodimers which are 
responsible for specific spikes within the virion envelope (Kikuchi et 
al., 1990; Stannard et al., 1987; van Drunen Littel-van den Hurk and
Babiuk, 1986).
An important function of all herpesvirus 'gCs', and the reason for 
our interest in the EHV-4 glycoprotein, is their interaction with the 
cellular and humoral immune system of the infected host. gC tends to be 
a major target of host humoral and cellular immune mechanisms (Ben- 
Porat et al.. 1986; Glorioso et al.. 1985 ).
Following mapping of the major glycoprotein genes of EHV-1, gpl3 was 
predicted to be a gC-type glycoprotein since its gene mapped at a 
position col inear with that of the gC gene of HSV-1 (Allen and Yeargan,
1987). Analysis of the amino acid sequence specified by the gpl3 gene 
confirmed that EHV-1 gpl3 , alternatively known as gp88 (Meredith et 
al., 1989), is a gC-type glycoprotein : gpl3 shares sequence identity
with gC and exhibits positional conservation of 4 cysteine residues 
suggesting a degree of structural similarity. Polyclonal antisera and a 
proportion of monoclonal antibodies raised against EHV-1 gpl3 are 
crossreactive with the EHV-4 glycoprotein identified as gpl3 (Allen and 
Bryans, 1986; Allen et al.. 1988) or gp92 (Meredith et al.. 1989). Such 
evidence indicates shared antigenicity of these proteins which might be 
expected to be reflected in similarity of their respective amino acid 
sequences and gene nucleotide sequences. On the basis of these 
studies, there is compelling, albeit indirect, evidence to suggest that 
gpl3 of EHV-4 is a gC-type glycoprotein and would thus be the expected 
product of an EHV-4 gC gene homologue. The term gpl3 is used
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throughout this thesis to refer to the product of the EHV-4 gC gene 
homologue. As yet all that is known of the EHV-1 and EHV-4 'gCs' is 
the C3b binding activity of the former and the capacity of both to 
elicit antibodies, some of which neutralise infectivity in the 
presence of complement ( Allen and Bryans, 1986; Allen and Coogle, 
1988; Bielefeldt Ohmann and Babiuk, 1988). The glycoproteins have also 
been implicated in interaction with cellular immune mechanisms 
(Bridges et al., 1988). Whether either glycoprotein exhibits any of the 
other functions assigned to gC-type glycoproteins remains to be 
determined.
To date the amino acid sequences of the gC-type glycoprotein of 
seven herpesviruses have been published - HSV-1 gC (Dowbenko and Lasky, 
1984; Draper et al.. 1984; Frink et al.. 1983; McGeoch et al.. 1988a),
HSV-2 gC (Dowbenko and Lasky, 1984; Swain et al.. 1985), PRV g 111
(Robbins et al.. 1986a), VZV gpV (Kinchington et al., 1986), BHV-1 gIII 
(Fitzpatrick et al.. 1989), MDV A antigen (Binns and Ross, 1989; 
Coussens and Velicer, 1988; Ihara et al.. 1989 ), and EHV-1 gpl3 (Allen 
and Coogle, 1988). Since the components of EHV-1 and EHV-4 are 
generally col inear (Cull inane et al.. 1988) the EHV-4 gC gene homologue 
was expected to map at a comparable position to the EHV-1 gpl3 gene 
(m.u. 0.114-0.136). This chapter describes the localisation of the
EHV-4 gpl3 gene and flanking genes by Southern analysis and sequence 
data, and reports on the similarity of the predicted EHV-4 gpl3 protein 
with other herpesvirus gC-type proteins (Nicolson and Onions, 1990).
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MATERIALS AND METHODS
1) Generation of EHV-1 gpl3 gene hybridisation probe
A BamHI library of EHV-1 strain HVS-25 in pBR322 was kindly provided 
by J.M. Whalley of the Macquarie Institute, Australia. The EHV-1 gpl3 
gene is localized within a BamHI/EcoRI fragment mapping between 0.114 
and 0.148 (Allen and Yeargan, 1987) - a subfragment of EHV-1 BamHI H 
(Whalley et al.. 1981). Recombinant plasmid pBR322:EHV-l BamHI H was 
digested with BamHI or BamHI and EcoRI, electrophoresed through a 0.7% 
agarose gel and the intact EHV-1 H fragment or BamHI/EcoRI subfragment 
excised and purified using Costar spin tubes (NBL). These probes were 
^P-labelled by nick translation in the presence of ar-^P-dCTP 
(Amersham Radiochemicals Ltd.).
2) Construction of EHV-4 recombinant plasmids
An EHV-4 strain 1942 BamHI library in pUC9 was constructed as 
previously reported (Cullinane et al.. 1988). Recombinant plasmid
pUC9:EHV-4 BamHI G was digested with a series of restriction enzymes 
to generate subfragments of EHV-4 G which were then isolated from 0.7% 
agarose gels and cloned into a Bluescript M13+ plasmid vector 
(Stratagene) by standard techniques (Maniatis et al.. 1982).
3) Southern Analysis
Recombinant plasmids containing EHV-4 BamHI fragments B and G - 
approximate map coordinates 0.01 - 0.17 - were digested with a series 
of restriction enzymes and the digest products electrophoresed through 
a 0.75% agarose gel to which ^P-labelled lambda Hind III fragments had 
been added as size markers. The gel was alkali denatured and 
neutralised and DNA fragments transferred to a Gene Screen membrane 
(New England Nuclear) by capillary action. The membrane was baked for 2 
hours at 80°C, prehybridised overnight at 42°C in 45% formamide, 4.2 x 
SSC, 4.2 X Denhardts Solution, 8% dextran sulphate, 0.04M NaPPi,
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80ug/ml salmon sperm DNA, 0.08% SDS and hybridised for a similar period 
following addition of 2 x 10^ cpm of denatured ^P-labelled EHV-1 H 
BamHI or BamHI/EcoRI probe DNA. The blot was rinsed with 2 x SSC,
washed for three 30 minute periods at 65°C in 1 x SSC, 0.1% SDS, rinsed
in 0.1 x SSC , dried and exposed to Fuji RX film overnight at -70°C in
the presence of a Cronex intensifying screen.
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RESULTS
1. Localisation of the EHV-4 gC gene homologue
1) Southern hybridisation
The EHV-1 gC gene homologue (gpl3) is localised within a BamHI/EcoRI 
subfragment ( map units 0.114 - 0.148) of EHV-1 BamHl H (m.u. 0.114-
0.164) (Allen and Yeargan, 1987; Whallev et al.. 1981) (Fig. la).
Given the reported colinearity between the EHV-1 and EHV-4 genomes 
(Cullinane et al.. 1988), we expected the EHV-4 gC gene homologue to be 
located within BamHI G (Fig. lb). Southern hybridisation experiments 
were performed in which fragments of EHV-1 DNA spanning the gpl3 gene 
were hybridised to fragments BamHI B and G of the EHV-4 genome in order 
to confirm colinearity prior to sequence analysis. Such analysis 
confirmed EHV-4 BamHI G as the probable site of the EHV-4 gpl3 gene 
since hybridisation was limited to G and to subfragments of G (Figs. 
2,3). A restriction map of BamHI G was determined by conventional 
techniques to aid in the identification of the crosshybridising region 
of G (Fig. 3c). EHV-1 H DNA hybridised to all EHV-4 G restriction 
fragments tested with the exception of a 1.9kbp BamHI/Sall fragment 
mapping to the left end of G (Figs. 2,3c). Hybridisation to a 0.3kbp 
EcoRI/EcoRI fragment mapping between two hybridising EcoRI fragments 
was not detected presumably as a consequence of the amount of 
radiolabelled probe bound being below the detection limit . The 
BamHI/EcoRI subfragment of EHV-1 H (m.u. 0.114-0.148) failed to
hybridise to the 0.95kbp EcoRI terminal fragment (Fig. 3). As 
hybridisation to the 0.3kbp internal EcoRI fragment was not detected 
with either probe , it was not clear whether the smaller BamHI/EcoRI 
probe shared homology with this fragment. Since the right terminal 
1.9kbp Bgll/BamHI fragment and the adjacent 1.9kbp BglI/BglI fragment 
co-migrated it was not possible to definitively conclude whether the
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probe hybridised to this fragment. However, comparison of binding of 
label to the 1.9kbp region of the BamHI/EcoRI-probed blot to that of 
the BamHI/BamHI-probed blot suggested lesser binding to the doublet by 
the smaller probe. We concluded from these analyses that the EHV-4 
gpl3 gene maps between the innermost Sail and EcoRI sites, possibly 
extending to the EcoRI site at 0.3 (Fig. 3c).
2) Sequence Analysis
In order to precisely localise the EHV-4 gpl3 gene, subfragments 
of the cross-hybridising region of EHV-4 G were cloned into a 
Bluescript plasmid vector and the nucleotide sequence of the termini of 
each fragment determined using commercially available Bluescript 
primers. Such analysis revealed a significant degree of homology 
between DNA spanning the rightward Bgll site and the central region of 
the EHV-1 gpl3 gene. Sequence analysis was extended from this region as 
detailed below.
2. Nucleotide Sequence of EHV-4 - Map Units 0.15-0.17 
The nucleotide sequence of 2.88 kbp of EHV-4 BamHI G (approximate 
map units 0.15-0.17) was determined according to the strategy outlined 
in Figure 4c and is detailed in Figure 5. Two major open reading 
frames , 0RF2 and 0RF3, and a partial ORF, 0RF1, were detected in 
transcriptional sense right to left (Fig. 4b).
0RF1 extends from the EcoRI site at bp 0 through to bp 233 and 
encodes the C-terminal region of a polypeptide. A potential 
polyadenylation signal, ATTAAA, is positioned across the termination 
codon. 0RF2 , which extends from an ATG at 412 to a TAA termination 
codon at 1867, was identified as the EHV-4 gC gene homologue through 
the sequence similarity of its 485 amino acid product to the gC-type 
glycoproteins of other herpesviruses. Comparison of 0RF2 to the gpl3
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gene of EHV-1 indicated 76% identity at the DNA level and 79% at the 
amino acid level. On the basis of the shared antigenicity of the gpl3 
glycoproteins of EHV-1 and EHV-4 the predicted product of 0RF2 is gpl3 
and the gene and gene product of 0RF2 are identified as such hereafter.
The DNA sequence upstream and downstream of 0RF2 was searched for 
characteristic gene control elements. The 5' non-coding region of many 
eukaryotic and viral genes contains two sequences required for precise 
or efficient transcription of the gene by RNA polymerase II - the TATA 
[TATA(A/T)A(T/A)] and CAAT [GC(C/T)CAATCT] boxes, positioned 26-34 and 
70-80 bp, respectively, upstream of the RNA pol II initiation site 
(Corden et al.. 1980). Several TATA homologues are located in the
immediate upstream of the EHV-4 gC gene. Of these, only 2 (at 345 and 
220) with a greater than 70% fit to the consensus sequence, have 
potential CAAT boxes at an appropriate distance upstream. Alignment of 
the EHV-1 and EHV-4 gpl3 DNA sequences revealed perfect alignment of 
the TATA box at 345 and its corresponding CAAT box (bp 297) with the 
putative promoter elements of the EHV-1 gpl3 gene (Fig. 6). However, 
given the extent of sequence homology within this region we cannot 
infer the conservation of these control element homologues is due to 
sequence constraint as a result of promoter functions. No consensus 
polyadenylation signal - AATAAA (Proudfoot and Brownlee, 1976) - was 
located within the immediate downstream region. However, two minor 
polyadenylation signal sequences -AATACA and ATTAAA (Birnstiel et al..
1985) - were located 40 and lOObp downstream of the TAA stop codon.
It is possible that in the EHV-4 gpl3 transcription termination and 
polyadenylation process a relatively uncommon core signal sequence is 
utilised. However, no equivalent polyadenylation signals are located 
within the corresponding region of the EHV-1 gpl3 gene (Fig. 6) 
suggesting that, in EHV-1 at least and perhaps in EHV-4, the gpl3 gene
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may be transcribed as part of a multigenic RNA with the RNA polymerase
II transcribing downstream of gC, possibly through 0RF3.
Two ATG codons are located within the first 100 bp of 0RF2. The ATG
at 412-414 seems the more likely initiation codon given that i) its
local nucleotide sequence - CAGCAATGG - gives a more favourable fit to 
the optimal mRNA translation initiation codon sequence of Kozak (1984, 
1986) - CC(A/G)CCATG(G)- than the ATG at 430-432 and ii) alignment of
the EHV-4 and EHV-1 gpl3 sequences brings the EHV-1 ATG initiation
codon, into alignment with EHV-4 ATG 412-414 (Fig. 6).
The codon usage of the EHV-4 gpl3 gene is indicated in Table 1 with 
the predicted amino acid composition of its product. The %GC of the 
gene is 48.4% which is similar to that of the EHV-4 gB gene (Riggio et 
al.. 1989). All 61 amino acid specifying codons are utilised.
0RF3 , or dsgC, maps downstream of the gpl3 gene and extends for 678
nucleotides . It shares no homology with VZV or HSV-1 genes in a 
comparable genomic position. TATA and CAAT homologues are located 
upstream of this ORF at 2065 and 2020 respectively. Codon usage is 
presented in Table 2.
3. Predicted Protein Products of QRF1. 0RF2. and 0RF3
1) EHV-4 UL43 gene homologue product
The 76 amino acid sequence specified by partial 0RF1 shares 
identity with the C-terminal region of the protein products of genes 
UL43 of HSV-1 (McGeoch et al.. 1988a) and 15 of VZV (Davison and Scott,
1986) to a level of 23% and 21% respectively (Fig. 7).
2) EHV-4 gpl3
At 485 amino acids in length with molecular weight 52513, the EHV-4 
gpl3 primary translation product is of comparable length to the 
equivalent protein in EHV-1 (468) (Allen and Coogle, 1988), PRV (479)
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(Robbins et al.. 1986a), HSV-1, HSV-2 (511,479) (Dowbenko and Lasky, 
1984; Swain et al.. 1985), MDV (501)(Binns and Ross, 1989; Coussens and 
Velicer, 1988 ) and BHV-1 (521)(Fitzpatrick et_aL_, 1989). The 591 
amino acid VZV gpV is longer due to the presence of direct repeat 
elements within its coding sequence (Kinchington et al., 1986).
A putative signal peptide was identified by a stretch of hydrophobic 
amino acids at the N-terminus evident within hydropathic analysis of 
gpl3 using the algorithm of Hopp and Woods (1981) or Kyte and Doolittle 
(1982 ) (Figs. 8,9). Using the eukaryotic weight matrix of von Heijne
(1986) the EHV-4 gpl3 signal sequence is predicted to be 32 amino acids 
in length with cleavage occurring between the Ala and Ser residues at 
positions 32 and 33 respectively. This predicted cleavage position 
is consistent with the '-3,-1' rule in that the side chains of the 
amino acids at positions -3 (Ala) and -1 (Ala) are small and uncharged. 
Furthermore, the existence of a glycine residue at -6 is consistent 
with the observation that strong helix breaking amino acids are often 
positioned between the hydrophobic core of the signal sequence and the 
-3 to -1 region.
The extracellular domain of gpl3 is predicted to span residues 33 to 
444 (Fig. 10). This 412 amino acid domain possesses 11 putative r e ­
linked glycosylation sites ( N-X-S/T (Hubbard and Ivatt, 1981) ) and
has a predicted secondary structure of predominantly beta sheets with a 
few alpha helices and turn regions (Fig. 9). Immediately contiguous 
glycosylation sites occur at two positions reducing the potentially 
functional N-linked glycosylation sites to 9. Critical antigenic 
determinants with respect to elicitation of virus neutralising antibody 
are likely to be located in this domain given its exposure on the 
surface of the virion or plasma membrane. Charged, hydrophilic amino 
acids are common features of antigenic determinants and the peak of
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hydrophilicity in a Hopp and Woods hydropathic plot often correlates 
with the position of an immunogenic epitope (Hopp and Woods, 1981). 
EHV-4 gpl3 may thus contain an antigenic determinant spanning residue 
409 (Asn) since this lies within the peak hydrophilicity point of the 
EHV-4 gpl3 plot (Fig. 8 ).
Amino acids 446 to 472 are enriched in hydrophobic residues and may 
constitute the glycoprotein transmembrane domain the function of which 
is to anchor the protein to the virion envelope or infected cell plasma 
membrane (Fig. 10). The predicted C-terminal structural organisation
of the gpl3 C-terminal domain contrasts with that of the EHV-4 gB
polypeptide in which a predicted 69 amino acid transmembrane domain 
comprising three loops traversing the membrane, is followed by a 
cytoplasmic domain of 109 amino acids (Riggio et al., 1989).
The putative C-terminal cytoplasmic domain spans residues 473 to 
485 , is hydrophilic in character and possesses a net positive charge 
of 2 .
EHV-4 gpl3 is most closely related to EHV-1 gpl3 (79%) followed by
PRV gIII (29%), BHV-1 (27%), HSV-1 gC, HSV-2 gC, and VZV gpV (25-26%),
and MDV A antigen (22%). It is evident from multiple alignments and 
other comparative analyses of herpesvirus gCs (Allen and Coogle, 1988; 
Binns and Ross, 1989; Fitzpatrick et al.. 1989) that the N-terminal 
half of the protein has been conserved to a lesser extent than the C- 
terminal half in the course of evolution. This is reflected in dot 
matrix comparisons of EHV-4 gpl3 with EHV-1 gpl3, BHV-1 g11, HSV-1 gC, 
and VZV gpV as presented in Figure 11. Features common to gC-type 
glycoproteins include a short, positively charged cytoplasmic domain 
and six sites of cysteine conservation (Allen and Coogle, 1988; Binns 
and Ross, 1989; Fitzpatrick et al.. 1989). A few of the putative N- 
1 inked glycosylation sites exist in similar positions but are not
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strictly conserved. For the purposes of comparing the EHV-4 gpl3 to 
other gCs in terms of these specifically conserved features an 
alignment of eight herpesvirus gC-type polypeptides is presented in 
Figure 12. Although single and double amino acid insertions and 
deletions occur throughout each sequence relative to the other, the 
majority of the misaligned residues are located within the N-terminal 
portion of the protein to EHV-4 residue 70. It is particularly evident 
between the two EHV gpl3s : identity within the region EHV-1 68-468, 
EHV-4 84-485 is 86% compared with 42% within the rest of the protein. 
EHV-4 gpl3 possesses cysteine residues at each of the six conserved 
positions - amino acids 256, 318, 357, 361, 390, and 416. Nine EHV-4 
gpl3 glycosylation sites are conserved in EHV-1 gpl3 and three in PRV.
A structural model has been proposed for BHV-1 gIII on the basis of 
similarity of certain regions of its extracellular domain to domains 
within members of the immunoglobulin super-family (Fitzpatrick et al.. 
1989). Greatest conservation was found across amino acids 261-370 of 
g111 and class II MHC constant domains. This part of g111 
corresponds to amino acids 236-330 of EHV-4 gpl3 which show a degree of 
similarity to the MHC domain (Fig. 13). The model also takes into 
account the probable role of disulphide bond formation in the 
determination of secondary and tertiary structure given the positional 
conservation of six cysteine residues within the extracellular domain.
3) EHV-4 0RF3
0RF3 encodes a 226 amino acid polypeptide, 'dsgc', which has no 
apparent identity with proteins encoded by HSV-1 and VZV genes mapping 
at a similar genomic position. Analysis of the predicted amino acid 
sequence indicates two interesting features of the polypeptide : a
lysine and arginine enriched region ( amino acids 54-65 ) and 6
potential N-linked glycosylation sites, N-X-S/T. Comparison of the
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predicted EHV-4 protein to proteins within the NBRF data bank using VAX 
software (Devereux et al♦. 1984) indicated limited regions of
similarity to domains within a variety of proteins. The highest score 
was attained in a comparison of the EHV-4 protein and a probable 
membrane antigen, pl40, of HVS: 22% identity between amino acids 85-165 
and 345-422 of the EHV-4 and HVS proteins respectively. No single 
region of the EHV-4 protein was overrepresented in the comparisons . It 
is not possible therefore to speculate on any function the EHV-4 
protein might have. Similar analyses of gC and thymidine kinase 
species have highlighted conserved functional domains such as the MHC 
class II-type domain and a nucleotide binding domain within these 
proteins and unrelated proteins, the similarity in the latter case 
being due to convergent rather than divergent evolution.
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Figure 6.1 a) Schematic representation of the map positions 
of 6 EHV-1 glycoprotein genes as determined by Allen and 
Yeargan, 1987. BamHI and EcoRI restriction maps of EHV-1
strain HVS25 (Whalley et al.. 1981; Robertson and Whalley,
1988) are detailed. The gpl3 gene maps within BamHI H hence 
the use of two hybridisation probes , BamHI H and 
BamHI/EcoRI H, in Southern analyses of EHV-4 DNA. 
b) BamHI restriction map of EHV-4 (strain 1942? Cullinane et 
al.. 1988) presented in such a way that the EHV-1 and EHV-4 
genomes align in terms of map units. On the basis of 
colinearity of the EHV-1 and EHV-4 UL components the EHV-4 
gp!3 gene would be expected to map within BamHI G .
Figure 6.1
Map Position of the EHV-1 crol3 Gene and of DNA 
Fragments used as Southern Hybridisation Probes
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Figure 6.2 Hybridisation of EHV-1 BamHI H DNA to BamHI G 
and BamHI B of EHV-4.
a) Agarose gel loaded with lambda Hindlll markers, BamHI , 
BamHI/EcoRI, BamHI/Bgll, BamHI/Bglll, and BamHI/Sall digests 
of pUC9:G, and BamHI digest of pUC9:B.
b) Autoradiograph of membrane prepared from above gel 
probed with EHV-1 BamHI H.
Figure 6.2
Hybridisation of EHV-1 BamHI H to EHV-4 DNA.g
Figure 6.3 Hybridisation of EHV-1 BamHI/EcoRI H to BamHI G 
and BamHI B of EHV-4.
a) Autoradiograph of membrane prepared from gel (Figure 6.2
a)) probed with EHV-1 BamHI/EcoRI H.
b) Region of cross-hybridisation of the probe with EHV-4 G.
Figure 6.3
Hybridisation of EHV-1 BamHI/EcoRI H to EHV-4 DNA
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Figure 6.4 Localisation of three ORF within a 2.88kbp 
region of EHV-4 BamHI G.
a) BamHI restriction map of EHV-4 (strain 1942; Cullinane et 
al.. 1988) with expansion of BamHI G to show the positions 
of Sail, EcoRI, Bgll, and Bglll restriction sites.
b) Expansion of the sequenced region of BamHI G with the 
three ORF identified by VAX analysis of start and stop codon 
positions (shown below) indicated by black boxes.
c) Sequencing strategy utilised. Arrows indicate regions of 
sequence elucidated using different primers and/or 
templates. Their direction indicates whether upper or lower 
strand sequence was determined.
Figure 6.4
Localisation of the EHV-4 ctp 13 Gene and Flanking ORFs
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Figure 6.5 Nucleotide sequence of 2.88 kbp of EHV-4 BamHI G. 
The predicted amino acid sequences of the products of three 
open reading frames are indicated below the coding 
sequence. Putative polyadenylation signals (PS) and TATA 
(T) boxes are underlined.
Nucleotide Sequence of 2.88kbp of EHV-4 BamHI G
E co R I
GAATTCACGCCACGGCCCACGCAGTTTGCCTGGTATTAGCAGCATTTGGGTATTCGGTGGCCGCTCCCATTTCGCTTGCATTTACTACGTCCGGGGGCGTACTTGGGGCTTTGTACCTTC 1 2 0  
I  H A T A H A V C V V L A A F G Y W V A A P I S L A F T T S G G V L G A L Y L
(P S -U L 4 3 )
GTAAGCGCGCAACGGGGGCCAGCCGTTTGGCCGCAACCCACATTTCAAGGTGGCTCATTGTTAGTGTGTATGTTGCAGCGGGTTTATGTTACGCAACTATAATCACACATTAAACATGTC 2 4 0  
R K R A T G A S R L A A T H I S R W L I V S V Y V A A G L C Y A T I I T H *  (0 R F 1 )
E coR I
AATTAGTATTAACAACAACCACAAGGTGTATTGATTTAAACATCGGTCGAATTCACATAAAGAAGGCCGCCTTTAAATGACACACTTTGGGGCACGGTATGCTTATAACTCTCCGACCAG 3 6 0  
(T * g p 1 3 )
AAGAGTTATTATTGTTCTTTGTGGAAAATCGCAAACATATAACCCACAGCAATGGGTTTGGTAAATATAATGCGATTCATAACATTTGCGTATATAATCTGTGGGGGGTTTATATTAACA 4 8 0
(g p 1 3 )  M G L V N I M R F I T F A Y I  I C G G F I L T
CGCACGTCTGGGACCAGTGCTAGCGCCAGTCCAGCCACACCAACCACAAATACTGGCGAAGGCACCAGTTCTCCAGTCACACCAACTTACACAACCAGTACGGACTCTAATAATTCAACA 6 0 0  
R T S G T S A S A S P A T P T T N T G E G T S S P V T P T Y T T S T D S N N S T
GCCACGAACAACTCAACCGATGTAAACGGCACCGAAGCTACACCAACGCCGAGTCACCCACATTCACATGAAAATACAATTACATGCACAAATAGTCTCATATCGGTTCCCTACTACACA 7 2 0  
A T N N S T D V N G T E A T P T P S H P H S H E N T I T C T N S L I S V P Y Y T
TCTGTTACCATTAACTGTTCTACAACAGTAAGTGTAAATCACAGTGAATACAGACTAGAAATTCACCTAAACCAGCGCACCCCATTTTCAGACACGCCTCCTGGTGACCAAGAAAACTAT 8 4 0  
S V T I N C S T T V S V N H S E Y R L E I H L N Q R T P F S D T P P G D Q E N Y
B g l I
GTTAACCACAACGCTACCAAAGACCAAACCCTGCTGTTATTTTCAACCGCACATTCTAGCGCGAAATCTCGAAGGGTTGGCCAGCTGGGCGTTATTCCAGACAGGCTACCTAAGCGTCAA 9 6 0  
V N H N A T K D Q T L L L F S T A H S S A K S R R V G Q L G V I P D R L P K R Q
CTGTTCAACCTCCCGGCCCACACGAACGGTGGTACAAATTTTCCACTAAACATAAAATCTATAGACTGGCGTACCGCGGGAGTTTATGTGTGGTACTTGTTTGCCAAAAACGGCTCACTC 1 0 8 0  
L F N L P A H T N G G T N F P L N I K S I D W R T A G V Y V W Y L F A K N G S L
ATTAACAGTACCAGCGTTACCGTGTTAACGTACAACGCACCCCTAATGGACCTCTCCGTTCACCCAAGTTTGAAGGGTGAAAACCACAGAGCCGTGTGCGTAGTTGCTAGCTACTTTCCC 1 2 0 0  
I N S T S V T V L T Y N A P L M D L S V H P S L K G E N H R A V C V V A S Y F P
CACAACTCTGTTAAGCTGAGGTGGTATAAAAACGCCAAAGAGGTTGATTTTACAAAGTATGTTACCAATGCTTCTAGTGTGTGGGTGGATGGTCTCATCACTCGCATCTCGACTGTATCA 1 3 2 0  
H N S V K L R W Y K N A K E V D F T K Y V T N A S S V W V D G L I  T R  I  S T V S
ATCCCAGCTGACCCCGACGAAGAATATCCCCCCAGCCTCCGCTGTAGCATAGAATGGTACAGAGACGAGGTATCCTTTTCTCGCATGGCCAAAGCAGGCACGCCCTCTGTGTTCGTGGCC 1 4 4 0  
I P A D P D E E Y P P S L R C S I E U Y R D E V S F S R M A K A G T P S V F V A
CCAACCGTGTCCGTAAACGTTGAAGATGGTGCAGCAGTTTGTACGGCAGAATGTGTACCTAGCAACGGAGTGTTTGTATCGTGGGTCGTTAACGACCATTTACCGGGGGTCCCATCACAA 1 5 6 0  
P T V S V N V E D G A A V C T A E C V P S N G V F V S W V V N D H L P G V P S Q
GACGTAACAACGGGAGTTTGCTCAAGCCACCCAGGATTAGTCAACATGCGGAGTAGCAGGCCCCTGTCGGAAGAAAACGGAGAGCGAGAGTA7AACTGCATCATAGAGGGTTACCCGGAC 1 6 8 0  
D V T T G V C S S H P G L V N M R S S R P L S E E N G E R E Y N C I  I  E G Y P D
GGCCTTCCAATGTTTTCTGACAGCGTTGTATATGATGCATCCCCTATTGTTGAGGACATGCCCGTTTTAACTGGCATCATCGCCGTTACTTGCGGGGCCGCAGCGCTAGCGCTGGTTGTT 1 8 0 0  
G L P M F S D  S V V Y D A S P  I V E D M P V L T G  I I  A V T C G A A A L A L V V
CTCATTACAGCCGTTTGTTTTTACTGCTCAAAACCCTCGCAGGTGCCGTACAAGAAAGCAGACTTCTAAGCTCGTCGTCAGTTTGAACAGCAGCTGGTTTTTTTAAATACAGTTCAAACC 1 9 2 0  
L I  T A V C F Y C S K P S Q V P Y K K A D  F *  (0 R F 2 )
(P S -g p 1 3 )
GCAGTCTGGCTGGCTGTCTTCACAAACGCACTCTTATAAATACGGTATTAAACATATGCGTTTTCATGCTCTAGGTGGAAACCGTTAGTTTTGTGTTACAATCGCGCCCCGGCTGGATTT 2 0 4 0
( T - d s g c )
ATAAAGCCATTTTACTCTGCATTATACGCTCATCTCTATGCAGCCATAACGTCTAAGTAAAGCGAAAATATGTCTGGAGACCCAACAGCTTCGCTAAAAGATTATCAATTACTGGAGCTT 2 1 6 0
( d s g c )  M S G D P T A S L K D Y Q L L E L
GATACAGCTGCCGGTAATGATCAAGCTCCCCAACTACCTACAAAGACTGTTTTGGGGTTTACACCACCGCTGCCGACTCTACCCCAACCAACCGAACTCGTTTATACAAAACGGCGCCGA 2 2 8 0  
D T A A G N D Q A P Q L P T K T V L G F T P P L P T L P Q P T E L V Y T K R R R
B g l I I
CCAAAACGCAGATCTAGATGCCGCTGCCTCTGTTTTACGATGGGTATGTTTGCGATGGGGGTTCTAATGACCACCACACTTTTGGTGTCTACCTTTGTCCTAACAGTACCCATGGTCGCG 2 4 0 0  
P K R R S R C R C L C F T M G M F A M G V L M T T T L L V S T F V L T V P M V A
CTACGCACAGCACCATGTCCAGCGCAAACCTTTGGTCTGGGTGACGAGTGTGTACGCCCCGTGTCGCTAGACGCTTACAACAGCAGCAACTCTAGCGAAATAGGGGCTGTATGTGGAGCA 2 5 2 0  
L R T A P C P A Q T F G L G D E C V R P V S L D A Y N S S N S S E  I G A V C G A
TATTCTGAGATGCCAGCCCCGGATAACACTACTGTCCTGATAATGAACCTTCTGGACTGCCTAAACATTGGCATCAACGAATCGGCTGGAGAAAAACTAAATCTGACGGACACACCACTT 2 6 4 0  
Y S E M P A P D N T T V L  I M N L L D C L N  I G I  N E S A G E K L N L T D T P L
B g l I
GCAAACTGTAACTTTTCACAAAACTCGGTATGCTCCAGAAAACGCGTTGGTGTGTGCTACGCCGCCCGCCCACTCAGCCCACTTGGAGAGTTGATTTACAAGGCCCGCCAGGCGCTTCGG 2 7 6 0  
A N C N F S Q N S V C S R K R V G V C Y A A R P L S P L G E L  I  Y K A L Q A L R
(P S -d s g c )
CTTGACCACATTCTTCCATTTTTGCAGTAATAGATAACTCCACGCTGGAATATACAGAGTTATAGGCGCAACATTTGACCCTGTTTAAAGGTGTTTGTGAGTGCTTAAATAAAGTATTAA 2 8 8 0  
L D H I L P F L Q *  (0 R F 3 )
Figure 6.6
Alignment of the EHV-1 and EHV-4 gp!3 Genes
(CAAT Box) (TATA Box)
E H V -4  GAATTCACATAAAGAAGGCCGCCTTTAAATGACACACTTTGGGGCACCGTATGCTTATAACTCTCCGACCAGAAGAGTTATTATTGTTCTTTGTGGAAAATCGCAAACATATAACCCAC
11ii111111Mi! i i i mu i m m  m mm imiiiiiiiiiimi miiiim m u mi m mi n m
E H V -1  GAATTCACATAAAGTAAAAC CCCTTAAAACTGACCCTTTG GTGCATGGTATGTTTATAA CTCTCCGACCAGTGGAGTTATTATCGTTTTTCGTGGGGAATAGCAAGCACCCGGCCCCCG  
(Initiation Met)
E H V -4  AGCAATGGGTTTGGTAAATATAATGCGATTCATAACATTTGCGTATATAATCTGTGGGGGGTTTATATTAACACGCACGTCTGGGACCAGTGCTAGCGCCAGTCCAGCCACACCAACCAC
i m i m m i i mi i i i m m  m iiiimi i mu i iimim mum i n i
E H V -1 CGAGATGTGGTTGCCTAATCTCGTGAGATTTGTGGCGGTCGCGTATCTAATCTGTGCCGGGGCGATATTAACTTATGCCTCTGGAGCTAGTGCTAGC TCCAGCCAGA GTACGCC 
E H V -4  AAATACTGGCGAAGGCACCAGTTCTCCAGTCACACCAACTTACACAACCAGTACGGACTCTAATAATTCAACAGCCACGAACAACTCAACCGATGTAAACGGCACCGAAGCTACACCAAC
m i i i i mi i i i mi i i 11 m mi i mi m m  m i m m  i m m
E H V -1  CGCTAC ACCAACTCA CACAACTCC G AATCTAACTACCGCACACGGCGCGGGCTCTGA CAAC ACAACT AAC GCAAACGGTACAGAATCTA
E H V -4  GCCGAGTCACCCACATTCACATGAAAATACAATTACATGCACAAATAGTCTCATATCGGTTCCCTACTACACATCTGTTACCATTAACTG TTCTACAACAGTAAGTGTAAATCACAGTGA
mi n mini inn n inn ii minimi n minim m m  n mm i ii i in i m m  i n n
E H V -1  CACACTCCCATGAAACCACAATCACCTGCACCAAGAGTCTCATATCTGTGCCCTACTACAAATCTGTCGATATGAACTGTACAACGTCGGTAGGCGTAAATTATAGCGA
E H V -4  ATACAGACTAGAAATTCACCTAAACCAGCGCACCCCATTTTCAGACACGCCTCCTGGTGACCAAGAAAACTATGTTAACCACAACGCTACCAAAGACCAAACCCTGCTGTTATTTTCAAC
in i n n in n i imnmmniimi i inn n ii in minim i inn inn inn n n n minimi inn
E H V -1  GTACCGCCTCGAGATTTACTTGAACCAGCGCACCCCATTTTCGGGTACGCCCCCCGGCGACGAAGAAAACTACATCAACCATAACGCCACCAAGGATCAGACTCTGCTGTTATTCTCAAC  
E H V -4  CGCACATTCTAGCGCGAAATCTCGAAGGGTTGGCCAGCTGGGCGTTATTCCAGACAGGCTACCTAAGCGTCAACTGTTCAACCTCCCGGCCCACACGAACGGTGGTACAAATTTTCCACT
in i n nnniiimi ii inn nnnmnni inn n inn inn n mini i minimi mum
E H V -1  GGCAGA GAGGAAAAAATCTCGAAGGGGTGGCCAGCTTGGAGTTATCCCAGACAGGCTACCAAAGCGCCAGCTGTTTAACCTTCCCCTCCACACGGAAGGTGGTACAAAGTTTCCACT 
E H V -4  AAACATAAAATCTATAGACTGGCGTACCGCGGGAGTTTATGTGTGGTACTTGTTTGCCAAAAACGGCTCACTCATTAACAGTACCAGCGTTACCGTGTTAACGTACAACGCACCCCTAAT
i in mm mi inn n ii n nil mini inn nnnni in i m nnnnnnnnnnn i in minimi i i
E H V -1  GACCATCAAATCTGTAGATTGGCGGACAGCCGGCATTTACGTGTGGTCCTTGTATGCCAAAAATGGCACGCTCGTTAACAGTACCAGCGTTACCGTCTCAACCTACAACGCACCGTTGCT 
E H V -4  GGACCTCTCCGTTCACCCAAGTTTGAAGGGTGAAAACCACAGAGCCGTGTGCGTAGTTGCTAGCTACTTTCCCCACAACTCTGTTAAGCTGAGGTGGTATAAAAACGCCAAAGAGGTTGA
mm minimi n mini mm nil in mm ii n iiiiiiimi nil in n mm mini inn in inn n
E H V -1  GGACCTTTCCGTTCACCCGAGCCTGAAGGGGGAAAACTACAGGGCCACGTGCGTCGTCGCAAGCTACTTTCCACACAGCTCCGTCAAGCTGCGGTGGTACAAAAATGCCCGCGAGGTGGA  
E H V -4  TTTTACAAAG TATGTTACCAATGCTTCTAGTGTGTGGGTGGATGGTCTCATCACTCGCATCTCGACTGTATCAATCCCAGCTGACCCCGACGAAGAATATCCCCCCAGCCTCCGCTGTAG
11111111111 inn i n n n mum n i n inn n inn n n n inn i in n n n inn i inn n nnnn
E H V -1  CTTTACAAAGTACGTTACGAACGCCTCAAGCGTGTGGGTAGACGGGCTAATCACGCGAATCTCTACGGTGTCTATCCCGGTTGATCCGGAGGAGGAATACACACCCAGTCTTCGCTGTAG  
E H V -4  CATAGAATGGTACAGAGACGAGGTATCCTTTTCTCGCATGGCCAAAGCAGGCACGCCCTCTGTGTTCGTGGCCCCAACCGTGTCCGTAAACGTTGAAGATGGTGCAGCAGTTTGTACGGC
mm ii i imi inn inn in mini nnnn n n innnnn ii mmnnnnm n inn n i n n nnnn
E H V -1  CATAGACTGGTACAGGGACGAAGTATCATTTGCTCGCATAGCCAAAGCTGGAACACCCTCTGTGTTTGTTGCCCCAACCGTGTCCGTTTCGGTAGAAGACGGAGACGCCGTCTGTACGGC  
E H V -4  AGAATGTGTACCTAGCAACGGAGTGTTTGTATCGTGGGTCGTTAACGACCATTTACCGGGGGTCCCATCACAAGACGTAACAACGGGAGTTTGCTCAAGCCACCCAGGATTAGTCAACAT
mi inn mi in inn nnnni ii nnnn mi inn n n m m  i inn inn in i m m  i inn n inn
E H V -1  TAAATGCGTACCGAGCACCGGGGTGTTCGTATCGTGGTCAGTGAACGACCACCTACCAGGGGTTCCGTCGCAAGACATGACAACCGGAGTCTGCCCTAGCCACTCGGGATTGGTTAACAT 
E H V -4  GCGGAGTAGCAGGCCCCTGTCGGAAGAAAACGGAGAGCGAGAGTATAACTGCATCATAGAGGGTTACCCGGACGGCCTTCCAATGTTTTCTGACAGCGTTGTATATGATGCATCCCCTAT
n n n mini n inn n ii in i mini mm mum inn nnnn n nnnn nil n nnnn n inn n
E H V -1  GCAAAGCCGCCGGCCCCTCTCAGAAGAGAATGGGGAGAGGGAGTATAGCTGCATAATAGAGGGGTACCCCGACGGCCTGCCTATGTTTTCGGACACAGTGGTATATGACGCCTCCCCGAT 
E H V -4  TG TTG AGGACATGCCCG TTTTAACTGGCATCATCGCCGTTACTTGCGGGGCCGCAGCGCTAGCGCTGGTTGTTCTCATTACAGCCGTTTGTTTTTACTGCTCAAAACCCTCGCAGGTGCC
minimi in inn n iniiiiiii nnnmnnnn ii n nnnn nnnn nnnn nnnnnnn ii inn nil in
E H V -1  TGTTGAGGACAGGCCGGTTTTGACGAGCATCATCGCAGTTACTTGCGGGGCCGCGGCACTGGCGCTGGTCGTTCTCATCACAGCCGTCTGTTTTTACTGCTCCAAGCCCTCACAGGCGCC  
( S t o p  C o d o n )
E H V -4  GTACAAGAAAGCAGACTTCTAAGCTCGTCGTCAGTTTGAACAGCAGCTGGTTTTTTTAAA TACAGTT C AAACCGCAGTCTGGCT GG
i inn if in 11 ii i n i m i m mini i mi i n mi n
E H V -1  GTACAAGAAGTCTGACTTTTAGGCTGGACCGCTCTCCCCCAAACAACCTATTTGTCAAAACTACAGTTTGAAGCGCTGGTAAAAACAGTAGGTGGGCTCCCACAAGTCGTCCGCATAGGC
(Polyadenylation Signal ?)
E H V -4  CTGTCTTCACAAACGCACTCTTATAAATACGGTATTAAACATATGCGTTTTCATGCTCTAGGTGGAAACCGTTAGTTTTGTGTTACAATCGCGCCCCGGCTGGATTTATAAAGCCAT
i n mini m m  mi ii i nil mini ii i n mini nnnn i nmnnnmm inn nnnnmni
E H V -1  CAACCGTACGCACAAACTCACTCTCGAGAATATGGCACTAAAAATATGCGGTTATACGCGCTAGGTGAAAACCGTTGGGTTTGTGTTACAATCGCGACCCGGTGATATTTATAAAGCCAT
Figure 6.6 Alignment of the nucleotide sequences of the EHV-4 
and EHV-1 gpl3 genes and of 5' and 3' noncoding DNA. Putative 
promoter and polyadenylation signal sequences are underlined 
as are the initiation Met and termination codons.
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Figure 6.7
Alignment of the Predicted Products of HSV-1 UL43 
and its VZV and EHV-4 Counterparts
VZV Gene 15 
EHV-4 
HSV-1 UL43 
VZV Gene 15
VZV Gene 15 
EHV-4 
HSV-1 UL43 
VZV Gene 15
Figure 6.7 Alignment of the predicted products of gene UL43
of HSV-1, gene 15 of VZV, and the rightward flanking gene (in
genome terms) of the EHV-4 gC gene homologue (C-terminal
region only). Conserved residues are indicated by vertical
lines.
EKKNLWVIVLYTTTSVTGIAVTFAGISWGAIIILTSTVAAGL--TCIQMMRLSVKPIDCFMAS
I I I II
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I I I I II III II Mill
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I II I II I
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Hydropathic Plot of EHV-4 gp!3
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Figure 6.8 Hopp and Woods (1981) hydropathic plot comprising 
analysis of the local hydrophil icity of each residue of the 
predicted EHV-4 gpl3 polypeptide using a six amino acid 
window. Positive values indicate a local hydrophilic 
environment: negative values a local hydrophobic environment.
Figure 6.9 Hydropathic and secondary structure analyses of 
EHV-4 gpl3 using algorithms available on VAX software 
(Devereux et al.. 1984). Hydropathic plots and predicted 
secondary structure features such as turns, alpha helices , 
and beta sheets are presented. The position of potential N- 
1inked glycosylation sites along the primary sequence is 
indicated.
Figure 6.9
Secondary Structure Analysis of EHV-4 gp!3
Figure 6.10 Predicted distribution of four structural 
domains within EHV-4 gpl3 on the basis of analyses of local 
hydrophobicity scores along the polypeptide (Hopp and Woods, 
1981). The 6 sites of cysteine conservation are indicated by 
black boxes (see Fig. 6.12). Potential N-linked 
glycosylation sites are underlined.
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Figure 6.10
Putative Structural Domains within the EHV-4 o p13 Polypeptide
Figure 6.11
Dot Matrix Plots of Herpesvirus gC-Tvoe Polypeptides
EHV-4 200
/
EHV-4 266
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Figure 6.11 Comparison of EHV-4 gpl3 with its counterparts
in EHV-1 (Allen and Coogle, 1988), BHV-1 (Fitzpatrick et al. , 
1989) , VZV (Kinchington et al. . 1986), and HSV-1 (Dowbenko and 
Lasky, 1984; Frink et al. . 1983) by dot matrix analyses. 
Parameters used were a 30 amino acid window and a stringency 
of 53%.
Figure 6.12
Multiple Alignment of Herpesvirus aC-Tvpe Glycoproteins
EHV-4 gp13 ........ MGLVNI MR FITFAYIICGGFILTRTSGTSASA....SPATPTTNTGEGTSSPVTPTYTTST..................
EHV-1 gp13 .MWLPNLVR FVAVAYLICAGAILTR YASGASASSSQSTPATPT HTT..........................................
PRV gl11....MASLARAMLALLALYAAAIAAAPSTTTALDTTPNGGGGGNSSEGELS--PSPPPTPAPASPEAGAVSTPPV..................
BHV-1 gl11....MGPLGRAWLIAAIFAWALLSARRGLAEEAEASPSPPPSPCPTETESSAGTTGATPPTPNSPDATPEDSTPG..................
HSV-1 gC..... ...............MAPGRVGLAVVLWGLLWLGAGVAGGSETASTGPTITAGAVTNATQAPTSGSPGSA..................
HSV-2 gC .............. MALGRVGLAVGLWGLLWVGVWVLAN--ASPGRTITVGPRGNASNAAPSASPRNAS.................
VZV gpV .............. MKRIQINLILTIACIQLSTESQPTPVSITELYTSAATRKPDPAVAPTSAASRKPDPAVAPTSAASRKPDPAVAPT
HDV A Ag .............. MLTPRVLRALGWTGLFFLLLSPSNVLGASLSRDLETPPFLS...............................
Cons .............. m v........ I..........--ss--t-t..... as..... s......................
EHV-4 gp13 -DSNNSTAT NNSTDVNGTEATPTSHPHSHENTITCTNSLISVPYYTSVYINCSTTVSVNHSEYRLEIHLNQ.............. R
EHV-1 gp13 --PNLTTAHGAGSDNTTNANGTESTH SHETTITCTKSLISVPYYKSVDMNCTT SVGVNYSEYR LEIY LNQ.............. R
PRV gl II PPPSVSRRKPPRN-NNRTRVHGDKATA.... HGRKRIVCRERLFSARVGDAVSFGCAVFPRAGETFEVRFYR................R
BHV-1 gl II ATTPVGTPEPPSVSEHDPPVTNSTPPPAPPED-GRPGGAGNASRDGRPSGGGRPRPPRPSICAPPKERKWMLCERE.............. A
HSV-1 gC ASPEVTPTSTPNP-NNVTQNKYYPTEPASPPTTPKPTSTPKSPPTSTPDPKPKNNTTPAKSGRPTKPPGPVWCDRRDPLARYGSRVQIRCR
HSV-2 gC -APRTTP...................TPPQPRKAT---KSKASTAKPAPPPKTGPPKTSSEP.... VRCNRHDPLARYGSRVQIRCR
VZV gpV SAATRKPDPAVAPTSAATRNPDPAVAPTS-AATRKPDPAANAQHSQPPFLFENIQCVHGGIQSIPYFHTFIMPCYMRLTTGQQAAFKQ--Q
MDV A Ag FDPSNISINGAPLTEVPHAPSTESVSTNSESTNEHTITTGKNAYIHNNASTDKQNAADTHKTPNILCDTEEVFVFLNETGRF........V
Cons --p..........n--- n........p......................n.................................r
EHV-4 gp13 TPFSDTPPGDQENYVNHNATKDQTLLLFSTAHSSAKSRRVGQLGVIPDRLPKRQLFNLP........................ AHTNGG
EHV-1 gp13 TPFSGTPPGDEENYINHNATKDQTLLLFSTAE-RKKSRRGGQLGVIPDRLPKRQLFNLP........................ LHTEGG
PRV gl 11 GRFRSPDADPEYFDEPPRPELPRERLLFSSANASLAHADALAPVWEGERATV................. -........... ANVSGE
BHV-1 gl 11 VAASYAEPLYVHCGVADNATGGARLELWFQRVGRFRSTRGDDEAVRNPFPRAP--PVLLFVAQNGSIAYRSAELGDNYIF PSPADP
HSV-1 gC FRNSTRMEFRLQIWRYSMGPSPPIAPAPDLEEVLTNnAPPGGLLVYDSAPNLTDPHVLWAEGAGPGADPPLY........... SVTGPL
HSV-2 gC FPNSTRTESRLQIWRYATATDAEIGTAPSLEEVMVNVSAPPGGQLVYDSAPNRTDPHVIWAEGAGPGASPRLY........... SWGPL
VZV gpV QKTYEQYSLDPEGSNITRWKSLIRPDLHIEVWFTRHLI-DPHRQLGNALIRMPDLPVMLYSNSADLNLINNPEIFTHAKENYVIPDVKTTS
MDV A Ag CTLKVDPPSDSEWSN-FVLDLIFNPIEYHANEKNVEAARIAGLYGVPGSDYAYPRQSELISSIRRDPQGTFWTSPSPHGNKYFIWINJCrTN
Cons — s— p-d-e...... at l-s--e r w-d--p p--1.............................
EHV-4 gp13 TNFPLNIKSIDWRTAGVYVWYLFAKNGSLINST-SVTVLTYNAPLMDLSVHPSLKGENHRAVCWASYFPHNSVKLRWYKNAKEVDFTKYV
EHV-1 gp13 TKFPLTIKSVDWRTAGIYVWSLYAKNGTLVNST-SVTVSTYNAPLLDLSVHPSLKGENYRATCWASYFPHSSVKLRWYKNAREVD FTKYV
PRV gl 11 VSVRVAA— DAETEGVYTWRVLSANGTEVRSA-NVSLLLYSQPEFGLSAPPVLFGEPFRAVCVVRDYYPRRSVRLRWFADEHPVDA-AFV
BHV-1 gl 11 RNLPLTVRSLTAATEGVYTWR- -RDMGTKSQRK-WTVTTHRAPAVSVEPQPALEGAGYAAVCRAAEYYPPRSTRLHWFRNGYPVE-ARHA
HSV-1 gC PTQRLIIGRVTPATQGMYYLAWGRMDSPHEYGT-WVRVRMFRPPSLTLQPHAVMEGQPFKATCTAAAYYPRNPVEFDWFEDDRQVENPGQI
HSV-2 gC GRQRLIEEELTLETQGMYYWWGRTDRPSAYGT-WVRVRVFRPPSLTIHPHAVLEGQPFKATCTAATYYPGNRAEFVWFEDGRRVFDPAQI
VZV gpV DFS-VTILSMDATTEGTYIWRVVNTKTKNVISEHSITVTTYYRPNITVVGDPVLTGQTYAAYCNVSKYYPPHSVRVRWTSRFGNIG-KNFI
MDV A Ag TMGVEIRNVDYADNYMQVIMRDHFNRPLIDKHI--YIRVCQRPASVDVLAPPVLSGENYKASCIVRHFYPPGSVYVSWRQNGNIATPRKDR
Cons ---1-i-s-d--T-G-Y-wr g st--vtv-tyr-P— l--hpvL-Ge-y-A-C-va-YyP--sv- IrWf-n— v.....
EHV-4 gp13 TNASSVWVDGLITRISTVSIPADPDEEYPP........ SLRCSIEWYRDEVSFSRMAKAGTPSVFVAPTVSVNVEDGAAVCTAECVPSNG
EHV-1 gp13 TNASSVWVDGL I TR I STVSI PVDPEEEYTP........ SLRCSIDWYRDEVSFARIAKAGTPSVFVAPTVSVSVEDGDAVCTAKCVPSTG
PRV gl 11 TNSTVADELGRRTRVSWNVTRADVPGLAAADAADALAPSLRCEAVWYRDSVASQRFSEALRPHVYHPAAVSVRFVEGFAVCDGLCVP-PE
BHV-1 gl 11 RDVFTVDDSGLFSR-TSVLTLE-DATPTAHPP— --- NLRCDVSUFQSANMERRFYAAGTPAVYRPPELRVYFEGGEAVCEARCVPEGR
HSV-1 gC DTQTHEHPDGF TTVSTVTSEAVGGQVPPR..... TFTCQMTWHRDSVTFSRRNATGLALVLPRPTITMEFGVRHVVCTAGCVPEGV
HSV-2 gC HTQTQENPDGF STVSTVTSAAVGGQGPPR..... TFTCQLTWHRDSVSFSRRNASGTASVLPRPTITMEFTGDHAVCTAGCVPEGV
VZV gpV TDAIQEYANGLF— SYVSASRIPQQKQMDYPPP.... AIQCNVLWIRDGVSNMKYSAWTPDVYPFPNVSIG11DGHIVCTAKCVPRGV
MDV A Ag DGSFWWFESGRGA--TLVSTITLGNSGIDFPP...... KISCLVAWKQ-GDMISTTNATAIPTVYHHPRLSLAFKDGYAICTIECVPSEI
Cons t......dGl--r-stVst......g— pp.... . IrC— W-rd-vsfsr--aagtp-Vy--Ptvsv-f-dg-aVCta-CVP-g-
Figure 6.12 (cont.)
EHV-4 gp13 VFVSWVVNDHLPGVPSQDVTTGVCSSHPGLVNMRSSRPLSEENGEREYNCIIEGYPDGLPMFSDSWYDASPIVEDMPVLTGIIAVTCGAA
EHV-1 gp13 VFVSWSVNDHLPGVPSQDMTTGVCPSHSGLVNMQSRRPLSEENGEREYSCIIEGYPDGLPMFSDTWYDASPIVEDRPVLTSIIAVTCGAA
PRV gl 11 ARLAWS--DHAADTVYHL— GACAEHPGL-NVRSARPLSDLDGPVDYTCRLEGLPSQLPVFEDTQRYDASPASVSWPWSSMIWIAGIG
BHV-1 gl 11 VSLRWTVRD--GIAPSRTEQTGVCAERPGLVNLRGVRLLSTTDGPVDYTCTATGYPAPLPEFSATATYDASPGLIGSPVLVSWAVACGLG
HSV-1 gC TFAWFLGODPSPAAKSAVTAQESC-DHPGLATVRSTLPIS-YDYS-EYICR-TGYPAGIPVLEHHGSHQPPPRDPTERQVIEAIEWV-GIG
HSV-2 gC TFAWFLGDDSSPAEKVAVASQTSC-GRPGTATIRSTLPVS-YEQT-EYICRLAGYPDGIPVLEHHGSHQPPPRDPTERQVIRAVEG-AGIG
VZV gpV VH FVWWVNDj^P INHENSEITGVCDQNKRFVNMQSSCPTSELDGPITYSCHLDGYPKKFPPFSAVYTYDASTYATTFSWAV11GAISI LG
MDV A Ag TVRWLVHDEAQPNTTYNTWTGLCRTIDRHRNLLSRIPVWDNWTKTKYTCRLIGYPFDEDKFQDSEYYDATPSARGTPMVITVTAVL-GLA
Cons vf--w-v-D--p— s----tgvC--hpglvn-rS-rPlS--dg--eY-Crl-GYP-glP-fsd— ydasP....p w — iav--G-g
EHV-4 gp13 ALALWLITAVC FY CSKPSQVPYKKAD F*
EHV-1 gp13 ALALWLITAVCFYCSKPSQAPYKKSD F*
PRV gl II I LAIVLVIMATCVYYRQAGP*
BHV-1 gl II AVGLLLV-AASCLRRKARVIQPGLTRARALGSAP*
HSV-1 gC IGVLAAGVLWTAIVYWRT SQSRQR HRR*
HSV-2 gc VAVLVAWLAGTAWYLTHASSVRYRRLR*
VZV gpv TLGLIAVIATLCIRCCS*
MDV A Ag VILGMG11MTALCLYNSTRKNIRI*
Cons -l-lv-vi-a-c..........
Figure 6.12 Multiple alignment of the predicted products of 
the HSV-1 gC gene (Dowbenko and Lasky, 1984; Frink et al., 
1983) and its counterpart in EHV-4, EHV-1 (Allen and Coogle,
1988), PRV (Robbins et al. , 1986), BHV-1 (Fitzpatrick et al.,
1989), HSV-2 (Dowbenko and Lasky, 1984; Swain et al.. 1985), 
VZV (Kinchington et al., 1986) and MDV (Binns and Ross, 1989) . 
A consensus line is detailed in which residues conserved in 4 
to 6 gCs are represented by lower case, residues conserved in 
7 or 8 gCs by upper case.
Figure 6.13
Comparison of Class II MHC Domain Sequences with 
BHV-1 and EHV-4 qp!3 Domains
MHCIIb2hu e P k V t V s P s k t q p 1 q h h n I 1 V c s V t d f y p g s i -
MHCIIb2ro e p t V t V y P t r t q p I e h h n I I V c s V t d f y p g n i -
MHCIIa2hu p p e V t V f s k s p V e I g q P n t I i c I v d n f f p p V V -
MHCIIa2ro a p q a t V f P k s p V I I g q P n t I i c f v d n i f p p V i -
BHV-1 gl11 a P a V s V e P q - p a I e g a g y a a V c r a a e y y p p r s t
EHV-4 gp13 A P L M D L S V H - p S L K G E N H R A V c V V A S Y F P H N S V
CONS - P - V t V - P - - p - - I g - - n - I V c - v  - - - - p - - - -
MHCIIb2hu e V r w f r n g q e e t a g V V s t g 1 1* r n g d u t - f q i 1 V
MHCIIb2ro e V r w f r n g q e e k t g V V s t g t i r n g d w t - f q t I V
MHCIIa2hu n i t w t r n g k P V t e g V s e t s f I s r s d h s - f r k f h
MHCIIa2ro n i t w I r n s k s V t d g V y e t s f I V n r d h s - f h k I s
BHV-1 g l 1 1 r I h w f r n g y P V - e a r h a r d V f t V d  d s g i f s r t s
EHV-4 g p 1 3 k L R u Y K N A K E V D F T K Y V T N A S s V W V D G L I T R I s
CONS - - - u - r N g - - V - - g V - - t - - - - - - d - - - f - - I -
MHCIIb2hu m 1 e m t p q s g d V y t - c q V e h P s i t s P I t V
MHCIIb2ro m I e m t p q s g e V y t - c q V e h P s i t s P V t V
MHCIIa2hu y I t f I P s a e d V y d - c r V e h w g i d e P I I k
MHCIIa2ro y I t f i P s d d d i y d - c k V e h w g i e e P V I k
BHV-1 gl11 V I t I e d a t P t - a h p p n I r c d v s - w f q s a n m e r
EHV-4 gp13 T V S - I P A D P D E E Y P P S L R C S I E - w Y R D E V S F S
CONS - I - - - P - - - d - y - ---- - C - V e h w - i - - P - - -
Figure 6.13 Comparison of a region of the predicted EHV-4 
gpl3 polypeptide to the corresponding region of BHV-1 gill 
which bears sequence similarity to MHC Class II domains 
(Fitzpatrick et al., 1989). MHC domain sequences detailed are 
consensus human and mice class Ila and b sequences (Figueroa 
and Klein, 1986; Kaufman et al.. 1984).
Table 6.1
Codon Usage of the EHV-4 op13 Gene
N.2nd
1 s t \
A
(26%)
C
(31%)
G
(17%)
T
(26%) 3rd Residue f (%)
A Lys 9 Thr 18 Arg 3 I le 9 A (26%) Ala 32 ( 6.6)
Asn 23 Thr 16 Ser 10 lie 7 C (31%) Arg 18 ( 3.7)
(32%) Lys 5 Thr 10 Arg 4 Met 7 G (17%) Asn 32 ( 6.6)
Asn 9 Thr 6 Ser 12 lie 7 T (26%) Asp 21 ( 4.3)
Cys 12 ( 2.5)
C Gin 4 Pro 15 Arg 3 Leu 6 A Gin 7 ( 1.4)
His 9 Pro 10 Arg 5 Leu 7 C Glu 20 ( 4.1)
(18%) Gin 3 Pro 5 Arg 1 Leu 7 G Gly 27 ( 5.6)
His 4 Pro 5 Arg 2 Leu 1 T His 13 ( 2.7)
H e 23 ( 4.7)
G Glu 14 Ala 9 Gly 5 Val 12 A Leu 30 ( 6.2)
Asp 16 Ala 12 Gly 9 Val 4 C Lys 14 ( 2.9)
(31%) Glu 6 Ala 5 Gly 5 Val 10 G Met 7 ( 1.4)
Asp 5 Ala 6 Gly 8 Val 23 T Phe 16 ( 3.3)
Pro 35 ( 7.2)
T End 1 Ser 10 End 0 Leu 6 A Ser 54 (11.1)
Tyr 11 Ser 4 Cys 6 Phe 4 C Thr 50 (10.3)
(19%) End 0 Ser 5 Trp 6 Leu 3 G T rp 6 ( 1.2)
Tyr 8 Ser 13 Cys 6 Phe 12 T Tyr 19 ( 3.9)
- Val 49 (10.1)
Table 6.1 Codon usage of the EHV-4 gpl3 gene and amino acid 
frequencies within its predicted product. The frequencies of 
each base within codon positions 1,2, and 3 are presented as 
percentages.
Table 6.2
Codon Usage of 0RF3
2nd A C G T
1s t \ (23%) (30%) (18%) (29%) 3rd Residue f (%)
A Lys 5 Thr 9 Arg 3 lie 2 A (25%) Ala 72 ( 8.4)
Asn 9 Thr 5 Ser 4 lie 1 C (23%) Arg 37 ( 4.3)
(26%) Lys 2 Thr 2 Arg 0 Met 8 G (22%) Asn 50 ( 5.8)
Asn 2 Thr 4 Ser 0 I le 3 T (30%) Asp
Cys
39
11
( 4.6) 
( 1.3)
C Gin 6 Pro 11 Arg 1 Leu 9 A Gin 16 ( 1.9)
His 1 Pro 4 Arg 8 Leu 3 C Glu 34 ( 4.0)
(29%) Gin 2 Pro 3 Arg 2 Leu 6 G Gly 46 ( 5.4)
His 0 Pro 1 Arg 0 Leu 8 T His
H e
17
58
( 2.0) 
( 6.8)
G Glu 4 Ala 3 Gly 4 Val 4 A Leu 92 (10.8)
Asp 6 Ala 5 Gly 1 Val 3 C Lys 29 ( 3.4)
(28%) Glu 4 Ala 4 Gly 3 Val 3 G Met 25 ( 2.9)
Asp 4 Ala 6 Gly 5 Val 4 T Phe
Pro
32
52
( 3.7) 
( 6.1)
T End 1 Ser 1 End 0 Leu 1 A Ser 71 ( 8.3)
Tyr 3 Ser 1 Cys 5 Phe 0 C Thr 58 ( 6.8)
(17%) End 0 Ser 4 Trp 0 Leu 4 G T rp 7 ( 0.8)
Tyr 3 Ser 5 Cys 5 Phe 7 T
i
Tyr
Val
40
69
( 4.7) 
( 8.1)
Tabl p. 6.7. Codon usage of 0RF3 and amino acid frequencies 
within its predicted product. The frequencies of each base 
within codon positions 1,2, and 3 are presented as 
percentages.
DISCUSSION
Sequence analysis of 2.88kbp of EHV-4 BamHI G revealed three open 
reading frames, two complete and one partial. The central ORF (0RF2) 
was identified as the EHV-4 gpl3 gene, a homologue of the HSV-1 gC 
gene. The partial ORF mapping to the right of the gpl3 gene (in genome 
terms)(0RF1) was identified as a homologue of HSV-1 gene UL43. Mapping 
to the left of the gpl3 gene was an ORF (0RF3) which could not be 
identified as a homologue of any HSV-1 or VZV genes. Comparison of 
the entire VZV and HSV-1 genomes has indicated this region of the 
genome corresponds to one of the few regions of the Uj_ component at 
which the two viral genomes encode nonhomologous proteins: HSV-1 gene 
UL45 encodes a 172 amino acid protein of unknown function transcribed 
in the same sense as gC ; VZV gene 13 encodes thymidylate synthetase 
which is transcribed in the opposite sense to gpV (Davison and Scott, 
1986; McGeoch et al., 1988a). It is thus possible the function
specified by 0RF3 may be unique to EHV-4 and its closest evolutionary 
relatives at least at this particular genome position. Given the high 
frequency of N-X-S/T sites within the predicted 0RF3 product it is 
tempting to speculate that 0RF3 encodes one of the EHV-1- and EHV-4- 
specific glycoprotein species for which a genome coding position has 
yet to be established. However, the predicted polypeptide lacks a 
characteristic N-terminaT signal peptide and C-terminal transmembrane 
domain . A short stretch of hydrophobic residues interspersed with Ser 
and Thr residues positioned N-terminal to three internal Met codons, 
Metyi,73,76, could potentially serve as a signal peptide with one of 
the internal Met codons acting as initiation codon. Alternatively, the 
first Met in the ORF could be used as the initiation codon since 
uncharacteristically long signal peptides have been identified in other 
glycoproteins, including EHV-4 gB (Riggio et al.. 1989). However, in
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gB-type glycoproteins the long signal peptide is hypothesised to result 
from sequence constraints imposed by the overlap of the gB gene with 
the ICP 18.5 gene homologue and no overlap exists in this situation.
In the absence of data linking the product of the 0RF3 gene to a 
specific EHV polypeptide the function of the 0RF3 product remains 
unknown.
The EHV-4 gpl3 gene maps between coordinates 0.15 and 0.17 within 
genomic fragment BamHI G. This coding position is consistent with that 
of VZV gpV (0.11; Davison and Scott, 1986; Kinchington et al.. 1986),
EHV-1 gpl3 (0.136-0.148; Allen and Coogle, 1988 ), and BHV-1 glII
(0.122-0.135; Fitzpatrick et al., 1989) and inverted relative to that 
of HSV-1 and HSV-2 gC (0.62-0.64; Frink et al.. 1983; Dowbenko and
Lasky, 1984 ) and MDV (Binns and Ross, 1989). In contrast, the PRV 
gIII maps within the central region of the component at 0.4, due 
to a 0.1-0.4 m.u. inversion ( Ben-Porat et al.. 1983; Robbins et al.. 
1984 ). Accordingly, in EHV-1, EHV-4 and VZV the gene is transcribed
from right to left, whereas in HSV (P|_ isomer), MDV, and PRV it is
transcribed in the opposite direction.
The coding region of the gpl3 gene of EHV-4 has a %GC composition 
of 48% which compares to 53%, 73%, 75% and 47% with the gC gene 
homologues of EHV-1, BHV-1, PRV, and VZV (Allen and Coogle, 1988; 
Fitzpatrick et al.. 1989 ; Kinchington et al.. 1986 ; Robbins et al.. 
1986a).
The gpl3 coding region is defined by an open reading frame of 1455 . 
base pairs or 485 amino acids. Although putative TATA and CAAT 
sequences are located upstream of the open reading frame it remains to 
be determined which of these are functionally operative. The HSV-1 gC 
gene is regulated as a gamma2 gene through signals specified within a 
15bp sequence element which includes the gC TATA box (Homa et al.
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1988). A CAAT box does not therefore seem to be required for HSV true 
late gene expression . The sequence ATTAAA, which serves as a 
polyadenylation signal in a minority of HSV-1 transcripts, is 
positioned lOObp downstream of the stop codon . The EHV-4 gpl3 may 
thus be transcribed, like PRV gIII (Robbins et al.. 1986a), as an
independent unit. No putative polyadenylation signal is specified 
within the corresponding region of the EHV-1 genome (Allen and Coogle,
1988) leading to the suggestion that the EHV-1 gpl3 gene may be 
transcribed as part of a multigenic RNA in an analogous manner to HSV- 
1 gC transcription in which the gC mRNA encodes both gC and a 172 
amino acid open reading frame, UL45, located just downstream of the gC 
gene (Frink et al.. 1983; McGeoch et al., 1988a). The HSV-1 UL45 gene 
is transcribed as an independent 730 bp mRNA under the control of its 
own promoter in addition to its transcription as part of the gC 
transcript (Frink et al.. 1983). Whatever the form of the EHV-4 gpl3 
transcript, whether uni- or multigenic, the existence of putative TATA 
and CAAT boxes upstream of EHV-4 0RF3 suggests it may similarly be 
transcribed under control of its own promoter. The protein encoded by 
0RF3 shares no significant homology with VZV or HSV-1 (I|_) genes encoded 
immediately left of the gC gene.
The predicted EHV-4 gpl3 protein is 485 amino acids in length with a 
molecular weight of 49117 on cleavage of the signal peptide. In 
contrast, gpl3 isolated from virions has an apparent molecular weight, 
as determined by SDS-PAGE, of approximately 92000 (Meredith et al..
1989) indicating that ' gpl3 is subject to co/post-translational 
processing. Such processing is likely to include cleavage of the 
putative 32 amino acid signal sequence, N-linked glycosylation at up 
to nine positions per molecule , and possibly, as in HSV-1 gC, 0-linked 
glycosylation and sulphation.
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Computer-assisted analysis of the primary sequence by hydropathic 
plot and secondary structure prediction algorithms (Queen and Korn, 
1984) permits the distinction of four structural domains i.e. an N- 
terminal signal sequence (amino acids 1-32), a large extracellular 
domain (amino acids 33-444) across which 11 putative glycosylation 
sites are distributed, a transmembrane domain (amino acids 445-472) and 
a polar C-terminal domain (amino acids 473-485). Although there is no 
biological evidence for the functional roles of specific domains within 
the EHV-4 gpl3, the essential role of the extreme N-terminal region for 
entry into the export pathway and the involvement of the putative 
transmembrane domain and C-terminal cytoplasmic domain in the 
efficiency of anchoring of the glycoprotein to the plasma membrane have 
been reported for the homologous PRV gIII and HSV-1 gC proteins 
(Enquist et al.. 1988; Holland et al.. 1984a, 1988; Robbins et al.. 
1989; Ryan et al.. 1987).
The degree of identity of EHV-4 gpl3 protein with other 
alphaherpesvirus gCs ranged from 25-29% with HSV-1 gC, HSV-2 gC, 
PRV g111, VZV gpV, MDV A antigen, and BHV-1 gill to 79% with EHV-1 
gpl3.
Fitzpatrick and coworkers (1989) have proposed, on the basis of 
their finding significant homology within a domain of BHV-1 g111 to 
that of class II MHC domains , that the herpesvirus gC-type 
glycoprotein may have been derived from a host cell gene encoding a 
member of the Ig superfamily. They have further proposed that the 
similar proposed structure of gIII and Ig superfamily domains may be 
involved in a role for gC in immune modulation.
Multiple alignment or matrix plot comparisons of the predicted 
protein sequence of herpesvirus gCs highlights a greater constraint on 
the sequence of the 3' end of the gene, encoding C-terminal amino
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acids. Allen and Coogle (1988) have proposed that the N-terminal domain 
of EHV-1 gpl3 may specify epitopes which elicit a protective immune 
response in which case the greater divergence of this domain may be a 
consequence of the selective advantage of N-terminal gpl3 variants in 
the infection of horses previously exposed to EHV. The greater 
conservation of the C-terminal domain may be due to sequence constraint 
imposed by some function conserved throughout the herpesvirus gCs. In 
HSV-1 gC the N-terminal domain is not restricted to an antigenic role 
since C3b binding activity of the protein is apparently dependent on 
structural elements within the N and C terminal regions of the protein 
(Huemer et al., 1989). EHV-1 is known to induce C3b binding activity on 
the surface of infected cells (Bielefeldt Ohmann and Babiuk, 1988) 
although this has yet to be assigned to a particular protein. EHV-4 
has yet to be tested in this respect but it might be expected that it 
too would specify C3b binding activity at least in the purified gpl3 
protein if not on the surface of infected cells. By binding C3b gC may 
act to inhibit the effect of the complement cascade such that virus or 
virus-infected cells are protected form complement-mediated damage 
(Fries et al.. 1986; McNearney et al.. 1987).
Allen and Coogle (1988) suggest the function of gC is adaptation to 
infection of the host species which is supported by evidence that the 
PRV, BHV and HSV 'gCs' at least are involved in adsorption to the host 
cell and might therefore specify tissue tropism. However, although gC 
is non-essential for the replication of herpesviruses such as HSV-1 
in vitro, field gC" viruses have not been isolated suggesting an 
additional important role in vivo perhaps in pathogenicity as in PRV . 
Whatever the function of the gC-type glycoprotein of herpesviruses it 
is clear that regions of the protein can tolerate greater divergence 
than others so the hypothesis of Allen and Coogle is likely to be true
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to an extent: parts of the polypeptide specifying immunodominant 
antigenic determinants , tissue tropism and adaptation to host niche 
exhibiting divergent sequence and other parts being more conserved to 
retain important functional conformations.
An immunodominant antigenic site of EHV-1 gpl3 comprising six 
continuous epitopes has been mapped to amino acids 136-191, 
corresponding to the major hydrophilic region within a Hopp and Woods 
hydropathic plot. Although the corresponding region of EHV-4 (amino 
acids 152-207) is hydrophilic in nature and may therefore be exposed on 
the surface of the protein constituting an antigenic domain, the major 
hydrophilic peak in the EHV-4 hydropathic plot is located around amino 
acid 409. Given the 79% identity between the EHV-1 and EHV-4 gpl3 
amino acid sequences it might be expected that the proteins possess 
type-common epitopes as is demonstrated by the cross reactivity of sera 
raised against EHV-1 or 4 gpl3 with the heterologous gpl3 (Allen and 
Bryans, 1986). However, Allen and coworkers have reported that 85% of 
immunodominant EHV-1 gpl3 antigens are type-specific (Allen et al..
1988). Given the 79% homology between the predicted primary translation 
products of the EHV-1 and EHV-4 gCs it seems unlikely that the protein 
would contain predominantly type-specific epitopes although the 
immunodominant epitopes may be specific to one or other type.
Studies on the gCs of herpesviruses are encouraging with regard to 
the potential of this protein as a vaccine component (see next 
chapter). However, the role of individual EHV-4 glycoproteins in the 
elicitation of a humoral and cell-mediated immune response has not yet 
been extensively studied.
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CHAPTER 7
ANALYSIS OF THE IMMUNOGENICITY OF EHV-4 gpl3 
AND gH PEPTIDES IN HAMSTERS
INTRODUCTION
This chapter outlines preliminary work designed to apply sequence 
data on the EHV-4 gpl3 and gH-type glycoprotein genes to the 
investigation of immunogenicity of their products.
Herpesvirus gC-type glycoproteins have been implicated in the 
elicitation of both humoral and cellular immune responses within the 
host and are often a major target of these mechanisms. PRV gIII is the 
immunodominant protein with respect to a PRV neutralising reponse 
(Ben-Porat et al.. 1986), and HSV-1 gC, VZV gpV, PRV gill, and BHV-1 
glII are targets for cytotoxic T-cells in animal models or the natural 
host (Fitzpatrick et al.. 1989; Giller et al.. 1990; Glorioso et al.. 
1985; Rosenthal et al.. 1987; Zuckermann et al.. 1990). Recombinant
vaccinia virus expressing HSV-1 gC and anti-gC monoclonal antibodies 
protect mice against HSV-1 challenge (Kumel et al.. 1985; Weir et al..
1989) suggesting that gC might be a useful constituent of a subunit 
vaccine. Studies on the gpl3 glycoproteins of EHV-1 and EHV-4 have 
similarly indicated an important role in interaction with host immune 
mechanisms. gpl3 is a major target of the humoral immune response and 
at least four neutralising epitopes (Allen and Bryans, 1986; Allen et 
al., 1988). Involvement in cellular immunity has been implied through
i) demonstration of lymphocyte transformation against an EHV-1 and EHV- 
4 protein fraction which contains gpl3 (Bridges et al.. 1988), and ii) 
complement mediated lysis of EHV-1 infected cells by anti-EHV gpl3 
monoclonal antibodies (MAbs) (Stokes et al.. 1991). Anti-EHV-1 gpl3 
monoclonal antibodies and a recombinant gpl3 vaccinia virus protect 
hamsters against challenge (Guo et al.. 1989, 1990; Shimizu et al.. 
1989; Stokes et al.. 1989, 1991).
Mapping of epitopes or epitope domains on herpesvirus glycoproteins 
has been approached in several ways including i) sequence analysis of
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monoclonal antibody resistant (mar) glycoprotein mutants , ii) 
analysis of the reactivity of short peptide sequences or protein 
fragments with anti-glycoprotein antibody , and iii) analysis of 
competitive binding of different monoclonal antibodies (Allen et al., 
1988; Brocade Wu et al., 1990; Fitzpatrick et al♦, 1990; Jacobs et 
al., 1990). The effectiveness of the analysis of the antigenicity of a 
given glycoprotein will depend on the source of the target material 
whether native glycoprotein purified from virion extract, intact or 
partial polypeptide expressed in a prokaryotic or eukaryotic expression 
system, or linear fragments produced by peptide synthesis.
A factor which might hinder the antigenic analysis of gC-type 
glycoproteins expressed in non-eukaryotic systems is the extensive 
glycosylation of the protein. Studies on HSV-1 gC have indicated that 
a proportion of epitopes are dependent on carbohydrate for their 
expression presumably because either the carbohydrate alters the local 
polypeptide conformation and/or is itself antigenic (Marlin et al., 
1985; Olofsson et al.. 1990; S.ioblom et al., 1987). Current evidence 
suggests the former option . Two antigenic sites exist - a
carbohydrate-dependent site (II) in the N-terminal half of the 
protein, and a carbohydrate-independent site (I) mapping from amino 
acids 297-360 (Marlin et al., 1985) (Figure 1). The carbohydrate
dependency of site II epitopes is apparently due to N-linked rather
than 0-1 inked oligosaccharides (Olofsson et al.. 1990). No data is
currently available on the glycosylation state of EHV-1 and EHV-4 gpl3 
and the dependency of their antigenic structures on carbohydrate 
residues other than that both glycoproteins possess potential N-linked 
glycosylation sites and both mature glycoproteins have an apparent 
molecular weight twice that predicted from the amino acid sequence. 
Although it seems likely that the HSV-1 gC and the EHV gpl3
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glycoproteins share some structural features given the conservation of 
several cysteine residues it is impossible to predict from existing 
data whether the EHV proteins will exhibit a similar distribution of 
carbohydrate-dependent and -independent epitope domains.
Current data on epitope domains within EHV glycoproteins is limited 
to studies on EHV-1 gpl4 and gpl3 (Allen and Coogle, 1988; Allen et 
al., 1988; Sinclair et al.. 1990; G. Allen, personal communication). An 
immunodominant domain has been identified within EHV-1 gpl3 spanning 
amino acids 136 to 191 (Allen and Coogle, 1988). The hydrophilic peak 
of the polypeptide sequence as predicted by the Hopp and Woods 
algorithm lies within this domain at amino acids 145-150.
Allen and coworkers (1988) analysed 42 EHV-1 gpl3-specific 
monoclonal antibodies for their type specificity and reactivity with a 
series of EHV-1 isolates to investigate the epitopic characteristics of 
the protein. The Mabs collectively interacted with at least 16 
epitopes. 85% of the Mabs were type-specific, 20% elicited the 
production of virus-neutralising antibody in the presence of
complement, and 90% varied between isolates. Four neutralising
monoclonals were isolated, one of which was cross reactive with EHV-4
gpl3. Sinclair and coworkers (1989) isolated three anti-gpl3 (EHV-1) 
monoclonal antibodies which recognise conformational epitopes and which 
neutralise EHV-1 infectivity in vitro in the presence of complement. Of 
these MAbs, two crossreact with EHV-4 but do not neutralise the virus 
. Sinclair and coworkers (1990) mapped epitope domains to EHV-1 and 
EHV-4 gpl3 by competitive binding of monoclonal antibodies. Their
results indicate that EHV-1 gpl3 possesses an epitope domain composed 
of both type-specific and type-common epitopes which elicit the 
production of antibody which neutralises EHV-1. Four type-specific 
domains were mapped, three to EHV-4 gpl3 and one to EHV-1 gpl3 which
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did not elicit production of neutralising antibody.
A second EHV-4 glycoprotein of interest in immunogenic terms is the 
gH-type glycoprotein. On the basis of work done on the gH-type 
glycoproteins of other herpesviruses including HSV-1, VZV, and EBV, 
this glycoprotein species is apparently either low in abundance and/or 
immunogenicity compared to several other glycoprotein species . 
Nevertheless gH-type glycoproteins specify at least one epitope that 
elicits the production of antibody which neutralises viral infectivity 
in the absence of complement.
HSV-1 gH can been produced in a mammalian transient expression 
system and in a recombinant vaccinia virus system to levels greater 
than that obtained in viral infection (Forrester et al.. 1990; Gompels 
and Minson, 1989 ). However, the glycoprotein produced differs
biologically from native viral gH in terms of its size, antigenic 
nature, and cellular localisation with no gH expressed on the infected 
cell plasma membrane. These differences can be partially resolved by 
superinfection of the transfected cells with wild type virus. A block 
in the transport of gH to the cell surface has also been reported for 
HCMV gp58 and EBV gp85 transfected into mammalian cells ( Cranage et 
al., 1988; Heineman et al.. 1988). This altered targetting of gH could 
be due to the absence of herpesvirus-specified proteins critical to the 
intracellular transport of gH. Alternatively, perhaps gH transport is 
dependent on gross effects of virus infection. Whichever is the case 
the analysis of gH immunogenicity is obviously hampered by its 
incorrect expression in eukaryotic transfection systems and by its low 
abundance within virions. The failure of PRV gH expressed in 
baculovirus to elicit neutralising antibody may be similarly due to an 
aberrant expression process (Petrovskis et al.. 1988).
As mentioned in Chapter 4, the gH-type glycoproteins of EHV-1 and
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EHV-4 have yet to be identified and as a result the involvement of 
these glycoproteins in eliciting an immune response is unknown. The 
fact that no monoclonal antibodies were raised to a product of the EHV- 
1 gH gene in the glycoprotein gene mapping study of Allen and Yeargan 
(1987) suggests that, like other gH-type glycoproteins, it may be low 
in abundance and/or immunogenicity.
Since sequence analysis of the EHV-4 gpl3 and gH genes provided us 
with predicted amino acid sequences for gpl3 and gH we set about to 
investigate the immunogenicity of peptides derived from the external 
domain of these glycoproteins. Three gpl3 and two gH peptide sequences 
were synthesised and their immunogenicity was determined in a hamster 
model by our collaborators, Dr. Anne Stokes, Dr. Keith Murray, and Dr. 
Tim Doel at the Institute for Animal Health , Pirbright.
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MATERIALS AND METHODS
1. Selection of Peptide Sequences for Investigation 
Peptides were selected from regions of the polypeptide predicted to 
be oriented on the surface of the molecule and therefore likely to be 
accessible to the immune system of the infected host. In the first 
instance the Hopp and Woods algorithm (1981) was used. As mentioned in 
Chapter 6 in connection with hydropathic analyses, different algorithms 
and predictive programs provide different outputs. In order to increase 
the chances that the tested peptides would be immunogenic, the 
polypeptide sequence was subjected to multiple predictive programs and 
peptides selected from those regions of the extracellular domain which 
were most frequently represented as putative surface regions. Peptide 
sequences of 17-20 amino acids in length were synthesised and a 
cysteine residue attached to the N or C terminus of each in case 
conjugation to carrier protein might be required at a later date 
(Fig. 2).
2. Immunisations and Immunological Assays 
Techniques utilised in this chapter are described in Stokes et al.. 
1989, 1991. Briefly, the experimental animals used were 6-8 week old
Syrian hamsters (Mesocricetus auratus) of the DSN inbred strain. 500ug 
doses of peptide were administered subcutaneously in an equal volume of 
complete Freunds adjuvant, to hamsters on day 0. Further immunisations 
were performed, in incomplete Freunds adjuvant as follows - days 14 
and 34 (peptides 15/89, 15/89, and 16/89), days 13 and 52 (peptide 
25/89), and day 14 (peptide 28/89).
Virus neutralising assays were conducted by incubating serial 
dilutions of hamster sera with guinea pig complement and 100 TCID^q 
units of virus at 37°C for 1 hour. The preparation was then added to
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equine foetal kidney (EFK) cells in monolayer culture and the 
cytopathic effect determined.
Complement-mediated antibody lysis (CDL) assays entailed the 
incubation of EHV-l-infected EFK cells radiolabelled with ^ C r  with 
heat inactivated hamster serum in the presence of guinea pig 
complement. Lysis of target cells was monitored by determining the 
amount of 5*Cr released into the medium from lysed cells.
Peptides were coated on ELISA plates at a concentration of 3ug/ml 
as solid phase for peptide-specific ELISAs.
Hamsters immunised with peptides 14/89, 15/89, and 16/89 were
challenged with 2x10^ 3  TCIDgQ units of EHV-1 strain Kentucky D (KyD) 
on day 64 ( administered intraperitoneally (i.p.)) . Hamsters
inoculated with peptides 25/89 and 28/89 (gH peptides) were challenged
i.p. with 1x10^ TCID5Q units of EHV-1 (KyD) on day 132 (peptide 25/89) 
or day 79 (peptide 28/89).
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RESULTS
1. Investigation of the Immunogenicity of EHV-4 gp!3 Peptides
A comparison of the HSV-1 gC, EHV-1 gpl3 (Allen and Coogle, 1988) 
and EHV-4 gpl3 glycoproteins is detailed in Figure 1 with the selected 
EHV-4 peptides underlined. On the basis of Hopp and Woods' algorithm 
(1981) the peak hydrophilic value of EHV-4 gpl3 occurred at amino acids 
406-411 (Fig.6 .8).One peptide was selected spanning this region, 16/89 
(amino acids 400-415), and two further peptides, 14/89 (37-54), 15/89
(157-176). These peptide sequences are compared to the corresponding 
regions of EHV-1 gpl3 in Figure 2. Peptide 16 is 'type-common' 
possessing 15 of 17 residues identical to those of the corresponding 
peptide in EHV-1 gpl3. Peptides 14 and 15 are more 'type-specific'in 
nature with 3/18 and 15/20 residues in common with the corresponding 
EHV-1 gpl3 peptides.
The immunogenicity of these peptides was investigated by the 
immunisation of hamsters with 500ug of peptide at 0, 14, and 34 days. 
Hamster sera was investigated at intervals for its reactivity against 
the peptide used in the immunisation (Table 1) and against whole virus 
(EHV-4) (Table 2). Each peptide elicited the production of anti-peptide 
antibody as demonstrated by the peptide-specific ELISA results (Table 
1). Anti-virus responses were evident within some, but not all, of the 
immunised hamsters (Table 2). Peptide 15 induced the highest titres of 
antibody against peptide and against whole virus. It is interesting 
that this peptide maps within part of the EHV-4 gpl3 polypeptide 
which shares sequence identity with the immunodominant domain of EHV-1 
gpl3 (Fig. 1). None of the hamster sera were capable of virus 
neutralisation in vitro (data unshown) and immunisation with the 
peptides did not protect hamsters against challenge with EHV-1 (Table 
3).
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Peptide 15 was reactive with an anti-EHV-1 gpl3 MAb pl7 produced by 
R. Killington and coworkers in Leeds mapping a linear epitope to amino 
acids 157-176 of EHV-4 and 141-159 of EHV-1 gpl3. Assuming the 
reactivity with the EHV-4 peptide is not spurious this suggests the 
epitope maps within the C-terminal end of the peptide where there is a 
run of six identical amino acids (Fig. 2).
2. Investigation of the Immunogenicity of EHV-4 gH Peptides 
Two peptides - amino acids 287-303 and 620-639 were selected from 
regions of the EHV-4 gH polypeptide predicted to be surface oriented. 
These peptides .are compared to similar regions of the EHV-1 gH 
polypeptide in Figure 2 (Robertson et al.. 1991).
Immunisation of hamsters with 500ug of peptides 25/89 and 28/89 
induced production of anti-peptide antibody and, in some hamsters 
(121,123,152,154,155) anti-virus (EHV-1 and EHV-4) antibody (Table. 
4 ). Neither peptide induced antibody which neutralised EHV-4 fn
vitro (data unshown). Sera with anti-EHV^4 antibody activity exhibited 
anti-EHV-1 activity indicating the induction of antibody to both EHV-1 
and EHV-4 proteins by immunisation with EHV-4 gH peptides. This is to 
be expected given the extent of identity between the peptides and their 
counterpart sequences in EHV-1 gH (Fig. 2).
Immunisation of hamsters with peptides 25/89 or 28/89 did not appear 
to induce protective immunity against EHV-1: virus titre in the liver 
and lungs of challenged hamsters was comparable to that of control 
(non-immunised) hamsters (Table 3).
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Figure 7.1
Alignment of the gC-Tvoe Glycoproteins of
EHV-1. EHV-4. and HSV-1
Peptide 14/89
EHV-4 gp13 ......MGLVNIMRFITFAYIICGGFILTRTSGTSASA SPATPTTNTGEGTSSPVTPTYTTSTDSNNSTAT-
I I I II II I I I  Nil  Mi l l  I I II
EHV-1 gp13 ......MWLPNLVRFVAVAYLICAGAILTRYASGASASSSQSTPATPTPTT............... PNLTTAH-
HSV-1 gC MAPGRVGLAWLWGLLWLGAGVAGGSETASTGPTITAGAVTN/UQAPTSGSPGSAASPEVTPTSTPNPNNVTQNKYYPTEPASPPTTPKPT
EHV-4 gp13 ....... NNSTDVNGTEATPTSHPHSHENTITCTNSLISVPYYTSVYINCSTTVSVNHSEYRLEIHLNQRTPFSDTPPGDQENYVNHNAT
I I INI I III l l l l l  l l l l l l l l  II INI I l l l l l l l l l l  I I I I I I I I Mi l l  III Hi l l
EHV-1 gp13  GAGSDNTTNANGTESTH SHETTITCTKSLISVPYYKSVDMNCTTSVGVNYSEYRLEIYLNQRTPFSGTPPGDEENYINHNAT
I I  I I II I
HSV-1 gC STPKSPPTSTPDPKPKNNTTPAKAKSGRPTKPPGPVWCDRRDPLARYGSRVQIRCRFRNSTRHEFRLQmRYSHGPSPPIAPAPDLEEVLT
*........... Carbohydrate-dependent Site II................
Peptide 15/89
EHV-4 gp13 KDQTLLLFSTAHSSAKSRRVGQLGVIPDRLPKRQLFNLPAHTNGGTNFPLNIKSIDWRTAGVYVWYLFAKNGSLINSTSVTVLTYNAPLMD
iiiiiiiiiii mi  iiniiiiiiiiiiiiiii ii iii iii iii iiiiii iii i m m  m i n i  m m  i
EHV-1 gp13 KDQTLU-FSTAE-RKKSRRGGQLGVIPDRLPKRQLFNLPLHTEGGTKFPLTIKSVDURTAGIYVWSLYAKNGTLVNSTSVTVSTYNAPLLD 
EHV-1 gp13 innmunodominant| |domain| | | | | | I I I  II
HSV-1 gC NITAPPGGLLVYDSAPNLTDPHVLWAEGAGPGADPP-LYSVTGPLPTQRLIIGRVTPATQGMYYLAWGRMDSPHEYGTWVRVRHFRPPSLT
............................... Carbohydrate-dependent Site II........................ *
EHV-4 gp13 LSVHPSLKGENHRAVCVVASYFPHNSVKLRWYKNAKEVDFTKYVTNASSVWVDGLITRISTVSIPADPDEEYPPSLRCSIEWYRDEVSFSR
I I I I I I I I I I I  II l l l l l l l l l  l l l l l l l l l l  l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  II III l l l l l l l  l l l l l l l l  I
EHV-1 gp13 LSVHPSLKGENYRATCWASYFPHSSVKLRWYKNAREVDFTKYVTNASSVWVDGLITRISTVSIPVDPEEEYTPSLRCSIDWYRDEVSFAR
I I I  III I I  I I I I II I III I I II I I I
HSV-1 gC LQPHAVMEGQPFKATCTAAAYYPRNPVEFDWFEDDRQVENPGQIDTQTHEHPDGF-TTVSTVTSEAVGGQVPPRTFTCQMTWHRDSVTFSR
-Carbohydrate-independent Site I-
P e p tid e  16/89
EHV-4 gp13 MAKAGTPSVFVAPTVSVNVEDGAAVCTAECVPSNGVFVSUVVNDHLPGVPSQDVTTGVCSSHPGLVNMRSSRPLSEENGEREYNCIIEGYP
i i i i i i i i i i i i i m  i iii m u  mi  iiiiii i l l i n i u m  m u  ii m u  i m i n i m u m  l i m n
EHV-1 gp13 IAKAGTPSVFVAPTVSVSVEDGDAVCTAKCVPSTGVFVSWSVNDHLPGVPSQDMTTGVCPSHSGLVNMQSRRPLSEENGEREYSCIIEGYP
I I II l l l l  III I I I I  I I II I I I II I III
HSV-1 gC RNATGLALVLPRPTITMEFGVRHWCTAGCVPEGVTFAWFLGDDPSPAAKSAVTAQESC-DHPGLATVRSTLPIS-YDYS-EYICR-TGYP
EHV-4 gp13 DGLPMFSDSWYDASPIVEDMPVLTGIIAVTCGAAALALWLITAVCFYCSKPSQVPYKKADF*
l l l l l l l l  I I I I I I I I I I I  l l l l  l l l l  II
EHV-1 gp13 DGLPHFSDTWYDASPIVEDRPVLTSIIAVTCGAAALALWLITAVCFYCSKPSQAPYKKSDF*
I I  I I
HSV-1 gC AGIPVLEHHGSHQPPPRDPTERQVIEAIEWVGIGlGVLAAGVLWTAIVYVVRTSQSRQRHRR*
Figure 7.1 Alignment of the gC-type glycoproteins of EHV-4, 
EHV-1, and HSV-1 with mapped antigenic sites of the latter two 
polypeptides indicated. Three EHV-4 peptides selected for 
immunogenic analysis are underlined.
0489946984
Figure 7.2
EHV-4 gpl3 and aH Peptides
14/89 P T T N T G E G T S S P V T P T Y T C EHV-4 37-54
I I I 3/18 identical
P A T P T H P T P N L T T A H G A G EHV-1 37-47
15/89 F S T A H S S A K S R R V G Q L G V I p C EHV-4 157-176
I I I I I I I I I I I I I I I 15/20 identical
F S T A “ E R K K S R R G G Q L G V I p EHV-1 141-159
16/89 R s S R P L S E E N G E R E Y N C EHV-4 400-415
I I I I I I I I I I I I I I I 15/17 identical
Q s R R P L S E E N G E R E Y S C EHV-1 383-399
25/89 C N R L P P R R R L E P P G P Y A G EHV-4 287-303
I I I I I I I I I I I I I 13/17 identical
N R R P S R L R L E P P G P H A G EHV-1 280-296
28/89 C L N T G L E D D G T T I H S Y G R S A N EHV-4 620-639
I I I I I I I I I I I I I I I I I I I 19/20 identical
L N T G F E D D G T T I H S Y G R s A N EHV-1 613-632
Figure 7.2 Identity of selected EHV-4 gpl3 and gH peptides 
with the corresponding regions of the EHV-1 gpl3 and gH 
glycoproteins (Allen and Coogle, 1988; J.M. Whalley, personal 
communication).
Table 7.1
Anti-crpl3 Peptide ELISA
Hamster Peptide 0
Time (days) 
14 20 34 44
96 14/89 <50 <50 <50 400 1600
97 14/89 <50 <50 200 >6400 >6400
98 14/89 <50 <50 100 400 800
99 14/89 <50 <50 50 1600 1600
100 14/89 <50 <50 <50 200 800
101 15/89 <50 <50 <50 1600 >6400
102 15/89 <50 <50 100 ' 3200
103 15/89 <50 >6400 >6400 >6400 >6400 '
104 15/89 <50 50 400 >6400 >6400
105 15/89 <50 <50 <50 3200 >6400
106 16/89 <50 <50 400 1600 1600
107 16/89 <50 50 50 50 400
108 16/89 <50 <50 <50 800 3200
109 16/89 <50 <50 50 3200 >6400
110 16/89 <50 <50 200 800 1600
Table 7.1 Anti-peptide antibody titres in hamster serum from 
animals inoculated with EHV-4 gpl3 peptides, 14/89, 15/89, and 
16/89. Values are given as the reciprocal ELISA titre. For < 
and > read ^  and Data from Stokes et al.. 1991.
Table 7.2
Anti-EHV-4 ELISA
Hamster Peptide 0 14
Time (days)
20 34 44
96 14/89 0.00 0.00 0.05 0.06 0.05
97 14/89 0.00 0.08 0.03 0.32 0.14
98 14/89 0.00 0.00 0.00 0.00 0.00
99 14/89 0.00 0.09 0.10 0.14 0.17
100 14/89 0.00 0.00 0.00 0.09 0.25
101 15/89 0.00 0.00 0.07 0.10 0.54
102 15/89 0.00 0.01 0.25 0.34 0.36
103 15/89 0.00 0.00 0.00 0.00 0.13
104 15/89 0.00 0.00 0.01 0.06 0.30
105 15/89 0.00 0.00 0.00 0.04 0.02
106 16/89 0.00 0.06 0.03 0.07 0.13
107 16/89 0.00 0.00 0.07 0.07 0.05
108 16/89 0.00 0.02 0.00 0.13 0.01
109 16/89 0.00 0.05 0.07 0.24 0.08
110 16/89 0.00 0.03 0.07 0.15 0.24
Table 7.2 Anti-EHV-4 activity of sera from hamsters 
inoculated with gpl3 peptides. Values are given as optical 
density with day 0 value taken as background. Serum samples 
were diluted 1/100. Data from Stokes et al.. 1991.
Table 7.3
Virus Titres in Tissues of Challenged Hamsters
Peptide Tissue Amount of virus in tissue 
(log10TCID50/g)
14/89 Hamster 96 97 98 99 100
Liver 4.5 2.5 3.0 5.0 3.5
Lung 2.0 <1.5 <1.5 <1.5 <1.5
15/89 Hamster 101 102 103 104 105
Liver 2.0 3.5 3.0 2.0 3.0
Lung 2.0 <1.5 <1.5 <1.5 <1.5
16/89 Hamster 106 107 108 109 110
Liver 4.0 3.5 4.5 <1.5 2.5
Lung <1.5 <1.5 3.0 2.0 <1.5
25/89 Hamster 121 122 123 124 125
Liver died 3.5 2.5 ND 4.0
Lung died <1.5 <1.5 ND <1.5
28/89 Hamster 151 152 153 154 155
Liver 2.5 3.5 3.5 <1.5 2.5
Lung <1.5 2.0 <1.5 <1.5 <1.5
Control Hamster 1 2 3 4 5
Liver 3.0 3.5 <1.5 3.0 4.0
Lung <1.5 <1.5 <1.5 <1.5 <1.5
Table 7♦3 Post challenge (EHV-1 KyD) virus titres in the 
liver and lungs of hamsters immunised with EHV-4 gpl3 and gH 
peptides. Control and gH peptide-immunised hamsters were 
challenged with 106 TCID50 units of virus and gpl3 peptide- 
immunised hamsters with 2xl05,3 units of virus. For < and > 
read < and >.
Table 7.4
Anti-qH Peptide and Anti-Virus ELISA Data
Hamster
0 13
Time
27
(days)
41 52 66 132
P ep tide 121 <50 3200 3200 >6400 >6400 10240 died
25/89 122 <50 <50 200 800 3200 200 >6400
123 <50 200 1600 3200 >6400 3200 >6400
Anti-Peptide 124 <50 <50 200 1600 >6400 3200
125 <50 100 1600 >6400 >6400 >6400 >6400
Peptide 121 <50 <50 800 <50 <50
25/89 122 <50 <50 <50 <50 <50
123 <50 <50 800 200 <50
Anti-EHV-1 124 <50 <50 <50 <50 <50
125 <50 <50 <50 <50 <50
Peptide 121 <50 <50 400 400 <50
25/89 122 <50 <50 <50 <50 <50
123 <50 <50 800 200 <50
Anti-EHV-4 124 <50 <50 <50 <50 <50
125 <50 <50 <50 <50 <50
Hamster Time (days)
0 14 22 29 38 79
Peptide 151 <50 <50 50 200 800 1600
28/89 152 <50 <50 100 800 3200 3200
153 <50 <50 <50 800 3200 1600
Anti-Peptide 154 <50 <50 <50 <50 50 >6400
155 <50 <50 <50 50 800 >6400
Peptide 151 <50 <50 <50 50
28/89 152 . <50 <50 <50 200
153 <50 <50 <50 <50
Anti-EHV-1 154 <50 <50 <50 200
155 <50 <50 <50 400
Peptide 151 <50 <50 <50 <50
28/89 152 <50 <50 <50 100
153 <50 <50 <50 <50
Anti-EHV-4 154 <50 <50 <50 50
155 <50 <50 <50 50
Table 7.4 Reciprocal titres of anti-peptide, anti-EHV-1, and 
anti-EHV-4 antibody in sera of hamsters immunised with 
peptides 25/89 and 28/89 (gH) as determined by ELISA. For < 
and > read ^ and Data from A. Stokes, personal
communication.
DISCUSSION
Immunisation of hamsters with peptides derived from regions of the 
predicted EHV-4 gpl3 and gH polypeptides resulted in the production of 
anti-peptide antibody in all hamsters. This indicates that the peptides 
were of reasonable immunogenicity, in the presence of adjuvant, without 
attachment to a carrier protein. It is possible that coupling of the 
peptides to hamster proteins by virtue of the terminal cysteine residue 
might have occurred thus increasing their effective immunogenicity 
(T. Doel, personal communication). It is interesting that all peptides 
elicited the production of anti-virus antibody in at least some 
hamsters. Thus antibody raised against linear peptide epitopes 
apparently crossreacts with gpl3 or gH as presented in the solid 
phase of the ELISA assay. With the caveat that the proteins might be 
partially denatured in that context, this suggests the methods used to 
locate parts of the polypeptide that might be surface oriented and 
therefore targets of the immune system are of reasonable predictive 
value. None of the peptides induced production of neutralising' 
antibody or protection against challenge. Of course it is possible that 
the majority of neutralising epitopes of EHV-4 gpl3 and gH are 
conformational in nature. Production of neutralising antibody by linear
peptides would then be dependent on the existence of sufficient linear
sequence within the conformational epitope such that anti-peptide 
antibody would crossreact with the native neutralising epitope at a 
detectable level (van Regenmortel, 1989) .
Further investigations are required before any linear epitopes 
possessed by the EHV-4 peptides are ruled out of any involvement in 
protection for a number of reasons -
i) Several reports have detailed elicitation of a protective immune
response on administration of two or more monoclonal antibodies which
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individually were nonprotective (Lussenhop et a!., 1988; Roberts et 
aL., 1985; van Drunen Littel-van den Hurk, 1985). Thus antibodies 
binding to different epitopes may act synergistically to induce 
protection. It is of interest that immunisation of guineapigs with gpl3 
and gpl4 of EHV-1 elicited a greater immune response than would be 
predicted from the responses to gpl3 and gpl4 separately (Guo et al., 
1990). It is therefore possible that combinations of peptides derived 
from EHV-4 glycoproteins might induce a protective immune response.
ii) Given that we are ultimately interested in epitopes which stimulate 
a protective immune response it is important not to focus too strongly 
on a neutralising antibody response since in vitro neutralising 
activity and in vivo protection are not necessarily correlated. For
example, non-neutralising monoclonal antibodies have been shown to 
induce protection on passive transfer (Stokes et al., 1989).
Furthermore, a hamster immunised with a portion of EHV-4 gpl4 (gB) 
expressed as a beta-galactosidase fusion product was protected against 
EHV-1 challenge yet analysis of sera at intervals indicated no 
neutralising response to EHV-1 (A. Stokes, M.P. Riggio, personal 
communication). In HSV-1 the protective immune response is comprised of 
contributions from not only antibody neutralisation but also from 
cellular mechanisms which recognise specific glycoproteins (Hall and
Katrak, . 1986). It is probable that the same applies to the EHV 
situation with cellular immune mechanisms perhaps playing a dominant 
role (Bryans, 1969).
iii) A final caveat with regard to the peptide studies is that the
immune response of a small animal model such as the hamster does not
necessarily correlate with that of the natural equine host : the entire 
surface of a non-self protein or peptide is likely to be antigenic in 
any animal yet the immunogenicity of a specific site may vary among
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different animals (Geysen et al., 1987).
Studies on the immunogenicity of peptides derived from the gC and 
gH-type glycoproteins of other herpesviruses have identified several 
epitopes. Five non-neutralising epitopes have been mapped to BHV-1 gill 
(gC) (Fitzpatrick et al.. 1990). Three peptides derived from the 
predicted VZV gpIII sequence have also been tested - amino acids 152- 
173, 793-803, and 828-841 - all of which elicited antibody reactive
with native gpIII (Keller et al.. 1987). Analysis of the
immunogenicity of an EBV peptide derived from amino acids 518-533 of 
the gH-type glycoprotein mapped a neutralising epitope to this part of 
the polypeptide although the affinity of polyclonal anti-peptide 
antibody for the epitope was low (Oba and Hutt-Fletcher, 1988).
The fact that a single immunodominant linear epitope domain has been 
mapped to the EHV-1 gpl3 glycoprotein is most encouraging with respect 
to the potential development of a peptide vaccine against EHV-1 or EHV-
4. A more comprehensive analysis of linear B-cell epitopes, and 
ideally also of T-cell epitopes, would seem a worthwhile exercise. Such 
studies coupled to monoclonal antibody studies and immunogenicity 
studies of intact gpl3 should shed light on the apparent type 
specificity of EHV-1 gpl3 (Allen et al.. 1988) despite the 79%
conservation of amino acid sequence between EHV-1 and EHV-4 gpl3.
gC-type glycoproteins have been implicated in immune evasion through 
three mechanisms : binding of complement component C3b (Smiley and
Friedman, 1985); binding of antibody by free extracellular glycoprotein 
(Isfort et al.. 1987); molecular mimicry of self epitopes (through 
homology to immunoglobulin superfamily members) (Fitzpatrick et al., 
1989). The ideal gC subunit or peptide vaccine would possess only B- 
and T-cell epitopes important in stimulating, as opposed to
suppressing, anti-viral immune responses and would render immune
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evasion mechanisms elicited by gC in the context of lytic infection 
inactive. Of course the ultimate test of such a vaccine would be its 
potential to elicit a protective immune response as compared to that 
of other vaccine designs such as live attenuated virus.
Whether or not EHV-4 gpl3 or gH peptides are eventually identified 
as eliciting a neutralising and/or protective immune response, analysis 
of the immunogenicity of peptides derived from these glycoproteins 
should provide some interesting data on their antigenic structure.
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CHAPTER 8 
GENERAL DISCUSSION
GENERAL DISCUSSION
Presented Data
The primary genes of interest in this study were the EHV-4 gene
homologues of HSV-1 genes encoding glycoproteins gC and gH and the TK 
gene. Sequence data is presented for these three genes and for a UL24 
gene homologue and a gene apparently unique to EHV-4. Partial sequence 
data is presented for UL21 and UL43 gene homologues. Analyses of these 
data provide information which can be used to deduce the amino acid 
sequences of the polypeptide products of these genes and which can be 
related, in a limited sense, to possible functional roles of the 
proteins. Additionally these data provide more general information of 
use in the evaluation of i) the relatedness of EHV-4 genes to their 
counterparts in other herpesviruses in terms of genome position and 
composition, and ii) the %GC content of the EHV-4 genome.
A summary of the alignment and relatedness of EHV-4 genes mapped in 
this project to genes in HSV-1 and VZV is summarised in Figure 1. One 
EHV-4 gene was identified which has no apparent homologue in HSV-1 or 
VZV, a gene , dsgC, mapping to the left of the gpl3 gene. Sequence data 
for the corresponding region of EHV-1 genome has yet to be published 
but one might expect , given the results of this thesis, that EHV-1 
would possess a counterpart of EHV-4 dsgC. The only other major 
difference between the sequenced parts of the EHV-4 genome and
equivalent regions in the genomes of HSV-1 and VZV is the existence 
of a region of direct repeat elements and a putative origin of DNA 
replication in the EHV-4 genome between the gH gene and the UL21 gene
homologue. Functional confirmation of the putative origin of
replication of EHV-4 could be achieved using the plasmid amplification 
assay developed by Stow (1982).
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Figure 8.1
Comparison of EHV-4. HSV-1, and VZV genome organisation 
across two parts of UL
I
>
X
Lll
5)
X
Figure 8.1 Comparison of the genome organisation of the EHV-4, 
HSV-1, and VZV genomes around the gC and gH gene loci. 
Transcriptional direction of genes is indicated by arrows and 
homologies ( at the amino acid level) by vertical bars.
The %GC content of the coding region of the gC, UL24, TK, gH, 
and dsgC genes of EHV-4 are compared to those of their gene
counterparts in EHV-1, HSV-1, and VZV in Table 8.1. The overall %GC for 
the complete sequence data presented in this thesis is 48%. Comparison 
of the EHV-1 and EHV-4 data suggests that the %GC of the complete EHV-4 
genome might be slightly lower than the experimentally determined %GC 
of EHV-1, perhaps in the order of 50%.
Comparison of the DNA identity between EHV-1 and EHV-4 DNA indicated 
identities greater, than the 17% homology derived by liquid
hybridisation data (Allen and Turtinen, 1982). For example, comparison 
of 2070bp spanning the EHV-4 gpl3 gene with the corresponding region of 
EHV-1 DNA indicated a nucleotide sequence identity of 66%. It is most
likely that similar comparisons within regions of the U$ component
would indicate a lower degree of nucleotide identity since this part of 
the genome is more divergent than U|_. Nevertheless, one would predict 
an overall sequence homology in the order of that between HSV-1 and
HSV-2 (50%) (Kieff et al.. 1971).
The amino acid identities of the EHV-4 gpl3, UL24, TK, and gH gene 
products with counterparts in EHV-1, HSV-1, VZV, HCMV, and EBV are 
presented in Table 2. The gC-type glycoprotein is the least well
conserved of the 5 gene products in terms of representation within 
herpesvirus genomes and in amino acid sequence. The TK and UL24 genes 
are the most conserved using the criteria employed.
Given the relatively high levels of identity, at the amino acid 
level, of the genes studied in this thesis to their EHV-1 counterparts 
it could be argued that the redesignation of these two viruses as 
separate types is unjustified. Certainly the sequence data currently 
available has suggested a lesser degree of divergence than might have 
been predicted from the completely distinct restriction endonuclease
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Table 8.1
Percentage GC content of the coding region of selected 
EHV-4, EHV-1, HSV-1, and VZV genes
dsgC gc UL24 TK gH Genome
EHV-4 50.4 48.4 49.7 51.8 44.5 ?
EHV-1 53.6 55.3 58.1 51.1 57
HSV-1 -- 68.3 64.6 65.3 66.7 67
VZV 47.2 46.0 45.3 44.4 46
Table 8.1 Comparison of the %GC composition of the coding 
portion of selected herpesvirus genes. Experimentally-derived 
values of overall %GC content are detailed for EHV-1, HSV-1, 
and VZV in the final column (Kieff et al.. 1971; Ludwig et 
al., 1972; Soehner et al.. 1965)
Table 8.2
Comparative identity of 4 EHV-4 genes with 
counterparts in five herpesviruses
VIRUS Type
% Identity (at amino acid level) 
to EHV-4 gene
gC UL24 TK gH
EHV-1 alpha 79 83 89 85
HSV-1 alpha 25 36 36 26
VZV alpha 26 37 35 32
HCMV beta - 23 - 18
EBV gamma - 23 25 17
Table 8.2 Percentage identity , at the amino acid level, of 
the gC, UL24, TK, and gH genes of EHV-4, EHV-1, HSV-1, VZV, 
HCMV, and EBV. Entire polypeptides were analysed with the 
exception of the EHV-4/EBV TK comparison in which amino acids 
27-326 of EHV-4 TK and 286-586 of EBV TK were analysed.
patterns manifested by EHV-1 and EHV-4 genomes. However, EHV-1 and 
EHV-4 seem to be related to a similar degree as that of HSV-1 and HSV-2 
which are regarded as separate types. Furthermore, EHV-1 and EHV-4 have 
distinct though overlapping disease sequelae and may differ in their 
latent characteristics. Thus, redesignation seems warranted.
Applications of the Data
With the long term aims of the group being the development of novel 
recombinant EHV vaccines and improved diagnostic techniques, the 
nucleotide sequence data presented in this thesis was obtained with the 
intention of utilising the data in three ways - i) to predict the amino 
acid sequences of the EHV-4 gpl3 and gH-type glycoproteins and to 
investigate the immunogenicity of peptides derived from these 
sequences, ii) to enable derivation of suitable primer sequences for 
use in polymerase chain reaction (PCR) amplification of EHV DNA, and
iii) to precisely localise the boundaries of the gpl3, gH, and TK genes 
to aid in the production of TK-deleted EHV-4 and in the development of 
EHV-4 glycoprotein expression systems or cloning cassettes.
The immunogenicity of three gpl3 and two gH peptides in hamsters 
was investigated. Anti-viral antibodies were raised against all 5 
peptides. However, no virus neutralising or protective immune response 
was elicited. This work leads on to a more comprehensive analysis of 
peptide immunogenicity. Of particular interest would be the analysis of 
the ability of antibodies in convalescent equine sera to bind epitopes 
within a range of gpl3 or gH peptides.
PCR-based diagnostic systems offer an alternative to current methods 
of identification of EHV-1 and EHV-4 which include virus isolation, 
serological analyses, DNA fingerprinting and/or Southern hybridisation, 
and monoclonal antibody typing (Allen et al. 1983b; Chowdhury et al..
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1986; Morris and Field, 1988; Yearoan et al.. 1985). PCR is an 
extremely sensitive technique whereby specific DNA sequences are 
amplified using minute amounts of target DNA as template. It has the 
potential to offer increased sensitivity and decreased sample analysis 
time over existing diagnostic techniques. Comparison of EHV-4 gene 
sequences presented in Chapters 4 and 6 to their EHV-1 counterparts 
permits the localisation of conserved sequence regions from which 
primers can be derived. These primers could be used to amplify both 
EHV-1 and EHV-4 in clinical samples such as nasal secretions. Typing 
of the viral DNA in the sample could be achieved by hybridisation of 
EHV-1- or EHV-4-specific probes to amplified DNA. The first report of 
PCR applied to EHV DNA amplification has recently been published 
(Ballagi-Pordany et al.. 1990).
The current impetus for research into various aspects of EHV 
molecular biology and pathogenesis is a result of increased funding by 
the equine industry which is ultimately directed towards development of 
novel vaccines against EHV-1 and EHV-4. As detailed in Chapter 1, an 
approach to the development of a novel EHV vaccine is the production of 
attenuated recombinant EHV-1 or EHV-4 viruses. The determination of the 
precise boundaries of the EHV-4 TK gene permits the construction of 
TK-deleted plasmid constructs, as presented in Chapter 3. These could 
be used in the production of TK- EHV-4 which could then be tested for 
its virulence properties relative to that of TK+ virus. Recombinant 
virus could be produced by cotransfection of TK-deleted plasmid DNA 
with intact TK+ EHV-4 or by cotransfection of a cosmid library of EHV-4 
containing a TK-deleted cosmid (Chapter 1, Fig. 7).
Information on the position and coding capacity of the gpl3 and gH 
genes could be applied to the development of subunit vaccines. Peptide 
sequences or polypeptides expressed in a suitable vector could be
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tested for their immunogenicity in small animals and ultimately in 
horses. Alternatively, these genes could be inserted into an attenuated 
EHV-1 genome in order to produce a bivalent vaccine strain which 
expressed immunodominant glycoproteins of both EHV-1 and EHV-4.
Whatever the outcome of EHV research in terms of novel vaccine 
development the studies underway should provide further insight into 
the pathology and molecular biology of these viruses.
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